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Abstract 
 
Cytochrome P450s provide a natural mechanism by which insects defend themselves against 
the relatively small number of insecticides approved by WHO in fighting malaria vectors. 
Three dimensional structures of these enzymes are important to aid our understanding of the 
mechanism of their action in dissipating the harmful effects of such insecticides. However, to 
date no coordinates of any insect P450 structure have been deposited in the Protein Data 
Base.  In this study a C-terminally, His-tagged, recombinant CYP6Z2, CYP for cytochrome 
P450, was constructed genetically and its expression and biochemical properties evaluated in 
an attempt to produce material suitable for crystallisation trials and ultimately X-ray 
structural analysis. 
The recombinant enzyme was purified in a soluble form through the introduction of a range 
of chemical agents including sodium cholate. A series of truncating mutants were constructed 
to determine the minimum set of primary structural elements that create a barrier to 
crystallisation. Genetically engineered truncations (11 amino acids and 22 amino acids) of the 
N-terminal hydrophobic region did not produce holoprotein. The N-terminal region appears 
to be essential to ensure the proper folding of insect P450 investigated, which may be the 
principal reason underpinning the lack of success in producing crystal structures for this 
group of enzymes.  
The homology model of CYP6Z2 used in this thesis, compared with those of the confirmed 
pyrethroid metabolisers; CYP6D1 and CYP6P3, revealed three key amino acid differences at 
their active sites. Single and double mutations of these three amino acids were constructed to 
explore their individual and joint roles in the metabolic activities of CYP6Z2. The single 
mutants, CYP6Z2 (Y102F) and CYP6Z2 (F212L) retained similar affinities as wild type for 
both benzyloxyresorufin (BR) and methoxyresorufin (MR) fluorescent probes. However, the 
IV 
 
turnover number of CYP6Z2 (Y102F) was 1.7-fold lower than the wild type for BR but 
shows improved activity with MR achieving 2-fold increase in turnover. CYP6Z2 (F212L) 
maintained the same turnover number with the wild type against BR but attained a 3.9-fold 
increase in activity against the methoxy derivative. Deletion of the positively charged 
arginine in CYP6Z2 (R210A) significantly improved the activity of the enzyme.  The 
turnover number increased by 3-fold against BR and the enzyme effectiveness also increased 
by 2-fold. To further investigate the roles of these residues, the same mutations were 
introduced into CYP6P3. The addition of a hydroxyl group in CYP6P3 (F110Y) changed the 
kinetic behaviour of the enzyme drastically: the mutant lost activity with the resorufin probe 
and the affinity for the DEF probe was lowered by 7-fold. Conversely, introduction of benzyl 
ring in CYP6P3 (L216F) did not affect the affinity, but the enzyme’s activity increased by 
15-fold with DEF. CYP6P3 (L216F) also improved the pyrethroid metabolising ability of the 
enzyme. These experiments clearly point to the important contribution of these amino acids 
in modulating the metabolic characteristics of these P450s. Similar studies were carried out to 
investigate the function of F115 in CYP6Z2 and CYP6Z3. This residue is frequently found 
close to the heam in P450s, where it is believed to play a key stabilising role in substrate 
recognition. A range of mutants were prepared and all produced holoproteins except F115H. 
The results presented in this thesis, point to a significant role in metabolic function for this 
residue, F115A, in CYP6Z3, and a rationalisation of the data is presented. 
Finally, the metabolic activities of CYP6Z2 and CYP6Z3 were compared in this study. 
Results presented here, suggest that both act independently in the presence of cytochrome b5 
in their activities against the resorufin fluorescent probes but their activities with diethyl 
fluorescein (DEF) probe increased significantly when cytochrome b5 is present. CYP6Z3 has 
2-fold turnover rate and 5-fold greater efficiency more than CYP6Z2 in dealkylation of BR 
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and 8-fold and 10-fold in turnover and efficiency respectively for MR. These metabolic 
comparisons suggest strongly that CYP6Z3 is an improved “version” of CYP6Z2.  
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Chapter 1 
 
1.1 The economic and medical importance of insects 
Insects belong to a class of invertebrates within the arthropod phylum (Chapman, 2009). They 
have a chitinous exoskeleton, three body parts, head, thorax and abdomen, three pairs of 
jointed legs, compound eyes and a pair of antennae. There are more than a million species 
described and they represent more than half of all known living organism (Chapman, 2009). 
Insects are considered to be both beneficial and harmful to humans. 
1.1.1 Beneficial insects 
Insects described as beneficial to man, are those that add value to the human race. Some of the 
beneficial insects are listed in Table 1.1 
Table 1.1: Beneficial insects and their advantage to man. 
Insect Benefit(s) 
Bees Honey, wax, pollination (Losey and Vaughan, 2006) 
Silkworm Silk (Losey and Vaughan, 2006) 
Ladybugs Predator of pest insects (Gullan and Cranston, 2009) 
Maggot Wound treatment (Whitaker et al., 2007) 
Cicada Source of protein (Gullan and Cranston, 2009) 
Dung beetles Decomposition and burial of dung (Losey and Vaughan, 2006) 
Lac Insects Shellac (used in dye, wood finishing, polish, food glazes etc) 
2 
 
1.1.2 Insect pests and vectors 
 
Insect pests are those considered to cause significant damage to farm produce, such as the  
locust, infrastructure, such as  termites and those that are parasitic, including lice and bed bugs 
(Bale et al., 2008). Insect vectors transmit infectious pathogens to another living organism 
(Roberts and Janovy, 2005) and have been reported to be responsible for close to 20% of all 
infectious diseases affecting people in developing countries (David et al., 2013). Mosquitoes 
are carriers of parasites and viruses responsible for human diseases typified by malaria and 
dengue (World Health Organization, 2010). 
Malaria is prevalent in tropical and subtropical regions (Caraballo and King, 2014) and 
presents a major hindrance to economic development in these regions. In 2005, it was 
estimated that over £8billion is lost annually in Africa as a consequence of the widespread 
distribution of malaria (Greenwood et al., 2005). Malaria in man is caused by infection with 
any of the five species of the single cell Plasmodium parasites: P. falciparum, P. vivax, P. 
ovale, P. malariae and P knowlesi (Collins, 2012, Mueller et al., 2007). The primary causative 
agent of fatal mortality rate is  P. falciparum, since P. vivax, P. ovale, P. malariae elicit milder 
type of malaria disease (Caraballo and King, 2014). Infection is transmitted by bites from an 
infected female mosquito of the Anopheles species, especially from An. gambiae and An. 
funestus. 
1.2 Vector control 
The World Health Organisation (WHO), other organisations and many countries have initiated 
several programmes to eradicate malaria. The two major strategies deployed to date are the 
development of drugs and vector control programs. However, the available drugs are expensive 
and the parasites are developing resistance at a significant pace (Djimdé et al., 2001, Price and 
Nosten, 2001, Wellems and Plowe, 2001). Chloroquine (CQ) drug was discovered in 1940 and 
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became first-line drug for the treatment of malaria. It was effectively used to treat and eradicate 
malaria in the 1950s. However, its use diminished and was banned in some countries as first-
line drug because of the emergence of malaria parasite developing resistance to the drug 
(Klein, 2013). Combination of sulfadoxine/pyrimethamine (SP) replaced CP but did not last 
long as front-line drug because of the wide spread of parasite resistance that emerged quickly 
(Roper et al., 2003). Artemisinin class drugs are currently the first-line malaria drug. However, 
there have been reports of a delayed-clearance phenotype, which is the first sign that resistance 
to the drug may emerge soon (Dondorp et al., 2010, Phyo et al., 2012). Vaccination, which 
would have been a practicable option to fight malaria parasite is still the subject of clinical 
trials (Agnandji et al., 2011). Therefore, developing a sustainable and effective vector control 
management program to prevent the transmission of the parasite is of paramount importance. 
Vector control includes the large-scale distribution of long lasting insecticide treated nets 
(LLINs) and insecticide residual sprays (IRS) in endemic regions (Bassat et al., 2008, Riveron 
et al., 2013). LLINs are impregnated with pyrethroid insecticides and are wash resistant (up to 
20 washes) (Atieli et al., 2010). Pyrethroid insecticides are the only group of insecticides 
approved by WHO to be used in conjunction with LLINs (Hougard et al., 2003). Whereas the 
four different insecticides groups approved by WHO: chlorinated hydrocarbons, pyrethroids, 
carbamates and organophosphates can be used in IRS (David et al., 2013). The vector control 
program is currently offering the most effective means of preventing malaria transmission 
(Stevenson et al., 2011). However, pyrethroid and DDT resistance in An. gambiae is  reported 
to be spreading across Africa (Yadouleton et al., 2010). 
1.2.1 Major insecticides used in vector control 
 
Insecticides are substances that have the capability to kill or debilitate  insects (Stephenson et 
al., 2006). The various classes of insecticides are described below. 
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1.2.1.1 Organochlorides 
 
This is the most widely used class of insecticides and includes dichlorodiphenyltrichloroethane, 
DDT. The insecticidal effect of this compound was discovered in 1939 and it has been used to 
control malaria morbidity and mortality since then (Dunlap, 1981).  
 
 
 
Figure 1.1: Dichlorodiphenyltrichloroethane (DDT). An organochloride insecticide.  
Its environmental effects on wild life, including egg shell thinning has led to a banning order  
for agricultural purposes, limiting its use to  disease vector control (van den Berg, 2009).  
1.2.1.2 Organophosphates & carbamates 
 
Organophosphates are esters of phosphoric acid and act as insecticides by interfering with 
acetylcholinesterase and other cholinesterases. They kill or disable insects by disrupting nerve 
impulses. These insecticides, unlike organochlorides, degrade at a significant rate with time, 
and do not cause bioaccumulation (Connell et al.). However, they have cumulative toxic effect 
to wild life. Malathion is one example of this class of insecticide. 
 
 
Figure 1.2: Malathion. An organophosphate insecticide.   
DDT 
 
Malathion 
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Carbamates, such as Bendiocarb (Figure 1.3) exhibit a similar mode of action as the 
organophosphates, causing reversible inhibition of acetylcholinesterases. Organophosphate 
irreversibly inactivate acetylcholinesterases (Robert, 2002).  
 
 
 
Figure 1.3: Bendiocard. A carbamate insecticide.  
1.2.1.3 Pyrethroids 
 
Pyrethroid insecticides are important in malaria control programs because they are the only 
insecticide class recommended by WHO for use in the manufacturing of LLINs, and remain 
widely used in indoor residual spray formulations. They are preferred to other insecticide 
classes, especially in household insecticides (Robert, 2002), because they are non toxic to 
humans at low concentration (less than 1/100
th
 pound of active ingredient per acre (Pears and 
Cranshaw, 2010)) required to be effective on insect and are easily degraded by sunlight under 
normal atmospheric conditions (Gilbert et al., 2005).  
Pyrethroids are synthetic analogues of pyrethrins from the pyrethrum flower. There are two 
classes of these insecticides based largely on their mode of binding to sodium channels (Figure 
1.6) and the presence of α-cyano group in their chemical structures (Gilbert et al., 2005).  
Bendiocarb 
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Type 1 pyrethroids bind preferentially bind to closed sodium-channels and do not have an α-
cyano group examples are shown below. 
 
 
 
Figure 1.4: Permethrin and etofentrox. Examples of type 1 pyrethroid insecticides.  
Type 2 pyrethroids bind preferentially to open sodium-channels and have an α-cyano group 
(Figure 1.5) 
 
 
 
Figure 1.5: Deltamethrin and cypermethrin. Examples of type 2 pyrethroid insecticides 
 
 
 
 
 
 
 
 
Etofentrox Permethrin 
 
Cypermenthrin 
 
Deltamethrin 
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Figure 1.6: Biochemical target sites of synthetic insecticides. Pyrethroids and DDT exert their 
toxic effect by blocking voltage-gated sodium channels, which generally produces fast knock-
down properties (kdr). Organophosphate (OP) and carbamate insecticides inhibit 
acetylcholinesterase (AChE) which plays an important role in terminating nerve impulses. The 
reduced sensitivity of AChE as a result of a gene mutation (MACE) causes resistance to OP 
and carbamate insecticides. ACh, acetylcholine; AchT, Ach transporter; AcOH, acetic acid; 
ChT, choline transporter; MACE, modified acetylcholinesterase; Vg-Na
+
 channel, voltage-
gated sodium channel; kdr, knock-down resistance (diagram taken from (David et al., 2013)) 
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1.3 Mechanisms of insecticide resistance 
 
Insecticide resistance in general, is the inherited ability of a strain of insects to survive 
doses of an insecticide that would ordinarily kill the majority of individuals in a normal 
population of the same species (World Health Organization, 1982). The mechanisms 
responsible for insect resistance are complex and include behavioural and/or physiological 
changes of insects. This might include, avoiding the insecticides, sequestration of the 
insecticide, altered penetration, target site alteration and bio-degradation (Gilbert et al., 
2005). Mosquitoes use target site modification and metabolic resistance as their insecticide 
resistance mechanisms (David et al., 2013). Target site resistance involves mutation that 
leads to well-defined target site alteration and resistance to insecticides (David et al., 2013, 
Donnelly et al., 2009). Metabolic resistance involves increased bio-degradation of the 
insecticides via overproduction of detoxification enzymes which includes P450s, 
glutathione s-transferases and carboxyesterases or cholinesterases (Hemingway and 
Ranson, 2000): these enzymes can act alone or in concert with each other (Fig. 1.7).  P450s, 
however, are the major enzyme family out of the detoxification enzyme groups that have 
been extensively reported to be associated with insecticide resistance (David et al., 2013).  
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Figure 1.7: Detoxification of deltamethrin by P450-mediated oxidation (dotted arrows) in 
combination with esterase-mediated hydrolysis (solid arrows) and followed by conjugation, 
figure taken from  (Anand et al., 2006). 
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1.4 The Cytochrome P450 family of enzymes 
 
Cytochrome P450s have been given several names based on their functions since they were 
first described by Hayaishi in 1955, who measured an enzymatic activity involved in the 
oxidative cleavage of catechol to mucoronic acid. He named the enzyme “pyrocatechase” 
(Hayaishi et al., 1955). Pyrocatechase thus became one of the first  enzymes to be discovered 
capable of incorporating atmospheric oxygen in the cleavage of the carbon chains of substrates 
(Denisov et al., 2005). These enzymes are called monooxygenases because they could 
incorporate hydroxyl groups into substrates; mixed function oxidases because each of the 
atoms of the atmospheric oxygen is used simultaneously, one incorporated into substrate and 
the other forming a water molecule; polysubstrate monooxygenases because they usually are 
not substrate specific; microsomal oxidases because they are usually found in the microsomes 
of eukaryotic cells; and haem thiolate proteins, because  haem is anchored  to the protein via a 
cysteine thiolate ligand (Feyereisen, 1999).  Presently, the unambiguous simple name “P450” 
without modifier is being used because of the characteristic peak at 450 nm (Estabrook, 1996). 
P450 enzymes are a large group of haem thiolate proteins, now known to be ubiquitous in 
Nature. Unlike other haem containing proteins, they absorb light maximally at 450 nm in the 
reduced carbon monoxide bound state. The molecular basis of cytochrome P450 absorbance in 
this range is the unusual structural environment of its liganding to the haem iron. Four ligands 
are provided by nitrogens on the haem ring. There are two vacant ligands above and below the 
plane of the haem: the fifth and sixth ligands. In cytochrome P450, the fifth ligand is occupied 
by a thiolate anion (Figure 1.8). The sulphur is derived from a conserved cysteine at the haem 
binding region of the active site. The sixth ligand position is usually temporarily occupied by a 
water molecule, which is displaced when the substrate binds to the active site (Shaik et al., 
2005). 
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Figure 1.8: The typical P450 haem iron with all the six ligands coordinated. 
(http://employees.scsbsju.edu/cschaller/Reactivity/oxygen/O ROSP450rest.png). 
 
1.4.1 Functional Roles of P450s 
 
There are two main functions performed by P450s. They metabolise xenobiotic compounds, 
which are exogenous to the organisms. They do these by either making the compound water 
soluble or they degrade the compound into non toxic metabolites (Hammock et al., 1985). The 
second function is important in the biosynthesis of signalling molecules which in turn are 
important for the control of development and homeostasis (Denisov et al., 2005). Drugs and 
xenobiotic removal, steroid hormones and fat soluble vitamin synthesis including conversion of 
polyunsaturated fatty acids into biologically active molecules are performed by P450s in 
mammalian tissues. The same roles are performed in insects where control of development and 
resistance to insecticides have been linked to P450s (Agosin, 1985, Feyereisen, 1999) 
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1.4.2 Nomenclature of P450 Enzymes 
Cytochrome P450 (CYP) is a ubiquitous class of enzyme in Nature but there exist numerous 
variants of CYP isoforms which are classified according to the similarities of their amino-acid 
sequences as follows:  
 Families - CYP families contain genes that have at least 40% sequence homology. 
 Subfamilies - Members of a subfamily must have at least 55% identity. 
 Individual genes – Specific Isoform 
Illustrated as follows: 
 
 
 
 
                                    CYP   6      Z       2 
 
 
 
                     Figure 1.9: P450 nomenclature chart 
 
 
 
 
 
 
Cytochrome 
P450 
Subfamily- >55% 
identity 
Specific Isoform 
Family- >40% 
identity 
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1.4.3 Classification of P450s based on the nature of their redox partners 
P450s are generally classified into two major classes. The classifications depend on the nature 
of the other protein(s) involved in their redox reactions (Nebert and Gonzalez, 1987). 
Class I P450- This class is made up of a two-component shuttle system consisting of an iron-
sulfur protein (ferredoxin) and ferredoxin reductase. This class is found on the membranes of 
mitochondria or in bacteria and is shown diagrammatically in Figure 1.10. 
 
 
 
Figure 1.10: Typical class 1 P450s in both eukaryotic and prokaryotic systems. Electrons are 
transferred from NAD(P)H via an FAD-containing ferredoxin reductase and an iron-sulphur 
containing ferredoxin to P450 (Paine et al., 2005). 
 
 
 
 
 
 
 
Prokaryotic system 
Eukaryotic system 
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Class II P450- This class is a single membrane-bound enzyme containing FAD and FMN 
cofactors.  This class is typified by the liver microsomal enzymes in mammalian cells: 
 
Figure 1.11: Typical class 2 P450s in both eukaryotic system and prokaryotes. Electrons are 
transferred from NADPH via diflavin (FMN and FAD) containing reductases. The reductases 
are bound to the endoplasmic reticulum in eukaryotes but fused to the P450s in prokaryotes e.g. 
P450 BM3 (Paine et al., 2005).  
There are some groups of P450s that can act alone (i.e. without a redox partner) such as  
CYP74A (Brash, 2009). P450 BM3 has a unique structure in which P450 is fused to  CPR, 
thereby making it self sufficient: it possesses the highest catalytic activity among the known 
P450s (Munro et al., 2002).  
 
 
 
 
Eukaryotic system 
Prokaryotic system 
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Figure 1.12: Electron transfer through the cytochrome P450–cytochrome P450 reductase 
complex taken from  (Ricoux et al., 2007). 
 
 
 
 
 
 
 
 
Membrane of the endoplasmic reticulum 
16 
 
1.4.4 Structure of the active site of P450 enzymes 
 
P450 enzymes have a common overall  structural topology even though their sequence identity 
is less than 20% across the gene superfamily (Hasemann et al., 1995).  The structural core of 
P450s is made up of four helices, with three parallel helices indicated as D, L and I as shown in 
Figure 1.13. Helix E is anti-parallel to the other helices (Presnell and Cohen, 1989). The 
prosthetic haem group is confined between the distal I helix and proximal L helix and bound to 
the adjacent Cys-haem-ligand loop which has the conserved amino acid sequence 
FxxGx(H/R)xCxG, the P450 signature. The cysteine is the proximal ligand to the iron in the 
haem. The sulphur in the cysteine forming the fifth ligand in the haem iron, which is a thiolate, 
and is the origin of the characteristic 450-nm Soret band observed for the ferrous-CO complex 
from where the P450 is named (Dawson et al., 1976). 
There are six substrate recognition sites in P450s which are regarded as flexible region of the 
active site that allow binding of substrates of different sizes (Gotoh, 1992). SRS1 is located at 
the B' helix region, SRS2 and SRS3 are parts of the F and G helices, SRS4 is part of I-helix, 
SRS5 is at β4 hairpin and SRS6 is at K helix β2 connecting region. Substrates bind to these 
SRS regions in an induced-fit mechanism for subsequent catalytic activity (Pylypenko and 
Schlichting, 2004). These SRSs have been shown through SDM to contribute to the functions 
of the P450s. SRS1, SRS4, SRS5, and SRS6 participating in formation of the catalytic site, 
while SRS 2 and SRS3 participate in the formation of the substrate access channel (Schuler and 
Berenbaum, 2013). 
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Figure 1.13: The typical conserved P450 fold illustrating the helixes, haem iron centre and the   
                       arrangement of the substrate recognition sites (Denisov et al., 2005). 
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1.4.5 Schematic illustrations of P450 catalytic cycle 
 
When a P450 is  at its “resting” state, it is mostly in the ferric Fe3+ form, owing to the relatively 
low reduction potential of the Fe
3+
/Fe
2+
 couple: the presence of the proximal thiolate ligand 
helps to maintain this low redox potential (Fantuzzi et al., 2004). In the absence of substrates, 
water coordinates at the sixth ligand to stabilise the low state of the ferric iron (Raag and 
Poulos, 1989). Substrate binding to the enzyme displaces the water molecule at the sixth distal 
ligand position and causes a shift of the resting low spin of the haem iron to high spin (Sligar, 
1976). The displacement of the water molecule at the sixth ligand thermodynamically 
destabilises the ferric state to be easily reduced by the presence of the first electron to the 
ferrous state (Haines et al., 2001).  
 
 
Figure 1.14: Resting state of P450, binding of substrate displacing water molecule and 
acceptance of the first electron. (http://employees.scsbsju.edu/cschaller/Reactivity/oxygen/O 
ROSP450bind.png). 
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Oxygen and carbon monoxide do not bind to the ferric form of the haem iron. However, they 
do bind when a reducing agent such as dithionite or P450 reductase reduces (using NADPH) 
the ferric haem iron to ferrous form. The ferrous CO versus ferrous difference spectrum is 
based on the ability of the P450  to bind CO when reduced and form the complex that 
specifically gives a spectrum with a peak at 450nm which is due to the signature cysteine 
thiolate to the 5
th
 ligand of the haem iron of the P450 (Klingenberg, 1958). Omura et al 
developed the extinction coefficients which enables the in vitro quantification of the P450s 
possible using sodium dithionite as reducing agent (Omura and Sato, 1962). 
 
 
 
 
 
Figure 1.15:  Peak at 450nm as seen when P450s are artificially reduced by sodium dithionite 
in the presence of CO 
 
Oxygen on the other hand binds to the reduced P450 to give the ferrous dioxygen complex 
Fe
2+
-OO or ferric superoxide complex Fe
3+
-OO
-
 because the iron is able to transfer an electron 
to the bound dioxygen (Momenteau and Reed, 1994). 
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Figure 1.16: Binding of oxygen and rearrangement of electrons resulting to formation of ferric 
superoxide. (http://employees.scsbsju.edu/cschaller/Reactivity/oxygen/O OSP450bind.png). 
 
 
 
 
Figure 1.17: Acceptance of second electron. The ferric superoxide is reduced with a second 
electron provided by the cofactor(s) to become ferric peroxide ion. 
(http://employees.scsbsju.edu/cschaller/Reactivity/oxygen/O OSP450peroxo.png). 
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Figure 1.18: Protonation steps. The ferric peroxide formed is protonated twice at the distal 
oxygen atom on the haem iron causing the heterolytic cleavage of the O-O bond and the release 
of water. This leaves an atom of electron-deficient oxygen on the haem. 
(http://employees.scsbsju.edu/cschaller/Reactivity/oxygen/O OSP450proton.png). 
 
 
The heterolytic cleavage of the O-O bond forms the ferryl-oxo porphyrin complex, which now 
possesses electron deficient oxygen. The iron in the haem has reservoir of electrons and could 
donate one electron to form iron (IV) or two to form iron (V) oxide complex. Porphyrin plays a 
key role in the activation of the oxygen on the haem iron at this point by donating an electron 
for the O-O bond cleavage (Dolphin et al., 1997, Goh and Nam, 1999, Stillman, 2000). 
 
Figure 1.19: Electron rearrangement between the haem and the bound atom for the formation 
of the activated oxygen. (http://employees.scsbsju.edu/cschaller/Reactivity/oxygen/O 
OSP450active.png). 
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Figure 1.20: Product formation and release. The unpaired electron of the oxygen on iron (IV) 
is a radical which P450 uses to carry out its various catalytic activities. 
(http://employees.scsbsju.edu/cschaller/Reactivity/oxygen/O OSP450CHAct.png). 
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Figure 1.21: The catalytic cycle of P450 (Denisov et al., 2005) 
 
 
There are three possible abortive steps in the catalytic cycle which are: 
I. Autoxidation of the oxy-ferrous complex in step 4- Here the oxygen is 
released as superoxide anion and the haem-iron goes back to step 1. 
II. Peroxide shunt in step 5 (a, b) – The peroxide or the hydroperoxide 
coordinated to the haem iron dissociates, forming hydrogen peroxide. 
III. Oxidase uncoupling in step 6- Instead of oxygenating the substrate the iron 
(V) oxide complex is oxidized to water. 
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1.4.6 P450 redox partners 
 
The transfer of each of the two electrons required for the effective functioning of P450s is 
provided by NADPH-cytochrome P450 reductase (CPR) alone or with contributions from 
cytochrome b5. 
1.4.6.1 NADPH-cytochrome P450 reductase 
CPR is a membrane-bound flavoprotein that transfers two electrons in a sequential process 
from NADPH to P450  (Paine et al., 2005). CPR is usually present at a molar ratio of  one tenth 
to one twentieth that of P450 (Feyereisen et al., 1990). CPR like P450s has an N-terminal 
hydrophobic region with which it interacts with the membrane and P450s (Black et al., 1979, 
Paine et al., 2005). 
The catalytic region of CPR has three domains which are made up of the FMN-binding 
domain, the NADPH/FAD binding domain and a linker domain located in between the 
NADPH/FAD sequence and considered to be serving structural role of positioning the other 
two major domain correctly for direct electron transfer (Paine et al., 2005).  
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Figure 1.22: Crystal structure of rat CPR domain showing the arrangement of the FMN and 
FAD domains with the linker in between (Paine et al., 2005) 
 
Electrons are transferred from NADPH to FAD and from FAD to FMN and finally passed on 
to the P450 enzyme (Paine et al., 2005). CPR can also transfer electron to cytochrome b5 
(Enoch and Strittmatter, 1979, Paine et al., 2005). The effects of the combination of CPR with 
cytochrome b5 in P450 reactions are discussed further below and also shown in Chapter 3 of 
this thesis. 
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1.4.6.2 Cytochrome b5  
 
Cytochrome b5 (b5) is a haemoprotein ubiquitous in Nature and contains protoporphyrin IX 
(Schenkman and Jansson, 1999).This haemoprotein is relatively low molecular weight, 
cylindrical and contains 6 helices and 5 β-strands (Lu et al., 1995). It is an acidic protein folded 
into two domains. The main and larger domain is the cytosolic haem containing the, amino–
terminal hydrophobic domain. The second domain is the smaller region joined to the globular 
region by a proline-rich motif of about 7 amino acid residues followed by 7 polar amino acids 
ending the polypeptide chain. The second domain has a net hydrophobic surface and forms the 
membrane binding carboxyl part comprising between 14 -18 amino acid residues (Scott 
Mathews, 1985). This haemoprotein, unlike P450, cannot interact with CO or oxygen, because 
the haem iron is coordinated both at the fifth and the sixth position by two histidines. However, 
it can act as an electron transfer intermediate between reductases and oxidative proteins 
(Schenkman and Jansson, 2003). The involvement of cytochrome b5 in P450 mediated 
reactions depends on the type of the P450 and the substrates involved (Kuwahara and Omura, 
1980). Substrates influence the affinity of P450 for NADPH-cytochrome P450 reductase 
(Tamburini et al., 1986), and also influence affinity between P450 and cytochrome b5 (Bonfils 
et al., 1981). 
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1.4.6.2.1 Functions of cytochrome b5 
 
1.4.6.2.2 Increased delivery of the second rate limiting electron 
 
Cytochrome b5, in ferric form, can be reduced by NADH-cytochrome b5 reductase or CPR and 
this ferrous cytochrome b5 could provide the second electron to the oxyferrous P450 (Correia 
and Mannering, 1973). This rate-limiting step was observed in ferrous cytochrome b5 
increasing the disappearance of oxyferrous complex (Noshiro et al., 1980). 
1.4.6.2.3 Increasing the coupling of activated oxygen on the haem iron 
Cytochrome b5 acts, depending on the substrate and the P450, to increase coupling of the 
activated oxygen on the haem iron by reducing the rate of release of superoxide which in turn 
results in  an increased product with lower formation of hydrogen peroxide (Qian et al., 1998). 
Cytochrome b5 performs this function by modulating the increase in the input of the second 
electron thereby reducing the uncoupling due to slow incorporation of the electron by NADPH-
cytochrome P450 reductase alone (Yoshio, 1981).  
1.4.6.2.4 Facilitating 2-electron uptake from NADPH by forming two-haemoprotein 
complex with P450 
 
P450 binds NADPH-cytochrome P450 reductase accepts an electron, dissociates, binds oxygen 
and rebinds to the reductase for the second electron (Schenkman and Jansson, 2003). 
Cytochrome b5 interacts with NADPH-cytochrome P450 reductase by charge-pairing 
(Nisimoto and Lambeth, 1985). It also associates with P450 by complementary charge-pairing 
(Tamburini and Schenkman, 1986). Thus cytochrome b5 can complex with P450 to form two-
hemoprotein and binds to NADPH-cytochrome P450 reductase. Cytochrome b5 in the complex 
oxidises ferrous haem iron in the first electron intake making the ferric haem iron to retake the 
second electron before dissociating from the CPR (Schenkman and Jansson, 2003). 
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1.4.6.2.5 Electron Facilitator 
It was observed in CYP3A4 that binding of cytochrome b5 induces a structural influence that 
affect the ability of the P450 to undergo redox changes. These changes facilitate conversion of 
the oxycytochrome P450 to yield more products and ferricytochrome P450 (Lipscomb et al., 
1976). 
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1.4.7 Reactions Catalyzed by P450s 
 
P450s use the same form of activated oxygen on compound 1 to catalyse various reactions 
ranging from hydroxylation, oxidation, alkylation, epoxidation delakylation, demethylation 
(Figure 1.18) and many more complex reactions (Isin and Guengerich, 2007). The catalysis via 
hydroxylations, oxidations and epoxidations of P450s are significant alternative for industrial use 
because chemical problems such as the use of chlorinated solvents and heavy metals as part of the 
catalyst are removed (Robins et al., 2009). 
 
 
 
 
 
 
Figure 1.23: Some of the reactions catalysed by P450s. 
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1.4.8 P450 Distribution in Nature 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.24: Pie charts of P450 distributions in nature 
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P450 is well distributed in all branches of the tree of life. Over 11,000 genes from 2,526 
subfamilies and 985 families have been documented across all the sphere of life (Nelson, 
2009). It is not surprising that plants have highest percentage of the P450 genes. They are 
stationary and could only defend themselves through breaking down of foreign substances 
having unrestricted access to them. They also synthesise other defence molecules like 
DIMBOA (2,4-dihydroxy-7-methoxy-1,4-benzoxazin-3-one), a powerful antibiotic 
(Glawischnig et al., 1999). 
1.4.8.1 P450s in human 
P450 enzymes are the most well-known group of drug metabolising enzymes in humans. 
Human P450s are primarily membrane-associated proteins positioned either in the inner 
membrane of mitochondria or in the endoplasmic reticulum of cells and prominently abundant 
in the liver (Rendic and Carlo, 1997). These P450s metabolize several endogenous and 
exogenous chemicals. They are present in most tissues of the body, and play key roles in 
hormone synthesis and breakdown, cholesterol synthesis, and vitamin D metabolism. P450 
enzymes also function to metabolize potentially toxic compounds, including drugs and 
products of endogenous metabolism such as bilirubin, principally in the liver (Berka et al., 
2011). The known clinically relevant human P450s are CYP3A4, CYP2D6, CYP1A2, 
CYP2C9, CYP2C19 and CYP2E1 (Martin and Fay, 2001). CYP3A4 is the most abundant P450 
in the liver (Shimada et al., 1994) and has broad capacity to oxidise structurally diverse 
substrates (Rendic and Carlo, 1997). Drug-drug interactions between substrates and inhibitors 
of CYP3A4  can profoundly affect safety or efficacy of drug therapy (Tanaka, 1998). 
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1.4.8.2 P450s in insects  
 
Insects have a repertoire of over 100 genes of P450s in their genomes (Arensburger et al., 
2010, Holt et al., 2002, Nene et al., 2007) thus providing protection against insecticides and 
xenobiotics. This group of enzymes has been identified to confer insecticide resistance on 
various vectors by increased metabolism of the insecticides manufactured to eliminate and 
eradicate the spread of parasites (Feyereisen, 1999, Ranson et al., 2002). The CYP6 family of 
cytochrome P450 has been reported to be over expressed in most insecticide resistance vectors 
(Nikou et al., 2003). CYP6A1 of the house fly, Musca domestica was first to be implicated in 
detoxification (Feyereisen et al., 1989). CYP6BQ9 of red flour beetle, Tribolium castaneum, 
was reported to have a major role in deltamethrin resistance (Zhu et al., 2010). 
In Drosophilia melanogaster, CYP6G1 was reported to be over transcribed in all the field 
isolates of DDT-resistant strains. These CYP6G1-related DDT-resistant strains also show 
broad cross–resistance to neonicotinoid, growth regulator, organophosphorus and carbamate 
insecticides (Daborn et al., 2002, Pyke et al., 2004). The CYP6 family  was also reported  in 
DDT and cypermethrin depletions in Musca domestica and Helicoverpa zea (Rupasinghe et al., 
2007). 
Anopheles gambiae, has been the major mosquito vector of malaria parasite Plasmodium 
falciparum in Africa and has over the years developed resistance to insecticides including 
dieldrin, DDT (dichlorodiphenyltrichloroethane) and pyrethroids (Coetzee et al., 1999). 
Microarray studies using fragments of 230 Anopheles gambiae genes identified five P450 loci, 
including CYP4C27, CYP4H15, CYP6Z1, CYP6Z2 and CYP12F1, that showed significantly 
high expression in DDT-resistant ZANU strain compared with susceptible Kisumu strain 
(David et al., 2005). Method used by David et al., 2005 is as follows: The microarray analysis 
was constructed containing fragments of 230 An. gambiae genes from families associated with 
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metabolic-based insecticide resistance. Each gene represented on the microarray was either 
obtained by PCR amplification or artificially synthesized as a 70-mer antisense oligo (Qiagen, 
Crawley, U.K.). To keep cross hybridization between closely related genes to a minimum, 
gene-specific segments were selected by using PRIMEGENS software 
(http://compbio.ornl.gov/structure/primegens). By using software default cut off values, 
fragments toward the 3′ end of the genes between 70 and 300 bp in length were selected as 
probes for the microarray, provided they matched the criteria of <75% similarity to all other 
genes in the An. gambiae genome. For genes having >75% similarity to another gene, 3′ UTRs 
were used for the probe design. Gene-specific fragments were obtained by PCR amplification 
from cDNA, cloned into pGEM T-easy vector (Promega), and sequenced. Subsequent PCR 
amplifications were performed with vector-specific primers, and the products were purified by 
using the QIAquick PCR purification kit (Qiagen). The 70-mer oligos and artificial spike-in 
controls were resuspended in nuclease-free water, and both quality and quantity checked on 
agarose gels before spotting. Arrays were spotted in duplicate onto gamma-amino-propyl-
silane-coated glass slides (UltraGaps, Corning) by using a Biorobotics Micro-Grid II printer 
(BioRobotics, Cambridge, U.K.). All genes were spotted in 50% DMSO (Sigma) at 
concentrations of 50, 200, and 1,000 ng/μl for spike-in controls, PCR products and 70-mer 
oligos, respectively. Four replicates of each PCR product and 70-mer oligo were spotted, as 
were eight replicates of spike-in controls. Printed slides were stored for 24 hours at room 
temperature in a desiccator before DNA fixation by using a UV auto crosslinker (power 600mJ, 
Stratagene). 
 CYP6Z1, CYP6Z2, CYP6M2, CYP6P3 and CYP325A3 were also identified by microarray-
based studies to be associated in pyrethroid resistance in An. gambiae (David et al., 2005, 
Müller et al., 2007, Müller et al., 2008, Nikou et al., 2003). CYP6P3 and CYP6M2 out of these 
P450s, were reported to be most widely over-transcribed in the resistance field populations 
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(Djouaka et al., 2008) and they have been heterologously expressed and confirmed to 
metabolise pyrethroids (Müller et al., 2008, Stevenson et al., 2011). 
Nikou et al (2003), reported that in An. gambiae the genes encoding CYP6Z1, CYP6Z2 and 
CYP6Z3 are tightly clustered on chromosome 3R. These three CYP6Z genes share common 
amino acid sequences. CYP6Z2 is 93.5% similar to CYP6Z3 and 69.4% similar to CYP6Z1. 
CYP6Z1 is in fact 70% and 69% similar to both CYP6Z2 and CYP6Z3 respectively (Chiu et 
al., 2008). Site directed mutagenesis was used in this study, especially on the amino acid 
residues at the active site of CYP6Z2 to understand their roles in the activity of this enzyme.  
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1.5 Mutagenesis 
 
Mutagenesis has made it possible for the functional and structural roles of amino acid residues 
in proteins of interest to be studied by comparing the characteristic of the mutant strains with 
the wild type (Ling and Robinson, 1997). Mutagenic agents were used to create mutations on 
gene of interest with phenotypic or selective screening means before the advent of SDM, which 
has strengthened the importance and possibility of making individual or combined mutations of 
the amino acid residues to be studied (Zoller, 1991). The use of polymerase chain reaction or 
non polymerase chain reaction has made it possible to make desired changes in mutations and 
expanded the use of mutagenesis to understand structure-function relationship in enzymes 
(Zoller, 1992). In vitro mutagenesis relies on the DNA template to be copied, short 
oligonucleotide primer(s) to be extended after binding to the template, DNA ingredients, the 
building blocks, in the form of the four dNTPs which are dATP, dCTP, dGTP, dTTP, and most 
importantly the DNA polymerase enzyme.  
1.5.1 Site directed mutagenesis (SDM) 
 
SDM is a targeted changes made to DNA sequence in order to characterise gene and protein 
structure-function relationship, binding domains of proteins, protein-protein interactions or 
active sites of enzyme. However, changing some specific amino acids may result in a drastic 
global conformational change or a mistargeting to the protein conserved signature site (Bordo 
and Argos, 1991). A good example is changing the conserved cysteine at the haem-binding 
loop needed for the thiolate bond with the haem iron in cytochrome P450. 
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The PCR methods to generate SDM are: 
1.5.1.1 Mutation at the terminal ends 
 
Mutations at the terminus are usually achieved using primers containing the desired mutation 
and a restriction digestion site. Reverse primer with the mutant codon and a forward primer 
with just restriction site or vice versa could be used depending on the position of the 
mutagenesis. The PCR product is digested and ligated into a vector (Vallette et al., 1989). 
1.5.1.2 Mutation in the middle of a gene 
 
Several methods could be used to create mutation in the middle of a large DNA, one of the 
methods uses four primers in two separate PCR. First two primers will be an outside forward 
primer with a middle reverse primer in the first PCR reaction and then outside reverse primer 
with inside forward primer. Either of the inside primers could carry the mutation desired. The 
PCR products will be two separate halves of the gene in tail-to-tail fashion that is then 
phosphorilated and fused in a ligation reaction (Hayashi et al., 1994).  
1.5.1.3  The quickchange SDM method 
 
This method utilises two same mutagenic forward and reverse primers which will annealed to 
the two strands of the circular DNA and then a nonstrand-displacing thermostable polymerase, 
e.g. Pfu Turbo polymerase will extend the two strands. The PCR product will be nicked 
circular strands. The PCR product will be separated from the template by digestion with DpnI 
which digests methylated DNA strands. The circular nicked dsDNA will be repaired when 
transformed into competent cells (Rabhi et al., 2004). 
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1.5.1.4 Mutation using megaprimer 
 
Megaprimer method can be used to create mutation anywhere within the gene sequence. In this 
method, two outside primers, forward and reverse, one middle primer containing the mutation 
are needed. This follows the method used by Pritchard et al (Pritchard et al., 1997). 
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1.6 Protein 3-dimensional modelling 
 
Homology modelling is the process of constructing an atomic resolution model of a desired 
protein from its amino acids sequence using a known experimentally determined three 
dimensional structure of a homologous protein as a template. Elucidating the structure of a 
protein is important in the study of the protein function, its interactions with ligands and other 
proteins (Krieger et al., 2003). Homologous modelling is generally based on the understanding 
that protein structure is remarkably determined by the sequence of its amino acids (Epstein et 
al., 1963) and that protein structures are more conserved in evolution than protein sequences 
(Chothia and Lesk, 1986, Chothia and Lesk, 1987). The many problems posed by experimental 
elucidation of protein structure through NMR and X-ray crystallography have made the use of 
modelling useful in in-silico study of structure-function of protein (Johnson et al., 1994). 
 
Steps followed in homology modelling are: template recognition, amino acid sequence 
alignment, alignment correction, backbone generation, loop modelling, side-chain modelling, 
model optimization and model verification through quality criteria and model quality (Krieger 
et al., 2004). 
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1.7 Aims of this project 
 
Cytochrome P450s in mosquitoes are becoming a major challenge for vector control 
management because of their role in providing a defence mechanism for this vector. However, 
to date, no insect P450 crystal structures have been published that might provide a molecular 
framework for rationalising the mechanism of insecticide metabolism.  
The aims of this project therefore are as follows: 
Through site-directed mutagenesis, examine the functional roles of the amino acid residues at 
the active sites of An. gambiae CYP6Z2 and CYP6P3 as revealed by in silico studies of their 
homology models. 
Characterise An. gambiae CYP6Z3 and CYP6Z2 with resorufin and diethyl fluorescein 
substrates and compare their pyrethroids metabolic activities. 
Establish expression and purification techniques for the full length 5xHis-tagged CYP6Z2 and 
investigate the effect of the truncation of the N-terminal hydrophobic domain of 5xHis-tagged 
CYP6Z2 will have on the proper folding of the enzyme.  
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Chapter 2 
2 Site directed mutagenesis to validate the roles of the amino acid residues identified by 
homology modelling in the active sites of CYP6P3 & CYP6Z2 
 
2.1 Introduction 
Specific CYP families are assigned to insect P450s; five are reported  to be specific for insects; 
CYP6, CYP9, CYP12, CYP18 and CYP4 (Feyereisen, 1999). Other P450s identified in insects 
are CYP304, CYP314 and CYP325 (David et al., 2013). The involvement of these CYP 
families in insecticide resistance of mosquitoes was well discussed in the review done by 
(David et al., 2013). The CYP6 family in mosquitoes has been heterologously expressed and 
validated to be metabolizers of two major groups of insecticides approved by WHO. DDT has 
been shown to be metabolised by CYP6Z1 in An. gambiae  (Chiu et al., 2008), whilst 
metabolic role of CYP6Z2 in An. gambiae  and its Aedes aegypti orthologue CYP6Z8  have 
been discovered to be involved in clearance of PBAlc (3-phenoxybenzoic alcohol) and PBAld 
(3-phenoxybenzaldehyde), which are common metabolites of carboxylesterases (Alexia et al., 
2013). Importantly, CYP6P9 and CYP6M7 in An. funestus  (Riveron et al., 2013, Wondji et al., 
2009) and their orthologues in An. gambiae , CYP6P3 and CYP6M2 (Müller et al., 2008, 
Stevenson et al., 2011) have become pyrethroid resistance markers. CYP6P7 and CYP6AA3 
also have both been confirmed to metabolise pyrethroids in An. minimum (Boonsuepsakul et 
al., 2008, Duangkaew et al., 2011).  CYP6G1 is associated with DDT resistance in Drosophila 
(Daborn et al., 2002), CYP6BQ9 was reported to have a major role in deltamethrin resistance 
in red flour beetle (Zhu et al., 2010), and CYP6D1 is a confirmed pyrethroid metaboliser in 
housefly (Zhang and Scott, 1996). 
CYP6Z2 in An. gambiae (McLaughlin et al., 2008) has been shown to fulfil the two 
conventional physiological functions of P450, i.e. control of development through hormone 
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biosynthesis and provision of the potential for xenobiotic metabolism: the main evidence 
comes from substrate binding and metabolism experiments carried out by these authors 
(McLaughlin et al., 2008). However, CYP6Z2 has only been shown to bind to permethrin and 
cypermethrin: it did not metabolise them (McLaughlin et al., 2008). Homology modelling of 
CYP6Z2 docked with these insecticides examined by McLaughlin et al., 2008 in their in silico 
studies revealed a non-productive binding phenomenon. They also constructed a three 
dimensional model of CYP6D1 revealing the amino acid residues in the active site and the 
productive binding of permethrin and cypermethrin.  
Comparing the composition of the amino acid residues at the active sites of the homology 
models of CYP6P3 and CYP6D1, pyrethroid metabolisers, with that of CYP6Z2 revealed three 
positions with different amino acid residues. Leucine at positions 53 and 216 are in both 
CYP6P3 and CYP6D1 active sites respectively. In CYP6Z2 phenylalanine replaces leucine at 
position 212, presenting a potential steric conflict with substrates. Tyrosine 102 in CYP6D1 is 
retained in CYP6Z2 but is replaced with phenylalanine in CYP6P3. Importantly, arginine, a 
positively charge amino acid, was seen at position 210 of the active site of CYP6Z2 close to 
the pyrethroids docked at the active site whereas asparagine, a neutrally charged amino acid, 
replaced arginine at this position in both CYP6D1 and CYP6P3. These observations made 
these three substitutions significant for investigations (Figures 2.1 and Table 2.1).  
Consequently, CYP6Z2 (F212L) and Y102F mutants were constructed based on the amino acid 
residues of CYP6P3 at the active site to examine the role of these amino acids at these 
positions. These residues were also swapped on CYP6P3 by constructing mutants CYP6P3 
L216F and F110Y to further establish their functions in the two P450s.  The effect of having 
arginine at the active site of CYP6Z2 instead of asparagine was also investigated with the 
construction of CYP6Z2 (R210A) mutant.  
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Figure 2.1 Structural alignment of the homology models of CYP6P3 (blue) and CYP6Z2 
(green). F110 and L216 in CYP6P3 are replaced with Y102 and F212 in CYP6Z2 respectively. 
The third position with F123 in CYP6P3 and F115 in CYP6Z2 is 4Å to the haem (red) and are 
conserved in all CYPs homology models examined. 
 
Table 2.1: Amino acid differences at the active sites of CYP6Z2 and CYP6P3 
P450 1
st 
Position 2
nd
 Position 3
rd
 Position 
CYP6Z2 F212 Y102 R210 
CYP6P3 L216 F110 N217 
 
 
F115 
Heam 
F123 
Y102 
F110 
F212 
L216 
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2.2 Materials & Methods 
2.2.1 Site directed mutagenesis 
All the CYP6Z2 and CYP6P3 mutants were generated using the Quick change Site-directed 
mutagenesis kit from Agilent using Pfu Turbo DNA polymerase except for CYP6Z2 (R210A) 
as explained below. The wild type ompACYP6Z2 was used as a template to generate the 
mutants as described in Mclaughlin et al (McLaughlin et al., 2008). ompACYP6P3 and 
mutants were provided by Dr. Cristina Yunta-Yanes at LSTM. (ompA is a bacterial outer 
membrane protein A, a leader sequence appended to the N-terminal CYP genes in order to 
direct the expressed protein to the membrane). 
The nucleotide sequence at the point mutation of CYP6Z2 R210A contained six bases that 
have multiple complementary sites on the pB13 plasmid. The properties of pB13 plasmid are 
stated in appendix 1. Therefore sequence confirmation of the SDM products gave several 
unexpected plasmid products. The mega primer method (Ling and Robinson, 1997) was 
therefore used to generate such mutants. A pCW-ompA 2 forward primer (Table 2.2) was used 
with the mutagenic reverse primer for R210A and ompACYP6Z2 as template in amplification 
reactions to generate product of about 700 bp containing the desired mutant. The product was 
then used in a second PCR with the same pCW-ompA 2 forward primer, but with another pB13 
downstream of the original reverse primer and pB13CYP6Z2 template without the ompA 
component. The product from this second PCR reaction was then digested with Nde1 and 
EcoR1 and ligated into pB13 plasmid digested with the same pair of restriction enzymes. The 
nucleotide sequence of the ligated ompACYP6Z2 (R210A) was then obtained by sequencing 
the PCR product in order to confirm the authenticity of the plasmid. The DNA sequence 
confirmation of R210A is shown in appendix 2. 
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Table 2.2: Mutagenic primers for the creation of double mutants CYP6Z2 (F212L,Y102A),     
                 CYP6Z2 (F212L,Y102F) and CYP6Z2(R210A) 
 
Mutants Template Forward Primer Reverse Primer 
CYP6Z2 
(F212L,Y
102F) 
pB13omp
ACYP6Z2
(F212L) 
5' GAT CGC GGT GTC TTC TGC 
AAT GAA GAG CAC G 3' 
5' TCT TCA TTG CAG 
AAG ACA CCG CGA TCG 
TGA AAG 3' 
CYP6Z2 
(F212L,Y
102A) 
pB13omp
ACYP6Z2
(F212L) 
5' GAT CGC GGT GTC GCC TGC 
AAT GAA GAG CAC G 3' 
5' TCT TCA TTG CAG 
AAG ACA CCG CAA TCG 
TGA AAG 3' 
*CYP6Z2
(R210A) 
pB13omp
ACYP6Z2 
5' CTA ATC GGG GAG CCA ACT 
TTA TCG 3' (mutagenic) 
 
5' CGA TAA AGT TGG 
CTC CCC GAT TAG 3' 
(Mutagenic) 
 
pB13omp
ACYP6Z2 
5' GGA GGT CAT ATG AAA AAG 
ACA G 3'  (pCW-ompA 2) 
5' CGA TAA AGT TGG 
CTC CCC GAT TAG 3' 
(Mutagenic) 
pB13CYP
6Z2 
5' GGA GGT CAT ATG AAA AAG 
ACA G 3'  (pCW-ompA 2) 
5' CGT ATC ACG AGG 
CCC TTT CG 3' -pB13 
sequencing primer 
* In creating this mutant, a “mega primer” was first generated with the reverse mutagenic 
primer. The product of this PCR reaction was added to the second PCR reaction. The double 
strand, when denatured during the PCR reaction serves as a primer in combination with the 
synthetic primer to generate the mutant. The PCR thermal cycle and reaction mixture are 
shown in appendix 3. 
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2.2.2 Co-expression of CYP6Z2, wild and mutants with P450 reductase 
In order to ensure optimised transformation efficiency for the co-transformations, E. coli 
JM109 cells were initially transformed with pACYC-AgCPR encoding the cytochrome P450 
reductase as described elsewhere (McLaughlin et al., 2008). These transformed cells were then 
subsequently made competent again and a 25 µl aliquot was used for all the co-transformation 
with wild type and mutant versions of ompACYP6Z2 in pB13. Luria agar plates supplemented 
with 50 µg/ml ampicillin and 25 µg/ml chloramphenicol were used to screen the colonies. A 
colony from the co-transformation was then used in overnight culture of Luria-Bertani broth 
supplemented with same antibiotic concentrations. Then 200 µl of the overnight culture was 
used to inoculate 200 ml Terrific Broth (1:1000) in a 1litre flask. The inoculated culture was 
incubated at 37
o
C with shaking at 200 RPM and growth monitored by absorbance at OD600. δ-
aminolevulinic acid (ALA), was added to a final concentration of 0.5 mM  when the OD600 
reached between 0.4-0.5 to boost the haem formation.  The incubation conditions were 
maintained until the OD reached 0.9-1.0 and IPTG added to final concentration of 1 mM to 
induce protein expression. ompACYP6Z2 (wild type) was expressed at 25
o
C, with shaking at 
120 RPM, while all the mutants were expressed at 21
o
C, 120 RPM. P450 absorbance maxima 
were monitored at 24 hrs and cells were then harvested at 36 hrs if such a signature absorbance 
signal at P450 was detected. The incubations at different temperatures were based on 
observations that the wild type expresses better at 25
o
C while mutants’ expressions are best at 
temperature
 
21
o
C.
 
Spheroplasts were prepared by centrifuging the 200 ml culture at 2800 x g for 20 minutes at 
4ºC in pre chilled 250 ml centrifuge bottles using the JLA 16.250 Beckman. The supernatant 
was discarded and the cell pellets re-suspended in 20 ml of 1x T.S.E. buffer on ice (2 x Tris-
Sucrose-EDTA (TSE) buffer was prepared by adding 0.1M Tris-acetate at pH 7.6 with 0.5M 
sucrose and 0.5mM EDTA. The mixture was then filter sterilized and stored at 4ºC). Previously 
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prepared 20 mg/ml of lysozyme (0.02 g/ml ddH20) in water was kept on ice and 250 μl of the 
prepared lysozyme solution used per 20 ml of cell suspension. The cell suspension was then 
transferred into an ice cold 50 ml centrifuge tube, gently mixed for 60 minutes while the cell 
walls are degraded to allow spheroplasts to form.  The 50 ml bottles were loaded into the JA 
25.50 rotor (Beckman) and centrifuged at 2800 x g for 25 minutes at 4ºC. The supernatant was 
discarded and the pellet(s) retained. The pellets were re-suspended with 8 ml of spheroplast re-
suspension buffer and 8 μl of 0.1M DTT.  
Protease inhibitors, aprotinin (trypsin inhibitor), leupeptin (cysteine, serine and threonine 
inhibitor) and PMSF (serine protease inhibitor) were added to the spheroplast preparation to 
final concentrations of 1 μg/ml for the peptides and 1 mM for the PMSF. The suspension was 
sonicated three times for 30 seconds (30 seconds on and 30 seconds off/intervals). The 
sonicated sample was loaded into 50 ml centrifuge tube and centrifuged at 30,000 x g for 20 
minutes at 4ºC. The supernatant was made up to 16 ml with ice cold ddH2O and transferred 
into 70 Ti ultracentrifuge bottles and loaded into a Beckman Ultracentrifuge and centrifuged at 
49,600 RPM (180000 x g), for 1hour, at 4ºC.  
The supernatant was removed using a pasteur pipette: the membranes appeared as a translucent 
red-brown pellet and the majority of the pellet was transferred to a dounce homogeniser on ice 
using a glass pasteur pipette to lightly scrape the pellet. Once most of the pellet had been 
transferred, 1ml of ice-cold 2X TSE buffer and 1 ml of water were added and the same pasteur 
pipette was used to re-suspend the remaining pellet which was also transferred to the dounce 
homogeniser. The liquid was loaded from the bottom of the homogeniser to avoid bubbles. 
Finally, 100 µl aliquots of the homogenised membrane sample were dispensed into eppendroff 
tubes and stored at -80ºC. The total protein was quantified using Bradford reagent (Bradford, 
1976). The P450 contents were characterised with respect to Fe
2+
-CO versus Fe
2+
 difference 
spectrum (Omura and Sato, 1964), and the Anopheles gambiae NADPH P450 reductase values 
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were quantified by cytochrome c reductase activity (Guengerich et al., 2009). The CPR 
quantifications are shown in appendix 4. 
2.2.3 P450 quantification of the CYPs expressed 
The expression of P450 was monitored in JM109 cells as follows. First, a 1 ml sample of a 
broth culture was centrifuged at 16,000 RPM for 5 minutes at 4
o
C. The pellet was then re-
suspended in 1 ml P450 spectrum buffer (100mM Tris, 10mM CHAPS, 20% glycerol and 
1mM EDTA) and divided equally into two dark cuvettes labelled blank (B) and experiment 
(E). A P450 scan program was opened in the UV-Spectrophotometer and each cuvette, B & E, 
placed in the slots for blank and experiment respectively. A base line was taken and the reading 
set to zero. The E cuvette was then removed and flushed with CO gas in a fume cupboard. 
Sodium dithionite salt was then added to the two cuvettes and the instrument set to read the 
ferrous-CO versus ferrous difference spectrum to quantify the P450. This same procedure was 
used for the P450 membranes prepared by adding 100 µl of membrane with 900 µl of P450 
buffer (ratio 1:10) and the mixture divided into two dark cuvettes labelled blank (B) and 
experiment (E). 
2.2.4 Enzyme assay 
The enzyme activity with resorufin derivatives as a substrate and diethyl fluorescein (DEF) 
were carried out in 96 well plates containing 50 mM potassium phosphate at pH 7.4. 10 pmol 
of membrane and 5 µmol/l benxyloxyresorufin (BR), metoxyresorufin (MR), ethoxyresorufin 
(ER), pentoxyresorufin (PR) and 20 µmol/l of diethyl fluorescein (DEF) were used in a total 
reaction volume of 100 µl. NADPH generating system, to generate steady electrons for the 
reaction, was prepared with 0.1 mmol/l NADP
+
, 0.25mmol/l MgCl2, 1mmol/l glucose-6-
phosphate and 1U/ml glucose-6-phosphate dehydrogenase. These are final concentrations in 
the 100µl of reaction volume used in the experiment.  For the determination of KM, with the 
probes, the reactions were carried out using 1 or 5 pmol of membranes and 0-1.2 µmol/l BR, 0-
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4 µmol/l for MR and 0-20 µmol/l for DEF. Fluostar Omega fluoroscan was used set at 30
o
C 
with filter combinations of 544 nm excitation and 590 nm emission for the resorufins, 485-12 
nm excitation and 520 nm emission for DEF. All reactions were carried out in duplicates and 
50-cycle fluorescent readings at a fixed 1500 gain. 
2.2.5 Thermostability assay 
This assay follows the same protocol as used in the fluorescent assays described in 2.2.4 except 
that 10 µl of the P450 enzymes to be examined were first incubated for 5 minutes at room 
temperature, 35
o
C, 40
o
C, 45
o
C, 50
o
C, 55
o
C, 60
o
C and 65
o
C. After incubation, 10 pmol of the 
enzymes was then used in 100 µl reaction final volume containing 5 µmol/L BR and NADPH 
regenerating system. 
2.2.6 Inhibition assay 
The inhibition assay was carried out with a range of concentrations of deltamethrin against  
fixed concentration of MR. The reaction mixture contained 50 mM potassium phosphate pH 
7.4, an NADPH regenerating system and 10 pmol of enzyme in a final volume of 100 µl. 
Deionised water was used to replace the NADPH regenerating system for the negative control.  
2.2.7 HPLC analysis 
 
Insecticides concentration of 20 μmol/l were incubated with 20 pmol of P450s at 30°C for 90 
minutes in the presence or absence of an NADPH generating system (5 mmol/l glucose 6-
phosphate, 1 U glucose 6-phosphate dehydrogenase, 1 mmol/l NADP) in a final volume of 200 
μl. The metabolic reactions were terminated by the addition of 200 μl of ice-cold methanol 
followed by incubation on ice for 10minutes. The samples were centrifuged at 16,000 x g, and 
150 μl of the supernatant transferred into HPLC vials. The substrates peaks eluted from the 
column were separated using a 250 × 4.6 mm (5 μm) Supelcosil LC-18-DB column (Supelco, 
Sigma-Aldrich, Gillingham, U.K.) and detected at 232 nm. 
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2.3 Results 
2.3.1.1 Expression of CYP6Z2 wild type and mutants 
 
All the single mutants of the ompACYP6Z2 created through SDM yielded holoproteins as seen 
in Figure 2.2. The wild type had the highest P450 content, at 8.4 µM. The P450 content 
increased with increasing bulkiness of the amino acid residue substituted. Replacing tyrosine 
with alanine gave the lowest value of 0.7 µM, but the P450 content increased to 1.9 µM when 
phenyalanine was replaced with leucine. Removal of the hydroxyl group of tyrosine gave a 
much lower quantity of 2.5 µM when compared to the wild type, but higher than the 
replacement with alanine or leucine. P450 content is measured at 450 nm and the aromatic 
rings can influence the reading because they do absorb light in the visible regions of 400 nm – 
800 nm (Schmid, 2001). However, Figure 2.2 shows that the wild type is more stable (i.e. folds 
properly and degrades slowly) than the mutants by yielding more of the holoprotein than the 
apoprotein as depicted by the appearance of lowest peak at 420 nm. The two double mutants 
created produced P420, indicative of misfolded cytochrome P450, although, the mutant 
F212L_Y102A still had activity when tested with BR (Figure 2.3). P420 is the inactive form of 
P450 resulting from lost of the haem, misfolding or unfolding of the protein.  
 
 
 
 
 
 
50 
 
(A) 
 
 
 
(B) 
 
 
Figure 2.2:  (A)-Fe
2+
-CO vs Fe 
2+
 difference spectrum CYP6Z2 and the single mutants.      
(B)- Bar chart illustrating the increasing P450 content with increase in the size of the amino 
acid residue substitutions. (n=1) 
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Figure 2.3: Fe
2+
-CO vs Fe 
2+
 difference spectrum of the double mutants showing P450 
expression. The P450 quantity computed for the two were negative because the absorbance 
units at 490 nm were higher than the readings at 450 nm. The amino acid sequence of the 
double mutants of Y102F_F212L and Y102A_F212L are shown in Appendix 5 and 6 
respectively. 
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2.3.1.2 Comparison of the specific activities of wild type CYP6Z2 and mutants CYP6Z2 
(Y102F) & CYP6Z2 (F212L) 
 
Four resorufin substrate probes, benzy-, methoxy-, ethoxy-, and pentoxyresorufin (BR, MR, 
ER and PR), were tested. The amount of resorufin released was derived from the Resorufin 
Standard curve shown in appendix 7. The wild type activity with the probes indicated high 
specific activity and preference for the phenolic group in BR (McLaughlin et al., 2008). The 
activity was reduced by 2.2-fold when the phenolic group was substituted with methoxy, and 
the activity progressively lost with increase in the length of the carbon chain in ethoxy and 
pentoxy derivatives of the probe. However, the phenolic group preference was lost when the 
aromatic residue of F212 was replaced with leucine F212L and tyrosine changed to 
phenyalanine Y102F. Although the intolerance to increasing aliphatic chain was retained, both 
mutants were able to dealkylate methoxy derivatives at higher rates than the phenolic group. 
The activities of F212L and Y102F were 3-fold and 2-fold respectively higher than the wild 
type in metabolising methoxy derivative of the resorufin (Figure. 2.4). 
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Figure 2.4: Specific activities of CYP6Z2 (wild), CYP6Z2 (Y102F) and CYP6Z2 (F212L) 
with the resorufin probes. The wild type activity against MR  & ER was lowest when compared 
to the mutants but had highest activity against BR. CYP6Z2 wild type has increased steric 
screening of oxidation with increasing alkyl chain length of substrate (McLaughlin et al., 
2008). The mutants F212L, which is within SRS 2, indicated that deletion of the aromatic side 
chain may have increased access of substrates into the active site of the enzyme. 
 
 
Table 2.3: Specific activities of CYP6Z2, CYP6Z2 (Y102F) and CYP6Z2 (F212L) against 
resorufin probes.  
 
CYP6Z2                                 BR
pmol/min/pmol 
P450 
MR 
pmol/min/pmol 
P450 
ER 
pmol/min/pmol 
P450  
PR 
pmol/min/pmol 
P450 
WT 
Y102F 
F212L                      
5.46±0.27 
3.88±0.16 
5.59±0.17 
2.52±0.016 
4.99±0.11 
6.37±0.051 
0.23±0.0028 
0.44±0.009 
0.53±0.020 
0.033±0.0005 
0.059±0.0009 
0.066±0.0027 
(Mean±SE, n=2) 
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2.3.1.3 Comparison of the kinetic parameters of the wild type CYP6Z2 and mutants 
CYP6Z2 (Y102F) & CYP6Z2 (F212L) for BR and MR resorufin probes 
 
The affinity for the phenolic derivative of the resorufin did not change significantly in the 
mutants compared to the wild type except for F212L, which shows a relatively weak affinity 
when compared with others. The affinity dropped by 1.1-fold and 1.5-fold for Y102F and 
F212L respectively (Table 2.4). The reduction in affinity in F212L may be due to the 
introduction of the aliphatic chain of the mutant. However, the turnover number of the mutant 
Y102F dropped by 1.7-fold when compared to the wild type while F212L was similar to the 
wild type. The differences in these two parameters compensated for each other in the resultant 
efficiencies of the two mutants computed from their KM and kcat values, which were similar, 
10.38 min
-1
µM
-1
 and 12.74 min
-1
µM
-1
 for Y102F and F212L respectively (Table 2.4). The KM 
values of the three were relatively low, which may explain why the efficiencies of the two 
mutants were similar. The catalytic efficiency of the wild type was the highest because of its 
preference for the phenolic group and high turnover number.  
The affinity of the wild type CYP6Z2 and the two mutants examined for MR showed similar 
results as BR. This may be due to the fact that these two positions are not involved in the 
binding of the substrates. However, turnover was increased by 2-fold in Y102F and 4-fold in 
F212L. The efficiencies of the mutants were therefore increased by 3-fold and 4-fold in Y102F 
and F212L mutants respectively (Table 2.5). All the mutants however have higher catalytic 
efficiencies with BR than with MR.  
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Figure 2.5: Michaelis-Menten plot of CYP6Z2 (wild) CYP6Z2 (Y102F) and CYP6Z2 
(F212L)-benzyloxyresorufin kinetics. Curve generated using Graphpad Prism 5 software with 
R
2 
for the curve fittings as 0.97, 0.98 and 0.99 respectively. 
 
 
Table 2.4: Benzyloxyreorufin kinetics of CYP6Z2 (wild), CYP6Z2 (Y102F) and CYP6Z2 
(F212L) 
CYP6Z2                                 KM  
 (µM)  
Kcat 
(min
-1
) 
Kcat/ KM  
      (min
-1
 µM
-1
)  
WT 
Y102F 
F212L            
0.51±0.076 
0.56±0.078 
0.75±0.088 
9.95±0.52 
5.76±0.29 
9.51±0.44 
19.74 
10.38 
12.74 
(Mean±SE, n=2) 
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Figure 2.6: Michaelis-Menten plot of CYP6Z2 (wild), CYP6Z2 (Y102F) and CYP6Z2 
(F212L)-methoxyresorufin kinetics. Curve generated using Graphpad Prism 5 software with R
2 
for the curve fittings as 0.99, 0.99 and 0.99 respectively. 
 
 
Table 2.5: Methoxyresorufin kinetics of CYP6Z2 (Y102F) and CYP6Z2 (F212L) 
CYP6Z2                                KM  
 (µM)  
Kcat 
(min
-1
) 
Kcat/ KM  
      (min
-1
 µM
-1
)  
WT 
Y102F 
F212L                
1.54±0.17 
1.15±0.16 
1.52±0.19 
2.01±0.11 
4.09±0.24 
7.84±0.48 
1.31 
3.6 
5.15 
(Mean±SE, n=2) 
 
 
 
 
 
 
 
 
57 
 
2.3.1.4 Specific activity of CYP6Z2 (R210A) with the resorufin probes and diethyl 
fluorescein (DEF) 
 
The equivalent CYP6Z2 R210 position is neutral in CYP6D1 and CYP6P3. Instead of arginine 
they both have asparagine at the active site. Thus CYP6Z2 R210A, was created to neutralize 
the positively charged residue and replace the bulky side chain group in the equivalent amino 
acid position. R210A was created instead of R210N because the amino acids sequence revealed 
another asparagine at N211 as shown in appendix 8 and appendix 9. Although this side chain 
was not seen in the active site, however, increasing bulky amino acid close to it may affect the 
catalytic cavity of the enzyme.  
The effect of cytochrome b5 on dealkylation of resorufin substrates by this mutant was also 
examined to establish if this P450 second redox partner will improve its activity. 
Results (Table 2.6) show that compared with wild type, R210A retained a preference for the 
phenolic derivative of resorufin. Specific activity was 2-fold higher for BR than MR which is 
similar to the wild type CYP6Z2. Activities with respect to ER and PR were also low for this 
mutant as were observed in the wild type and the previous mutants investigated. Addition of 
cytochrome b5 slightly increased the activity of BR by 27% but did not have any effect on MR, 
ER and PR. However, cytochrome b5 had a 2-fold stimulatory effect on the dealkylation of 
DEF by R210A. The stimulatory effect of cytochrome b5 with CYP6Z subfamily was further 
investigated in chapter 3. 
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Table 2.6: Specific activities of CYP6Z2 (R210A) against the four resorufin probes 
Compound                                 pmol/min/pmol 
P450 
Without b5 
pmol/min/pmol P450 
With b5 
% Increase in 
activity 
Benzyloxyresorufin  
Methoxyresorufin 
Ethoxyresorufin 
Pentoxyresorufin                  
7.24±0.44 
3.61±0.13 
0.29±0.0003 
0.053±0.0008 
9.24±0.86 
3.46±0.14 
0.26±0.009 
0.049±0.0027 
27.6 
-4.21 
-8.65 
-6.95 
 (Mean±SE, n=2) 
 
 
 
Table 2.7: Specific activity of CYP6Z2 (R210A) with the DEF probe 
Compound                                 RFU/min/pmol 
P450 
Without b5 
RFU/min/pmol P450 
With b5 
Fold Increase  
DEF  658.70±8.7 1,359±22.5 2-fold 
(Mean±SE, n=2) 
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2.3.1.5 Comparison of the kinetic parameters of wild type CYP6Z2, Y102F & F212L 
and R210A 
The kinetic parameters of R120A were compared with the wild type and the other previously 
examined mutants, Y102F and F212L using BR probe (Table 2.8). 
 The KM of R210A was 0.69 µM which was within the same range of the wild type, Y102F and 
F212L. However, the deletion of the positively charged arginine increased the turnover number 
by 3-fold when compared with both the wild type and mutant F212L and by 6-fold when 
compared with Y102F.  
The deletion of the positively charged amino acid residue also improved the enzyme efficiency, 
comparing the ratio of Kcat/ KM of the mutant with the wild type. The efficiency increased by 2-
fold when compared with the wild type and was 4-fold better than Y102F and F212L.  
 
 
 
 
 
 
 
 
 
 
 
60 
 
 
 
 
 
Michaelis-Menten Plot
0 1 2 3
0
5
10
15
20
25
CYP6Z2(R210A)
[Benzyloxyresorufin]M
pm
ol
/m
in
/p
m
ol
 P
45
0
 
Figure 2.7: Michaelis-Menten plot of CYP6Z2 (R210A)-benzyloxyresorufin kinetics. The 
curve was generated using Graphpad Prism 5 software. R
2 
for the curve fitting is 0.99 
 
 
Table 2.8: Benzyloxyresorufin kinetic parameters of CYP6Z2 (R210A) compared with the 
wild type  CYP6Z2 and mutants Y102F and F212L 
CYP6Z2                                 KM  
 (µM)  
Kcat 
(min
-1
) 
Kcat/ KM  
      (min
-1
 µM
-1
)  
WT 
Y102F 
F212L 
R210A   
0.51±0.076 
0.56±0.078 
0.75±0.088 
0.69±0.061 
9.95±0.52 
5.76±0.29 
9.51±0.44 
30±1.053 
19.74 
10.38 
12.74 
43.48 
 (Mean±SE, n=2) 
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2.3.1.6 Inhibition assay to determine binding ability of the wild type CYP6Z2, Y102F 
and F212L with deltamethrin 
 
The abilities of the wild type CYP6Z2 and the mutants to bind deltamethrin were tested in the 
inhibition assay of the enzymes’ activities with methoxyresorufin in the presence of the 
insecticide. 
The wild type and the mutants examined exhibited ability to bind to deltamethrin. The 
insecticide inhibited the activities of the enzymes against the resorufin probe by more than 50% 
as shown below: 
 
 
Figure 2.8: Inhibition assay of CYP6Z2-mediated methoxyresorufin O-debenzylation (MROD) 
reaction with deltamethrin as inhibitory ligand. 6 µM MR was used and no deltamethrin was 
added in the control experiment.  
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Figure 2.9: Inhibition assay of CYP6Z2(Y102F) -mediated MROD reaction with deltamethrin 
as inhibitory ligand. 4µM MR was used and no deltamethrin was added in the control 
experiment.  
 
 
 
Figure 2.10: Inhibition assay of CYP6Z2(F212L) -mediated MROD reaction with deltamethrin 
as inhibitory ligand. 3 µM MR was used and no deltamethrin was added in the control 
experiment. 
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2.3.1.7 Metabolic assay with deltamethrin 
 
The abilities of the wild type and the mutants, F212L and Y102F to metabolise deltamethrin 
was examined. While F212L did not show activity against deltamethrin, Y102F showed 
improved activity. It achieved 54.6 % depletion (percentage difference in the amount of 
insecticide in the NADPH negative control and that remaining in the NADPH positive reaction 
mixture) when freshly prepared membranes were used in the depletion assay.  This improved 
activity was 16.3-fold higher than the activity of the wild type. However, improved activity 
was only observed when fresh membranes were used. This may be because the enzyme was 
losing activity when freeze thawed.  
Combining the HPLC analysis with Mass Spectrometry analysis of metabolites would provide 
unequivocal evidence for mutants exhibiting improved insecticide metabolism. 
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Figure 2.11: Deltamethrin metabolism comparison of wild type CYP6Z2 and mutants F212L 
and Y102F from freshly prepared enzymes. The mutant Y102F showed improved metabolic 
activity against deltamethrin while no activity was detected for F212L. (Mean±SE, n=3). 
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The same pattern was observed with the third mutation at R210A. Three repeated depletion 
assays were done with the freshly prepared membrane showing 53% depletion of deltamethrin.  
 
 
Deltamethrin % Depletion
CY
P6
Z2
R2
10
A
0
20
40
60
%
 D
ep
le
tio
n
 
Figure 2.12: Deltamethrin metabolism comparison of wild type CYP6Z2 and mutant R210A 
from freshly prepared enzymes. R210A showed increased activity against deltamethrin more 
than the wild type. Mean±SE, n=3). 
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2.3.2 Wild type CYP6P3 and mutants, CYP6P3 (Y110F) and CYP6P3 (L216F) 
2.3.2.1 Specific activities of CYP6P3 & the mutants with resorufin probes and DEF 
 
The abilities of CYP6P3 and Y110F and L216F to metabolise resorufin probes were analysed. 
The amino acid sequence of the wild type CYP6P3 is shown in appendix 10. Only the wild 
type and L216F indicated low activities against BR and PR even in the presence of cytochrome 
b5. The presence of cytochrome b5 appears to have inhibitory effect rather than stimulatory for 
these resorufin probes in the two enzymes. The inhibitory effect with BR substrate was more 
than with PR. The activities of the wild type and L216F against BR were reduced by 2.5-fold in 
the presence of b5. The wild type lost 2.5-fold activity against PR in the presence of 
cytochrome b5. 
While the effect of cytochrome b5 was inhibitory with the resorufin probe, the effect was 
stimulatory for DEF probe. Increase in activities of more than 7-fold were achieved in the wild 
type and L216F, while cytochrome b5 appeared to have obligate role (i.e. its presence is a must 
for activity to occur)  in the activity of F110Y which had fold increase of over 80 (Schenkman 
and Jansson, 2003). Changing the side chain at position 216 from aliphatic residue to aromatic 
residue changed the activity of the native protein significantly by 18.6-fold increase and 
introducing hydroxyl group into the active site of the native protein at position 110 reduced the 
activity by 4.2-fold.  
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Figure 2.13: Bar chat of specific activities of CYP6P3 and CYP6P3 (L216F) with or without 
b5 against BR and PR. The effect of b5 was clearly seen in the activities of the wild type and 
mutant against BR. The effect on both isozymes was inhibitory. The activities of the enzymes 
against PR were too low and almost insignificant for comparison. 
 
Table 2.9: Specific Activities of CYP6P3 and L216F with or without b5 against BR & PR 
CYP6P3 
                                 
Benzyloxyresorufin 
pmol/min/pmol 
P450 
Without b5 
Benzyloxyresorufin 
pmol/min/pmol 
P450 
b5 
Pentoxyresorufin 
pmol/min/pmol 
P450 
Without b5 
Pentoxyresorufin 
pmol/min/pmol 
P450 
b5 
Wild 
F110Y 
L216F                      
0.035±0.0034 
ND 
0.033±0.0033 
0.0146±0.0018 
ND 
0.0131±0.0013 
0.0089±0.003 
ND 
ND 
0.0074±0.0001 
ND 
0.00055±0.00015 
 (Mean±SE, n=2). F110Y did not have activity against any of the resorufins and wild type and 
L216F did not show activity against MR.  
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Figure 2.14: Bar chat of the specific activities of CYP6P3, F110Y and L216F with or without 
b5 against DEF probe. The presence of b5 increased the activities of the wild type and mutants 
against DEF. L216F had the highest activity. 
 
Table 2.10: Specific Activities of CYP6P3, F110Y and L216F with or without b5 against DEF 
CYP6P3 
                                
DEF 
RFU/min/pmol 
P450 
Without b5 
DEF 
RFU/min/pmol P450 
With b5 
Increase 
WT 
F110Y 
L216F                      
4.65±0.45 
0.1±1.00 
86.60±7.01 
34.55±2.05 
8.35±0.25 
633.70±3.30 
7.43-fold 
83.5-fold 
7.3-fold 
 (Mean±SE, n=2) 
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2.3.2.2 Comparison of kinetic parameters of CYP6P3, mutants F110Y & L216F 
 
F110Y indicated a shift in the affinity of CYP6P3 when hydroxyl group was added to the 
phenolic ring of the phenylalanine. The affinity of the enzyme to bind DEF probe increased by 
6-fold when compared with the wild type and L216F. However, L216F still maintained its 
huge increase in activity of over 15.3-fold activity over the wild type as indicated by the Vmax 
generated from the Michaelis-Menten equation (Table 2.11). 
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Figure 2.15: Michaelis-Menten plot of CYP6P3, F110Y and 216F -DEF kinetics. The rate of 
activity of L216F is 15-fold higher than the wild type and 65-fold higher than F110Y. The 
curves were generated using Graphpad Prism 5 software. R
2 
for the curve fittings are 0.98, 0.92 
and 0.99 for wild type, F110Y and L216F respectively. ((Mean±SE, n=2) 
 
Table 2.11: Kinetic parameters for DEF by CYP6P3, F110Y and L216F 
Enzyme                                 KM 
(µM) 
Vmax 
(RFU/min/pmole P450) 
CYP6P3 
CYP6P3_F110Y 
CYP6P3_L216F           
7.14±1.06 
1.15±0.28 
6.12±0.78 
39.75±2.99 
9.36±0.67 
611±37.73 
 (Mean±SE, n=2) 
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2.3.2.3 Thermostablity of CYP6P3 and the mutants 
 
The addition of phenolic residue in L216F and hydroxyl residue in F110Y improved the 
thermostability of the native CYP6P3 protein significantly when tested with DEF. The mutant 
L216F was still 90% active at 50
o
C and F110Y 80% active at 45
o
C whereas the wild type 
completely lost activity at temperatures above 40
o
C.   
 
 
 
Figure 2.16: Thermostability test of CYP6P3, F110Y and L216F using DEF substrate. The 
mutants had increased thermostability than the wild type. L216F was more stable than F110Y. 
The addition of the phenylalanine at this position also improved the metabolic activity of the 
enzyme.  
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2.3.2.4 Pyrethroid metabolic profile of CYP6P3 and mutants  
 
The mutants created were examined in their abilities to change the metabolic profile of 
CYP6P3 against pyrethroids. Both type 1, permethrin, and type 2, deltamethrin & cypermethrin 
pyrethroids were investigated. The assay measured the disappearance of insecticides in the 
positive control (NADPH added) compared with the negative control (no NADPH). The 
chromatograms are displayed in appendix 11. 
The increased activity of L216F in the fluorescent probe analysis was also retained in the 
metabolism of the pyrethroids. This mutant had improved metabolic activity against all the 
three pyrethroids examined when compared with the wide type. Also, the reduction in activity 
of the mutant F110Y was reflected in the metabolism of the insecticides. F110Y lost 2.3-fold 
activity against cis isomer of permenthrin and 1.2fold against deltamethrin and cypermethrin. 
Table 2.12: Pyrethroid insecticides depletion assay 
Insecticide                                 CYP6P3 
% depletion 
F110Y 
% depletion 
L216F 
% depletion 
Deltamethrin 
Permethrin- Cis                         
Permethrin -Trans                    
Cypermethrin 
100 
100 
100 
75.4±12.78 
83.46±8.31 
42.07±0.44 
100 
58.89±0.38 
100 
100 
100 
100 
 % depletion of substrates (Mean±SE, n=3) 
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2.4 Discussion 
 
The value of in silico methods for predicting the behaviour and or analysing the outcome of 
site directed mutagenesis experiments, forms the basis of this Chapter. Three specific amino 
acid residues have been highlighted by a combination of sequence alignment and evaluation of 
homology models of CYP6D1 and CYP6P3 and differences are suggested with that of 
CYP6Z2. McLaughlin et al (2008) noted that the active site side chain, F212 of CYP6Z2  is 
absent from CYP6D1(McLaughlin et al., 2008): instead L53 is positioned at the active site of 
CYP6D1, in three dimensional terms. The presence of leucine at the active site of a known 
pyrethroid metabolizer, CYP6P3 (Müller et al., 2008), supports this judgement, where instead 
of F212 it has L216 at the same position (again in 3D) in the active site. Also absent at the 
active site of CYP6P3 is Y102 found in CYP6Z2, which is replaced by F110. In addition, the 
effect of the positively charged arginine at the active site of CYP6Z2 which is replaced with 
asparagine in both CYP6D1 and CYP6P3 was examined.  
CYP6Z2 binds cypermethrin and permenthrin in a non productive binding therefore this 
enzyme is unable to metabolise the pyrethroid insecticides (McLaughlin et al., 2008). An 
essential role of clearance of metabolites, PBald (3-phenoxybenzaldehyde) and PBA(3-
phenoxybenzoic acids, of carboxylesterases has been confirmed for CYP6Z2 which has linked 
the enzyme to pyrethroid insecticide resistance (Alexia et al., 2013) . However, similarities of 
the amino acid residues at the active site with known pyrethroid insecticide metabolisers with 
just 1 or 2 amino acid difference could make this enzyme to be an artefact: replaced 
metaboliser  (David et al., 2013), or a metaboliser in waiting.  
 
 
 
73 
 
 
 
Figure 2.17: Homology models of CYP6P3 overlaid with CYP6Z2 and deltamethrin, in blue, 
docked at the active site. Haem iron is shown as red and the amino acid residues swapped in 
the two P450s are shown side by side close to the substrate. CYP6P3 (F110) is shown in green, 
CYP6Z2 (Y102) in yellow, CYP6P3 (L216) in orange and CYP6Z2 (F212) in magenta. The 
substrate is 4.1 Å to the haem centre. 
 
 
Figure 2.18: Homology models of (B) CYP6Z2 with permethrin docked in the active site, (C) 
CYP6D1 with permethrin docked in the active site. 
Mclaughlin et al. 2008 
 
 
(B) 
F110 
Y102 
F212 
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The results in this chapter clearly revealed the roles of the 3 amino acids examined. The 
affinity of the mutants for their substrates compared with the wild type, as shown by their KM 
values, was similar for all the resorufin probes. However, the efficiency of CYP6Z2 increased 
by 2-fold when the positively charged arginine was replaced with alanine in R210A. Residue 
R210 was predicted to be involved in protein-ligand hydrogen bonds in permethrin docked in 
CYP6Z2 (McLaughlin et al., 2008). The exchange of tyrosine for phenyalanine and 
phenyalanine for leucine in F110Y and L216F mutants respectively in CYP6P3 revealed 
significant changes in the activities of the native protein. The activities of CYP6P3 and the two 
mutants were low generally for resorufin probes. However, F110Y completely lost activity to 
dealkylate BR and L216F did not show significant activity against PR. Cytochrome b5 was 
inhibitory rather than stimulatory when introduced for these resorufin probes. Conversely, the 
introduction of cytochrome b5 was stimulatory for DEF substrate. The effect was evidently 
shown with the increase in activity of L216F with DEF. Activity of F110Y against DEF was 
much lower when compared with the wild type and L216F but the affinity for DEF was the 
strongest suggesting this position may be involved in binding of the DEF substrate. 
The metabolic activity against deltamethrin of the mutants created in CYP6Z2 was not very 
clear in this result. However, mutant Y102F and R210A show some level of activities when 
freshly prepared enzymes were used. Similar mutation of F110Y in CYP6P3 reduced the 
metabolic activity against the pyrethroids examined. However, a change to phenylalanine from 
leucine in L216 of CYP6P3 improved the activity to deplete pyrethroids better than the native 
enzyme. Thermal stability of CYP6P3 was also significantly increased with the introduction of 
the hydroxyl group in F110Y and the aromatic ring in L216F. 
From these results, changing tyrosine to phenyalanine and mutating the arginine in the active 
site of CYP6Z2 could lead to depletion of pyrethroids.  
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The ability of P450s to catalyse the insertion of oxygen in a wide variety of substrates has 
attracted interest in these enzymes by the pharmaceutical industries (Faber and Johnson, 1996, 
Sono et al., 1996). However, their low stability and the need of redox partners have been the 
limitations in their technological applications (Joo et al., 1999). The improved thermostability 
and metabolic activity of CYP6P3 (L216F) suggests that increasing the number of aromatic 
residue in P450s might improve their stability for industrial use. The number of nucleotide 
change made and impact on the enzyme activity are shown in appendix 12. 
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Chapter 3 
3 Investigating the role of Phe115 in the CYP6Z subfamily and comparing kinetic 
parameters and pyrethroid activities of CYP6Z2 and CYP6Z3  
3.1 Introduction 
 
Nikou et al (2003) reported that in An. gambiae the genes encoding CYP6Z1, CYP6Z2 and 
CYP6Z3 are tightly clustered on chromosome 3R. The different expression levels of these 
three CYP6Zs in the three developmental stages of An. gambiae suggested diverse roles for 
these P450s in this insect (McLaughlin et al., 2008). CYPZ1 is predominantly expressed in the 
adult stage (Nikou et al., 2003) and has been heterologously expressed to confirm it 
metabolises DDT (Chiu et al., 2008). CYP6Z1 may thus have a protective role in metabolising 
and detoxifying DDT in the adult mosquito.  
CYP6Z2 is found expressed at high level in the larvae and at  a reduced level in the adult stage 
(Nikou et al., 2003). An. gambiae is an aquatic herbivorous feeder during the larval stage and 
CYP6Z2 can metabolise plant toxins such as α-naphto-flavone (ANF), thus may play a 
chemoprotective role during the aquatic life stage (McLaughlin et al., 2008) .  CYP6Z2 also 
binds to JH-III hormone, which is involved in insect development and metamorphosis 
(McLaughlin et al., 2008). CYP6Z2 has been confirmed to have secondary role in pyrethroid 
metabolism in processing metabolites generated by carboxylesterase led (and possibly P450) 
metabolism of pyrethroids (Alexia et al., 2013). CYP6Z2 has also been shown to metabolise 
carbaryl, a carbamate insecticide (Chiu et al., 2008). Finally, CYP6Z3 is  expressed 
predominantly in larvae and pupae stages (Nikou et al., 2003). Muller et al identified CYP6Z3 
among those P450s whose gene expression was associated with pyrethroid resistant An. 
gambiae strain from Ghana (Müller et al., 2007).  However, this P450 has yet to be 
functionally characterised. 
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These three CYP6Z genes share common amino acid sequences. CYP6Z2 is 93.5% similar to 
CYP6Z3 and 69.4% similar to CYP6Z1. CYP6Z1 is in fact 70% and 69% similar to both 
CYP6Z2 and CYP6Z3 respectively (Chiu et al., 2008). The amino acid residues of the P450s 
are 494, 490, and 492 for CYP6Z1, CYP6Z2 and CYP6Z3 respectively as stated in appendix 
13, 14 and 15.  However, CYP6Z1 can metabolise DDT and CYP6Z2 cannot (Chiu et al., 
2008). The ability of CYP6Z1 to metabolise pyrethroid insecticides has not been reported.  
Efforts were made here to express CYP6Z1 in E. coli  as for CYP6Z2 (McLaughlin et al., 
2008), but these attempts were unsuccessful. 
Phe
115
 is well conserved in the three CYP6Z isoforms and it is positioned in the substrate 
recognition site 1 (SRS1) in between B-C loop. The residue protrudes into the active site over 
the haem iron (Chiu et al., 2008), and it is  4.1Å close to one of the pyrrolic groups of the  
haem (Figure 3.1). The effect of this aromatic ring and its pi electrons close to the porphyrin of 
the haem was investigated using SDM technique to mutate the Phenylalanine to other related 
and unrelated amino acid residues.  
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Figure 3.1 Homology model of CYP6Z2 viewed with Pymol showing the haem in rainbow 
colour and Phe
115
 residue in yellow at a 7.1 Å to the haem center and 3.1 Å to the pyrrole of the 
haem.  
 
 
 
 
Figure 3.2: Homology model of CYP6P3 showing the haem in red colour, Phe
110
 in green and 
Phe
123
 in blue. Phe
110
 is 12.1 Å and 13.6 Å to the nearest pyrroles of the haem, while Phe
123
 is 
4.1 Å to the nearest pyrrole of the haem. Phe
123 
of CYP6P3 occupies the same position as 
Phe
115
 of CYP6Z2 when the two were compared.  
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3.2 Materials & Methods 
3.2.1 Site directed mutagenesis 
 
The protocol described in Chapter 2 was used to generate all the mutants created in this 
chapter:  the primers and templates are stated in Table 3.1. 
3.2.2 Thermostability assay 
 
As described in chapter 2. 
3.2.3 Effects of a range of concentrations of cytochrome b5 on CYP6Z family 
 
Two reaction mixtures following the fluorescent assay protocol were used to evaluate 
concentration of cytochrome b5 needed in the activity of CYP6 family used in this experiment 
against DEF probe. Reaction mixture 1 contained 100 pmol of cytochrome b5 as used in 1:10 
reaction ratio, 10 pmol membrane, 20 µmol/l DEF and NADPH regenerating system (as 
describe in chapter 2). Reaction mixture 2 contains 10 pmole of membrane, 20 µmol/l DEF and 
regenerating system without cytochrome b5. Reaction mixture 2 was used in serial dilution of 
reaction mixture 1 to achieve 50% downward dilution reaction mixtures. 
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Table 3.1: F115 mutagenic primers for CYP6Z2 and CYP6Z3 
Mutants Template Forward Primer Reverse Primer 
CYP6Z2(F115A) pB13ompACYP6Z2 5' TTC TCG GCC AAT 
CTG GCC GCT CTG 
CCC GGT CAG 3' 
5' CTG ACC GGG CAG 
AGC GGC CAG ATT 
GGC CGA GAA 3' 
CYP6Z2(F115L) pB13ompACYP6Z2 5' TCG GCC AAT 
CTG CTC GCT CTG 
CCC GGT 3' 
5' ACC GGG CAG AGC 
GAG CAG ATT GGC 
CGA 3' 
CYP6Z2(F115Y) pB13ompACYP6Z2 5' TCG GCC AAT 
CTG TAC GCT CTG 
CCC GGT 3' 
5' ACC GGG CAG AGC 
GTA CAG ATT GGC 
CGA 3' 
CYP6Z2(F115W) pB13ompACYP6Z2 5' TCG GCC AAT 
CTG TGG GCT CTG 
CCC GGT 3' 
5' ACC GGG CAG AGC 
CCA CAG ATT GGC 
CGA 3' 
CYP6Z2(F115H) pB13ompACYP6Z2 5' TCG GCC AAT 
CTG CAC GCT CTG 
CCC GGT 3' 
5' ACC GGG CAG AGC 
GTG CAG ATT GGC 
CGA 3' 
CYP6Z3(F115A) pB13ompACYP6Z3 5' GTC GGC CAA 
CCT GGC CGC CCT 
GCC CGG CC 3' 
5' GGC CGG GCA GGG 
CGG CCA GGT TGG 
CCG AC 3' 
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3.2.4 Cloning and expression of CYP6Z1 in JM109 
 
cDNA of CYP6Z1 in pGEM-T easy holding vector was used in the subcloning carried out in 
this experiment. To confirm the gene and plasmid from previous cloning construct, the plasmid 
was digested with EcoRI. This digestion is expected to cut out the gene from the plasmid since 
the vector has two unique EcoRI sites. DNA mini-prep of the gene (prepared as described in 
chapter 4) was then sent for sequencing with information to the sequencing lab, SienceBiolab, 
to use standard primers of T7 promoters (forward and reverse). JM109 ompA-leader sequence 
was directly copied from the JM109 cells being used for the P450 expression. This was done 
by using ompA 2 forward primer with a reverse primer designed to have the reverse of the C-
terminal of ompA leader sequence fused with the reverse sequence of the N-terminal of 
CYP6Z1. The genomes in JM109 cells were used as template in the first PCR reaction. The 
PCR product was ran on agarose to confirm product. Then the product was recovered from the 
gel and purified using Qiagen miniprep kit. The purified product then served as part of the 2
nd
 
PCR. In the 2
nd
 PCR, another reverse primer was designed to have the reverse sequence of the 
C-terminal of CYP6Z1 with EcoR1 site. This reverse primer was then used with ompA forward 
primer in the 2
nd
 PCR comprising the short oligo product from the first PCR and the pGEM-
Teasy plasmid with the cDNA of CYP6Z1 serving as template. The PCR product was run on 
gel and purified and subjected to EcoRI and NdeI digestions (restriction endonuclease 
enzymes). The digested product was then ligated into pB13 plasmid digested with same 
restriction endonuclease enzymes. CYP6Z1 gene was reconstructed in another subcloning 
when this construct was not producing holoprotein. The DNA sequence of CYP6Z1 is shown 
in appendix 16. 
This new construct was made to have a chimera truncation of the N-terminal hydrophobic 
region of the CYP6Z1 by replacing it with the modified N-terminal sequence of CYP6Z2. This 
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was achieved by designing a reverse primer with 21 nucleotides from the end of the 21 amino 
acid residues of the N-terminal of CYP6Z2 fused to the 21 nucleotide of the beginning of the 
22
nd
 amino acid of CYP6Z1 as shown below. ompA forward primer was used with 
pB13CYP6Z2 as template in a PCR reaction to generate oligo having ompA leader with the N-
terminal sequence of CYP6Z2 linked to part of the CYP6Z1 sequence starting from the 22
nd
 
amino acid residue. 
Forward Primer: 5'GGAGGTGCATAGAAAAGACAG 3' 
Reverse Primer: 5'CCCCTGTCGATCCCAGTACGAGTAGATGTAGCGGAGCACGAG  
 
 
The oligo product was ran on agarose gel, confirmed, purified and used as part of the 2
nd
 PCR 
reaction with pGEM-Teasy plasmid holding the cDNA of CYP6Z1 as template, CYP6Z1 
reverse primer and ompA forward primer. The length of the PCR product was confirmed on 
agarose gel, recovered, purified and digested with EcoR1 and Nde1 and then ligated into pB13 
plasmid. The new construct was then sent for sequencing. 
The method for inducing the expression of CYP6Z2 and CYP6Z3 as described in chapter 2 was 
used. Two other expression methods, cold shock induction and heat shock induction were also 
employed. In the cold shock induction, 1µg/ml tetracycline was added alongside IPTG while 
6ml ethanol was added for the induction of the heat shock (Kusano et al., 1999). 
 
 
 
 
N- Terminal CYP6Z2 N- Terminal CYP6Z1 
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3.3 Results 
 
3.3.1 P450 contents of expressed mutant isoforms of CYP6Z2 
 
Functional mutants F115A, F115L, F115Y and F115W were expressed in E.coli (Figure 3.3). 
F115A shows highest peak at 420nm than the rest indicating fast conversion to apoprotein 
(Flanagan et al., 2004). This mutant was later discovered to degrade faster than the other 
mutant isoforms expressed as evidenced by the P450 peak being lost within 3months at -80
o
C.  
The introduction of a charged residue through F115H mutant did not yield P450 peak. 
3.3.2 Specific activities of CYP6Z2 and mutants against resorufin & DEF probes 
 
The fluorescent probes, BR, MR, ER, PR and DEF were used to test the enzyme activities of 
the mutants that expressed P450 peaks. Only F115A isoform had activity with BR (Figure 3.5). 
The BR activity of the mutant F115A was reduced by 13-fold when compared with the wild 
type.  No activity was detected for any of the mutants against the DEF probe. 
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Figure 3.3: Fe
2+
-CO vs Fe 
2+
 difference spectrum of CYP6Z2 and the mutants, F115A, F115L 
and F115Y. The wild type had more intact holoprotein than the mutants. The spectral shift 
observed is because P450 exhibits spectrum between 448 – 452nm (Schenkman and Jansson, 
2006).  
 
 
 
 
 
Figure 3.4: : A- Fe
2+
-CO vs Fe 
2+
 difference spectrum CYP6Z2 and F115A, F115L, and 
F115Y- P450 contents in (µM). The bar-chat of the peaks at 450nm of the wild type and 
mutants to show the quantities of the intact holoprotein expressed for the membrane prepared. 
Expression was carried out at optimised conditions and n=1. 
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Figure 3.5: Specific activities of CYP6Z, F115A, F115L, F115Y and F115W against BR. The 
wild type and mutants that expressed intact holoprotein were tested with P450 probe, BR. Only 
F115A had activity.    
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3.3.3 Optimisation of cytochrome b5 concentration for metabolic assay 
 
Serial dilution of b5 concentrations used with 1pmole of CYP6Z2 and CYP6Z3 indicated that 
ration 1:10 combination of the enzymes produced highest dealkylation of DEF substrate. The 
activity reduced to 40% and 80% in ratio 1:5 for CYP6Z2 and CYP6Z3 respectively. 
 
 
Figure 3.6: Serial dilution of cytochrome b5 concentrations against 1 pmol of P450 in DEF 
dealkylation reaction. CYP6Z3 had higher activity against DEF than CYP6Z2 however they 
both showed similar reaction rates with the increasing concentrations of b5. Highest enzyme 
activity was recorded at ratio 1:10 for the two P450s. 
 
 
 
 
 
 
 
 
 
0 
20 
40 
60 
80 
100 
120 
0.625 1.25 2.5 5 10 
%
 a
ct
iv
it
y 
o
f 
10
 p
m
o
l b
5 
P450:b5 ratio (1:b5) 
CYP6Z2 
CYP6Z3 
87 
 
3.3.4 Comparison of specific activities of wild type CYP6Z2 and wild type CP6Z3 with 
resorufin probes and DEF with and without cytochrome b5 
 
CYP6Z2 and CYP6Z3 retained their preference for the phenolic derivatives of resorufin. 
However, activities of CYP6Z3 against the four resorufin probes were higher when compared 
with CYP6Z2 (Table 3.2). 
Table 3.2: Comparison of dealkylation of resorufin probes between CYP6Z3 and CYP6Z2 
 
 
 
 
 
 
 
 
(Mean±SE, n=2) 
 
The effect of cytochrome b5 was on BR activity was examined. The addition of cytochrome b5 
did not have any effect on the activities of either CYP6Z2 or CYP6Z3 to dealkylate  BR (Table 
3.3). 
 
  
 
 
 
 
                                CYP6Z2 
pmol/min/pmol P450 
CYP6Z3 
pmol/min/pmol P450 
Increase  
BR 
MR 
ER 
PR 
5.46±0.27 
2.52±0.016 
0.23±0.003 
0.033±0.0005 
25.19±1.3 
18.46±0.63 
1.9±0.033 
0.098±0.013 
4.6-fold 
7.3-fold 
8.2-fold 
3-fold 
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Figure 3.7: Effect of b5 on P450 activity. Bar chat of specific activities of CYP6Z3 and 
CYP6Z2 against BR with or without b5. The presence of b5 did not have noticeable effect in 
both dealkylation reactions. 
 
Table 3.3: Specific activities of CYP6Z3 and CYP6Z2 against BR with or without b5 
Enzyme                                 Without b5 
pmol/min/pmol P450 
b5 
pmol/min/pmol P450 
CYP6Z2  
CYP6Z3                        
7.24±0.32 
23.73±0.10 
7.61±1.51 
25.73±1.36 
 (Mean±SE, n=2) 
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However, the addition of cytochrome b5 increased the activities of both enzymes when DEF                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
was used as a substrate. The activity of CYP6Z2 was increased by 3.5-fold while CYP6Z3’s 
activity was increased by 1.8-fold as shown below. 
 
 
 
 
 
 
 
Figure 3.8: The influence of cytochrome b5 on the specific activity of CYP6Z3 and CYP6Z2 
against DEF, with or without b5 investigating effect of addition of cytochrome b5 to the 
reactions 
 
Table 3.4: Specific activities of CYP6Z3 and CYP6Z2 against DEF with or without b5 
Enzyme                                 Without b5 
RFU/min/pmol P450 
b5 
RFU/min/pmol P450 
Increase 
CYP6Z2  
CYP6Z3                        
320.7± 12.00 
1,310±1.35 
1,134±13.15 
2,411±21.30 
3.5-fold 
1.8-fold 
 (Mean±SE, n=2) 
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3.3.5 Comparing kinetic parameters of CYP6Z2 and CYP6Z3  
 
The kinetic parameters of CYP6Z2 and CYP6Z3 were examined and compared using BR and 
MR.   Both enzymes maintained their preference for BR. CYP6Z3 achieved 2-fold activity and 
7-fold efficiency in dealkylation for BR and MR respectively. CYP6Z2 had 8-fold activity and 
14- fold efficiency against BR and MR respectively 
Overall CYP6Z3 proved to be more active and more efficient than CYP6Z2. It had 2-fold 
turnover rate and 5-fold higher enzyme effectiveness than CYP6Z2 in the dealkylation of BR, 
and 8-fold and 10-fold in turnover rate and efficiency respectively for MR. 
. 
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Figure 3.9: Michaelis-Menten plot of CYP6Z3 & CYP6Z2 -BR kinetics. CYP6Z3 showed 
higher turnover number and affinity for BR than CYP6Z2. The curve was generated using 
Graphpad Prism 5 software. R
2 
for the curve fitting are 0.99 and 0.95 for CYP6Z3 and 
CYP6Z2 respectively. 
 
 
Table 3.5: Kinetic parameters of BR dealkylation by CYP6Z3 and CYP6Z2. 
 
 
 
 
 (Mean±SE, n=2) 
 
 
 
 
Enzyme                                 KM
(µM) 
Kcat 
(min
-1
) 
Kcat/ KM 
(min
-1
 µM
-1
) 
CYP6Z2 
CYP6Z3                        
0.68±0.069 
0.28±0.056
8.62±0.35 
18.70±1.17 
12.72 
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Figure 3.10: Michaelis-Menten plot of CYP6Z3 & CYP6Z2 -MR kinetics. CYP6Z3 showed 
higher turnover number and affinity for MR than CYP6Z2. The curve was generated using 
Graphpad Prism 5 software. R
2 
for the curve fitting are 0.99 and 0.99 for CYP6Z3 and 
CYP6Z2 respectively. 
 
 
 
Table 3.6: Kinetic parameters for MR dealkylation of CYP6Z2 and CYP6Z3  
 
 
 
(Mean±SE, n=2) 
 
 
 
 
Enzyme                                 KM  
 (µM)  
Kcat 
(min
-1
) 
Kcat/ KM  
      (min
-1
 µM
-1
)  
CYP6Z2 
CYP6Z3                        
1.07±0.15 
0.84±0.11 
0.97±0.06 
7.75±0.43 
0.9 
9.22 
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3.3.6 Thermostability of CYP6Z2, CYP6Z3 and CYP6P3 compared 
 
The thermostability of the three enzymes was tested using DEF.  CYP6Z3 was most stable, 
maintaining 100% of its activity until 55
o
C. CYP6Z2 had lost 70% of its activity at same 55
o
C 
and CYP6P3 was no more active at this temperature just above 40
 o
C.  
 
Figure 3.11: Thermostability of CYP6Z2, CYP6Z3 and CYP6P3 compared as a percentage of 
activity against DEF at 25
o
C. CYP6Z3 had highest thermostability and CYP6P3 the least. 
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3.3.7 Pyrethroid insecticides metabolic profiles of CYP6Z2 and CYP6Z3 compared with 
CYP6P3 
The abilities of the two isoforms to metabolise pyrethroid insecticides were examined side by 
side with CYP6P3, a known pyrethroid metaboliser (Müller et al., 2008). 
CYP6Z3 was able to achieve 50% of the metabolic activities of CYP6P3 in depleting 
pyrethroid insecticides. It also showed 100% depletion of pyriproxyfen, a pyridine-based 
pesticide. 
Table 3.7: Insecticide metabolic activities of CYP6Z3 and CYP6Z2 compared with CYP6P3 
as control 
Insecticide                                 CYP6Z2 
% depletion 
CYP6Z3 
% depletion 
CYP6P3 
% depletion 
Deltamethrin  
Permethrin- Cis                         
Permethrin -Trans                    
Cypermethrin  
Pyriproxyfen  
13.22±4.25 
11.50±0.85 
5.98±1.17 
5.31±1.77 
- 
58.61±2.56 
55.79±1.49 
25.52±2.66 
40.99±1.36 
100±0 
100 
100 
100 
75.4±12.78 
59.29±5.66 
         % depletion of substrate (Mean±SE, n=3) 
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3.3.8 Effect of mutating F115 on the kinetic parameters of CYP6Z2 and CYP6Z3 
 
The two P450 isoforms, CYP6Z2 and CYP6Z3, were mutated to their F115A mutant isoforms. 
The DNA sequence confirmation of CYP 6 Z3 F115A is shown in appendix 17. The mutation 
was done at this position to further establish that the aromatic residue close to the haem may be 
involved in the stability of the formation of the activated oxygen (compound 1) used by P450s 
for catalytic activities. 
The turnover numbers of the mutants were reduced significantly when compared with the wild 
types. CYP6Z2 (F115A) activity was reduced 2.3-fold and CYP6Z3 (F115A) 19.7-fold 
compared with the wild types.  The efficiency of CYP6Z2 (F115A) was reduced by 14-fold 
and CYP6Z3(F115A) by 50-fold when compared with the wild type in BR dealkylation 
reaction (Table 3.8). 
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Figure 3.12: Michaelis-Menten plots: A- CYP6Z2 and CYP6Z2 (F115A), B- CYP6Z3 and 
CYP6Z3 (F115A). -BR kinetics. Substitutions of phenylalanine in both enzymes reduced the 
turnover rates of the enzymes. The curves were generated using Graphpad Prism 5 software. R
2 
for the curve fitting are 0.99 and 0.99 for CYP6Z2 and CYP6Z2 (F115A) respectively and 0.96 
and 0.95 for CYP6Z3 and CYP6Z3 (F115A) respectively. 
 
Table 3.8: Kinetic parameters for BR dealkylation of CYP6Z2, CYP6P6Z2 (F115A), CYP6Z3 
and CYP6Z3 (F115A) 
Enzyme                                 KM 
(µM) 
Kcat 
(min
-1
) 
Kcat/ KM 
(min
-1
 µM
-1
) 
CYP6Z2 
CYP6Z2(F115A) 
CYP6Z3 
CYP6Z3(F115A)                        
0.35±0.038 
2.078±0.20 
0.28±0.05 
0.67±0.14 
9.99±0.37 
4.311±0.25 
18.70±1.18 
0.91±0.07 
28.54 
2.07 
67 
1.34 
         (Mean±SE) 
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3.3.9 Effect of mutating F115 on pyrethroid insecticide metabolic profiles of CYP6Z3 
 
The effect of the loss of activity with the mutation at F115 was also tested in the ability of 
CYP6Z3 in retaining its metabolic profiles of pyrethroid insecticides. The results show that the 
mutant lost 44-fold of its activity against deltamethrin and 16-fold against cypermethrin, type-2 
pyrethroids. While the mutant recorded 3.6-fold lost in activity against permenthrin, a type-1 
pyrethroid. 
Table 3.9: Metabolic assay with pyrethroid insecticides 
Insecticide                                 CYP6Z3 
% depletion 
F115A 
% depletion 
Reduction 
Deltamethrin  
Permethrin- Cis                         
Permethrin -Trans                    
Cypermethrin  
62.74 
55.79±1.49 
25.52±2.66 
40.99±1.36 
1.40±0.85 
15.10±0.98 
7.52±3.81 
2.50±1.10 
44-fold 
3.6-fold 
3.4-fold 
16-fold 
 % depletion of substrate (Mean±SE, n=3) 
 
 
 
 
 
 
 
 
 
 
 
98 
 
3.3.10 Comparison of the thermostability of mutant CYP6Z3 (F115A), CYP6Z2 (Y102F), 
CYP6Z2 (F212L) and CYP6Z2 (R210A)  
 
The thermostability of CYP6Z3 (F115A) and the wild type was investigated and compared 
with the thermostability of mutations created at other positions on CYP6Z2. This was done to 
further investigate if the phenylalanine 4Å to the haem is contributing to the stability of the 
activated oxygen. The phenylalanine mutation at other positions away from the haem is not 
expected to have effect on the thermostability of the mutants. There was a visible 5
o
C shift to 
the left in the stability of the enzyme when Phe
115
 was mutated to alanine. This stability shift 
was not observed in the other mutations created away from the haem as illustrated below: 
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Figure 3.13: Thermostability assay of: A- CYP6Z3 and mutant F115A. B- CYP6Z2 and 
mutants Y102F ,F212L. C- CYP6Z2 and mutant R210A. Y axis computed as a percentage of 
the reaction activity of each enzyme against BR at 25
o
C. 
 
 
 
 
 
 
 
-20 
0 
20 
40 
60 
80 
100 
120 
140 
25 35 40 45 50 55 60 65 70 
%
 o
f 
2
5
o
C
 
Thermostability assay (oC) 
CYP6Z3 
CYP6Z3(F115A) 
-20 
0 
20 
40 
60 
80 
100 
120 
140 
25 35 40 45 50 55 60 65 70 
%
 o
f 
2
5
o
C
 
Thermostability assay (oC) 
CYP6Z2 
Y102F 
F212L 
 
-20 
0 
20 
40 
60 
80 
100 
120 
25 35 40 45 50 55 60 65 70 
%
 o
f 
2
5
o
C
 
Thermostability assay (oC) 
CYP6Z2 
CYP6Z2(R210A) 
100 
 
3.4 Discussion 
 
CYP6Z1 from An. gambiae was expressed successfully in Sf9 insect cells and was confirmed 
as a DDT metaboliser (Chiu et al., 2008). However, the ability of the enzyme to metabolise 
pyrethroid insecticides have not been documented. This may be due to the fact that 
heterologous expression of the enzyme in E.coli has been difficult. CYP6Z1 shares 69% 
primary structural similarity with both CYP6Z2 and CYP6Z3. CYP6Z2 was successfully 
expressed in E. coli but only after,  the cDNA was modified by changing the second amino acid 
codon from phenylalanine to alanine and making the subsequent seven amino acids AT rich by 
“silent” mutagenesis (McLaughlin et al., 2008). The modified cDNA subcloned into the 
expression vector, pB13, yielded holoprotein and the enzyme’s substrates and inhibitors have 
been characterised (McLaughlin et al., 2008).  The only modification made to CYP6Z3 used in 
this experiment was the change of the second amino acid from phenyalanine to alanine and was 
successfully expressed in E. coli using pB13 plasmid. However, similar efforts made with 
CYP6Z1 did not produce holoprotein even when N-terminal chimera of the modified sequence 
of CYP6Z2 was created. The wild type ompACYP6Z1 and the CYP6Z2-N-terminal chimera 
variant were also induced under cold shock response (this involves translational regulation), 
using tetracycline selection, and heat shock response (associated with protein folding through 
molecular chaperons), using ethanol, but none produced holoprotein.  
These methods were used successfully to express “recalcitrant” P450 cDNAs (Kusano et al., 
1999). CYP6Z1 may be more different from the other two isoforms at the translational level 
and its amino acids assembling may be facing codon usage bias when expressed in E.coli. 
Expressing the gene in a bacterial strain fortified with plasmids expressing the rare tRNAs, or 
in a yeast host, may improve the protein expression prospects. 
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Both CYP6Z2 and CYP6Z3 expressed in this thesis shared the same metabolic behaviour with 
the fluorescent probes used in the characterisation of An. gambiae CYP6Z2 with its inhibitors 
and substrates (McLaughlin et al., 2008). The two isoforms do not need cytochrome b5 in the 
dealkylation reactions with the resorufin probes and both have their activity enhanced 
significantly with cytochrome b5 in the dealkylation of DEF. However, CYP6Z3 has higher 
activity, is more thermostable and indicated higher metabolic activity against pyrethroids than 
CYP6Z2. Although CYP6Z2 shares 94% identity with CYP6Z3, the differences in the amino 
acid residues starts at SRS 2 with 2 out of 7 amino acids similar. SRS 2 is involved in the 
substrate access (Schuler and Berenbaum, 2013) and affects the entry and exit of substrate.  
Phe
115
, is conserved in these three isoforms and predicted by homology modelling to be close 
to the haem (Chiu et al., 2008). P450s have relatively high proportions of occurrence of 
phenyalanine at the active site as part of the hydrophobic core. CYP3A4 has a unique 7 
phenylalanine-cluster, with five of them involved in “closing of the roof” of the active site 
above the haem (Yano et al., 2004). In human CYP2D6, Phe
481, 483  
, located in the β1-4 loop 
and Phe
120
 in B'-C loop were described to have a concerted or individual role for the phenolic 
group in ligand orientation (Flanagan et al., 2004). Phe
120
 in human CYP2D6 was mutated to 
F120A, F120L, F120H and F120S by Flanagan et al to investigate its role in substrate binding 
and catalysis. All these mutants created via SDM expressed holoenzymes, including the mutant 
to histidine residue and their kinetic parameters with bufuralol established. (Flanagan et al., 
2004). However, similar mutations in CYP6Z2 at F115 to F115A, F115L, F115Y, F115W and 
F115H produced holoprotein except for F115H.  However, only F115A, a neutral substitution 
both in terms of steric and charge effects, was able to show activity against resorufin probes. 
F115L, F115Y and F115W (Figure 3.4) expressed stable holoprotein but did not have activity 
against the resorufin probes (Figure 3.5). Similar mutation on CYP6Z2 (F212L) gave activity 
against resorufin probe and CYP6P3 (F110Y) was still able to metabolise pyrethroid 
102 
 
insecticides as shown in chapter 2. Residue F212 in CYP6Z2 and residue F110 in CYP6P3 are 
at their respective active sites and are 12.1Å and 13.4Å away from the porphyrin of the haem 
(Figure 3.2). The Phe
115
 in CYP6Z2 was suggested to be involved in substrate positioning for 
catalysis (Alexia et al., 2013), this study has however revealed that this residue may be 
involved in stabilising the coupling of the oxygen on the haem-iron for catalysis to occur 
because of its proximity to the porphyrin of the haem. The porphyrin is important in the 
activation of the oxygen on the haem iron by donating electron for the O-O cleavage and the 
resultant formation of the active iron oxide complex known as compound 1 (Dolphin et al., 
1997, Goh and Nam, 1999, Stillman, 2000). Phe
115
 is 4.1Å close to the haem (Figure 3.1) and 
its π-electrons may be contributing to the stability of compound 1. This may be the reason why 
mutants F115L, F115Y and F115W could not dealkylate the probes because there may be 
uncoupling of the oxygen at the catalytic cycle. The same mutation created in CYP6Z3 
(F115A) supported this argument with the lost in activity of this mutant against pyrethroids 
when compared with the wild type. Further experiments to examine the presence of peroxide or 
superoxide anion (both products of uncoupling events) in F115L, F115L, F115W dealkylation 
reaction is however required to ascertain which of the shunt is at play in the uncoupling events. 
The shift in the thermostability of the mutants is also an indication of the stability role being 
played by Phe
115
.  
 
 
 
 
 
 
 
103 
 
Chapter 4 
 
4  Establishing suitable expression and purification methods for full length 5xHis-
tagged CYP6Z2 & the N-terminal truncated isoforms 
4.1 Introduction 
 
Insecticide resistance conferred on insects, especially mosquitoes, by P450s is increasingly 
threatening the gains made from vector control programs (Hemingway and Ranson, 2000). The 
WHO report of 2013 established that over 3.4 billion people are at risk of becoming infected 
with the malaria parasite transmitted by mosquitoes (World Health Organization, 2013). This 
potential loss of lives has been the driving force in efforts to understand the structural basis of 
those P450s responsible for the resistances of the insecticides approved to be used by WHO. 
However, no crystal structure of insect P450 has been solved to date and the knowledge of the 
molecular structure of the insect P450s have only been possible through homology modelling 
(Jones et al., 2010, Karunker et al., 2009, Lertkiatmongkol et al., 2011). Conversely, in silico 
homology modelling study is at best an explanatory tool rather than predictive tool (Szklarz et 
al., 1995).  Although, the sequence of the side chains thought to constitute the active site 
conformation of P450s are well conserved,  the spatial relationships of the residues of known 
crystal structures varies (Podust et al., 2001). These variations underscore the importance of a 
definitive crystal structure of a representative P450 from each family for better understanding 
of the structure- function of this enzyme class  (Scott et al., 2001). 
 
P450s in eukaryotes are membrane bound enzymes and their heterologous expression in E. coli  
typically results in low yields,  because E. coli does not have an internal membrane system 
appropriate to accommodate  the large microsomal recombinant proteins being expressed (Li 
and Chiang, 1991). More importantly is the effect of the dominant hydrophobic N-terminal 
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signal domain of eukaryotic P450s on the solubility of the expressed recombinant protein 
(Sagara et al., 1993).  
The first P450 to be purified in quantities sufficient for crystallisation trials was camphor P450 
from Pseudomonas putida (Poulos et al., 1987). The lack of an N-terminal trans-membrane 
region in prokaryotes is thought to be a key factor in increasing their solubility in cytosol and 
P450BM3 was also crystallised 6 years after P450CAM (Ravichandran et al., 1993). More 
prokaryotic P450 crystal structures have been subsequently determined and they have provided 
useful templates on which molecular models of eukaryotic P450s were created, until the first 
eukaryotic crystal structure was published (Scott et al., 2001). The latter was in large part made 
possible by modifications of the N-terminal trans-membrane region. 
The first mammalian P450 to be crystallised was rabbit CYP2C5 (Poulos and Johnson, 2005). 
The authors deleted the N-terminal trans-membrane domain and created a chimeric enzyme 
that contains amino acid substitutions from CYP2C3. These substitutions were known to 
convert CYP2C5 to a monomer in high salt buffers (Cosme and Johnson, 2000). N-terminal 
truncations of CYP2C3 and CYP2C5 alone produced dimers and tetramers respectively in high 
salt buffers without the use of detergent (von Wachenfeldt et al., 1997). This engineering of the 
N-terminal deletions and modifications have made it possible for more eukaryotic P450s, in 
sub families 2B, 2C and 3A, to be crystallised (Schoch et al., 2004, Scott et al., 2003, Wester et 
al., 2003, Williams et al., 2004, Williams et al., 2003, Yano et al., 2004). However, deletion of 
N-terminal trans-membrane sequence in CYP2C1 did not produce a properly folded P450 (Hsu 
et al., 1993) and truncated CYP2D6 was expressed in a multimeric form in the absence of 
detergent (Kempf et al., 1995). Improvements have been observed in the expression of N-
terminal trans-membrane truncated isomers of CYP2B subfamily through additional 
modification, including the insertion of positively charged amino acids at the N-terminus. 
However the holoprotein expressed formed large aggregates and only achieved 100% 
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monomeric status in the presence of 0.25% cholate (Scott et al., 2001). Human CYP3A4 
however was successfully crystallised with just the deletion of the N-terminal domain without 
any further modifications (Yano et al., 2004).  
The aim in this chapter is to develop expression and purification methods for the full length 
CYP6Z2 with 5 histidines attached to the C-terminal to aid purification by affinity 
chromatography, and to examine the effect of truncating the N-terminal trans-membrane 
sequence on the folding and expression of the truncated isomers.  
The full length 5xHis-tagged CYP6Z2 and two N-terminal truncations of this full length, by 11 
and 22 amino acids independently, were used in this experiment. While the full length 
expressed as holoprotein, the two truncated isoforms expressed as apoprotein. 
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4.2 Materials & Methods 
4.2.1   Transformation and plasmid preparation and analysis 
 
The nucleotide sequence of the construct pB13, expressing His-tagged CYP6Z2 was obtained 
to confirm its authenticity. pB13 is a modified form of pCW Ori (Barnes et al., 1991). 
Competent DH5α cells, (CaCl2 method) were transformed with the plasmid by the heat shock 
method.  The transformed cells were then spread on agar plates containing 100 µg/ml 
ampicillin and incubated at 37°C overnight. A colony was picked and inoculated in 3.5 ml LB 
medium with 100µg/ml ampicillin overnight at 37°C. A glycerol stock of 800 µl of incubated 
culture and 200 µl of glycerol was prepared and stored at -80°C. The remaining culture was 
used to prepare plasmid DNA using a Qiagen miniprep kit. The plasmid extracted was 
subjected to single and double restriction digestions using EcoRI and NdeI and the products 
examined on a 1% agarose gel electrophoresis to confirm the predicted sizes.  
4.2.2 Primer design for pB13 insert sequencing   
 
Three oligonucleotides were designed and synthesised as sequencing primers for the gene 
cloned into pB13. The forward and reverse primers were complementary to pB13 DNA 
sequences approximately 100 bases flanking on both sides of the multiple cloning regions. The 
middle primer was complementary to the centre of the CYP6Z2 gene. These primers were used 
to confirm the DNA sequences of all genes cloned into pB13 used in this project, using the 
Corefacility Centre, Medical School, Sheffield. 
Sequencing Primers: 
Forward: 5' ACA GGA TCA GCT TAC TCC CC 3' 
Reverse:  5' CGT ATC ACG AGG CCC TTT CG 3' 
Middle:  5' GCC GTG CTA ATC GGG GAC GC 3'  
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4.2.3 Modification to the histidine sequence attached to the CYP6Z2 gene. 
 
Nucleotides encoding the run of 5 histidines were identified from the sequencing data, attached 
in frame, downstream of the 3' end of the CYP6Z2 cDNA. However, there was an 
unintentional addition of a base pair after the fifth histidine codon which would cause a shift of 
the stop codon during protein expression. Therefore, the gene was further modified with the 
following mutagenic primers to delete the unwanted base pair. 
Mutagenic primers for modification: 
Forward: 5' CAT CAC CAT CAC CAT TGA GAA TTC CCG GG 3' 
Reverse: 5' CCC GGG AAT TCT CAA TGG TGA TGG TGA TG 3' 
 
4.2.4 SDM procedure for the plasmid modification 
 
The single mutagenic reverse primer SDM method (Vallette et al., 1989) was used to effect this 
reversion because the required SDM position has 7 nucleotides complementary to 2 other 
locations in pB13. In this method the mutagenic reverse primer, the forward primer, from the 
sequencing primer, and the His-tagged CYP6Z2, as template, were all used for the first PCR. 
The PCR product was then digested since the reverse primer has an EcoRI site at the 3' end and 
the forward primer generated the NdeI at the 5' end. The digested product was then ligated into 
a similarly digested product of pB13. 
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4.2.5  Construction and cloning of truncated versions of 5xHis-tagged CYP6Z2 
 
Table 4.1: Primers and template for the creation of truncated 5xHis-tagged CYP6Z2 isomers  
 Template Forward primer Reverse primer Amino acids 
deleted 
5xHis-tagged 
CYP6Z2Δ3-25 
 
5xHis-tagged 
CYP6Z2 
5' CAT ATG 
GCT GGA CTT 
CCT CAT CTA 
AAG CCA GA 
3' 
5' CCC GGG 
AAT TCT CAA 
TGG TGA TGG 
TGA TG 3' 
23 
5xHis-tagged 
CYP6Z2Δ3-
13(5H) 
 
5xHis-tagged 
CYP6Z2 
5' CAT ATG 
GCT TTT CTC 
GTG CTC CGC 
TAC ATC TA 3' 
5' CCC GGG 
AAT TCT CAA 
TGG TGA TGG 
TGA TG 3' 
 
11 
The start codon and the second amino acid codon are mutated to alanine codons to increase 
expression, were retained in the truncated isomers as highlighted.  
 
 
The PCR for the generation of truncated mutants was carried out using Phusion High Fidelity 
Polymerase as described in appendix 3. The PCR product was purified and excised from a 1% 
agrose gel using a Qiagen gel extraction kit. The purified product and pB13CYP6Z2 were 
digested with EcoR1 and Nde1 to produce compatible flanking ends on both the truncated PCR 
products and digested pB13. The mixtures, after incubation at 37
o
C for 1 hour, were ran and 
excised from a 1% agarose gel and the key bands purified as above and then ligated using T4 
ligase enzyme. DH5α competent cells were transformed with the ligation mixture and the 
recovered plasmids were sent for sequencing. 
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4.2.6  Expression of the full length 5xHis-tagged CYP6Z2 and the truncated isomers 
A modified form of the  protocols for expression and purification of CYP2B subfamily (Scott 
et al., 2001) were utilised in this experiment.  
The confirmed plasmids were used to transform E.coli JM109 K made competent with 
transformation buffer 1, (prepared with 100 mM RbCl, 50 mM MnCl2, 30 mM potassium 
acetate, 10 mM CaCl2, 15% glycerol, pH adjusted to 5.8 with acetic acid) and transfer buffer 2, 
(prepared with 10 mM MOPS, 10 mM RbCl, 75 mM CaCl2, 15% glycerol, pH adjusted to 6.8 
with KOH) using the heat shock method of transformation. A single colony from the 
transformation plate was used to inoculate a 20 ml LB supplemented with 100 µg/ml ampicillin 
and incubated at 37°C overnight. Then, 15 ml of the overnight culture was used to inoculate 
250 ml of terrific broth supplemented with 100 µg/ml ampicillin, which was then grown to an 
OD600 of 1–1.5 at 37°C (Scott et al., 2001). Expression was induced by adding IPTG to 1 mM. 
ALA was added to 80 mg/l as a precursor for haem synthesis. Imidazole was added to 5 mM at 
the time of induction to stabilize the holoprotein. The culture was grown for additional 24 
hours at 30°C with shaking at 120 RPM. The cells were harvested by spinning at 5000 RPM 
for 15 minutes at 4°C with a JA-14 fixed angle rotor in a Beckman JA-21 centrifuge.  
4.2.1  Affinity chromatography and purification of full length 5xHis-tagged CYP6Z2  
Purification was performed at 4°C. Cell pellets were re-suspended in 500 mM potassium 
phosphate, 10% glycerol, 10 mM β-mercaptoethanol (βME) with 0.4% sodium cholate, pH7.4 
and homogenised using a hand homogeniser. The homogenate was then sonicated for 30 
seconds and 45 seconds  cooling on ice three times, followed by centrifugation for 35minutes 
at 31,000 RPM (113,000 x g) using a fixed-angle Ti 50.2 rotor in a Beckman Ultracentrifuge. 
The supernatant was applied to a Ni
2+
-NTA column previously equilibrated with 500 mM 
potassium phosphate, 10% glycerol 10 mM βME with 0.4% sodium cholate at pH 7.4. The 
column was washed with the following buffers: (1) 500 mM buffer A with 0.1% sodium 
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cholate, (2) 10 mM buffer (A) with 20 mM imidazole, and (3) 10 mM buffer (A) with 40 mM 
imidazole. The protein was eluted with 10 mM buffer (A) plus 500 mM imidazole. 0.5M NaCl 
was added to the elution buffer (buffer (A): potassium phosphate, 10% glycerol, and 10mM β-
ME). All the fractions collected were run on SDS-PAGE and were subsequently analysed by 
Western Blotting. 
4.2.2 Ion exchange purification of the partially purified full length 5xHis-tagged CYP6Z2 
The DNA sequence of the CYP6Z2(5H) was translated into its ORF in order to calculate its 
Isoelectric Point(pI), which is the pH at which full length 5xHis-tagged CYP6Z2 carries no net 
charge. Online ExPASy - Compute pI/Mw tool was used. The pI was 8.04 and at working pH 
of 7.4 the protein is expected to have net positive charge. Both cationic and anionic ion 
exchange, SP Sepharose and Q Sepharose respectively were used to further purify the 
expressed full length 5xHis-tagged CYP6Z2. 
4.2.3 SDS-PAGE analysis 
In this experiment, 10% SDS- PAGE resolving gel was used by preparing 3.3 ml of 30% 
acrylamide solution, 2.5 ml of resolving gel buffer (1.5 M Tris plus 0.4% SDS, pH 8.8) 4 ml 
distilled water, 10 µl TEMED and 200 µl of 10% ammonium persulphate. The stacking gel was 
prepared using 1 ml 30% acrylamide solution, 1.5 ml stacking buffer (0.5 M Tris plus 0.4% 
SDS pH 6.8), 3.4 ml water, 10 µl TEMED and 100 µl of 10% ammonium persulphate. The gel 
was ran with running buffer (25 mM tris base, 250 mM glycine and 0.1% SDS) for the first 
10min at 80V to allow the sample stack properly and then the voltage increased to 100 Volts 
for another 60minutes. Standard Protein Ladder was run with the samples. The SDS gel was 
either stained using Coomassie staining solution or used for immunoblotting. 
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4.2.4 Immunobloting 
Nitrocellulose membrane was cut to the size of the gel and packed into the immunoblotting 
cassette with absorbent papers, filter pads, all previously soaked in the transfer/running buffer, 
Towbin Transfer Buffer (25 mM tris base, 192 mM glycine, 20% methanol). The cassette was 
then loaded into the immunobloting tank and ran for 90 minutes at 200 mA. The nitrocellulose 
paper with the transferred samples from the SDS gel was first rinsed in phosphate buffer saline, 
PBS, (80 mM di-sodium hydrogen orthophosphate, 20 mM sodium di-hydrogen 
orthophosphate and 100 mM NaCl) and then blocked with 1% BSA in T-PBS (0.1% tween-20 
in PBS prepared) at room temperature for 1hour. The BSA blocked nitrocellulose membrane 
was then rinsed in T-PBS for 5minutes and then incubated for another 1hour with the antibody, 
Hisprobe-HRP in 1% BSA in T-PBS buffer. HisProbe-HRP is a nickel (Ni
2+
)-activated 
derivative of horseradish peroxidase (HRP) that enables direct detection of His-tagged proteins 
and other histidine-rich proteins in western blots. After the incubation the membrane was 
rinsed with T-PBS first and then PBS to remove the tween detergent. ECL kit reagent 
(Amersham ECL Prime Western Blotting Detection Reagent (GE-Healthcare) was then used to 
develop the probe for capturing in the dark room on the developing machine.  
4.2.5 Bradford total protein quantification 
Bradford reagent from BioRad protein assay solution was used to quantify the total protein 
content. The method is based on Coomassie blue G-250: the solution is red-brown in its acidic 
solution when not bound to protein. However, when proteins bind to the dye, the pKa of the 
dye shifts causing the dye to become blue and then measured at 595 nm (Bradford, 1976). 
Protein standard curve was prepared using known concentrations of prepared BSA and the 
quantity of the protein samples derived from the standard curve (Appendix 18). The samples 
were diluted in 100-fold dilution to fit into the curve. 
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4.2.6 P450 quantification of the full length 5xHis-tagged CYP6Z2 expressed 
Quantification of the expressed P450 was carried out as described in chapter 2.  
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4.3 Results 
 
4.3.1 Confirmation of Insert and Plasmid 
 
The plasmid pB13 5xHis-tagged CYP6Z2 is a variant of the gene cloned and described by 
Mclaughlin et al. (McLaughlin et al., 2008). However, this clone variant did not have the 
bacteria ompA leader sequence. The CYP6Z2 insert is flanked at the 5' end by Nde1 and at the 
3' with EcoRI. It has total length of 1.5kbp and the pB13 5kbp as shown below in the 1% 
agarose gel confirming the plasmid and the insert. 
 
 
 
 
 
Figure 4.1:  1% agarose gel image of the digested sample with standard DNA markers for size 
confirmation. Lane1 is hypperladder1, lane 2 is EcoR1 digestion, lane 3 is EcoR1 and Nde1 
digestions, showing the CYP6Z2 cut out of pB13. The insert is 1.5k bp while the pB13 plasmid 
is 5k bp. 
 
 
 
 
 
1 2 3 
1.5k bp 
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4.3.2 Expressed full Length 5xHis-tagged CYP6Z2 and the truncated isoforms 
 
The yield of P450 holoenzyme expression was monitored under a range of growth conditions. 
Expression of the full length at 25
o
C with shaking at 150 RPM yielded 33.18 nmol/l culture of 
P450 after 24 hours of incubation. The quantity increased by 3.9-fold at 48hrs but the 
expressed P450 was lost at 72hours. The truncated isoforms did not give properly folded 
protein in all of these experimental conditions used. 
Cells of the full length grown at 30
o
C and shaking at 200 RPM yielded 146.7 nmol/l culture of 
P450 after 24 hours incubation but this was progressively lost by 1.2-fold after 48hours and by 
1.5-fold at 72 hours. The third set of growth conditions at 30
o
C and shaking at 120 RPM gave 
119.12 nmol/l culture of P450 after incubation for 24 hours and progressively increased by 2.6-
fold at 48 hours and 5.3-fold at 72 hours (Figure 4.2) 
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Figure 4.2: The P450 yield at different incubation temperature, shaking and time. The yield at 
30
o
C and shaking at lower speed was highest and seems the best condition for JM109 E. coli 
cells in expressing the P450 and for the formation of the thiolate bond needed in the formation 
of properly folded CYP6Z2. 
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The expressed full length CYP6Z2 yielded P450 holoenzyme and also showed peak at 420nm, 
indicating degradation of the enzyme being expressed. The two truncated isomers however, did 
not produce P450 peak. The peak at 420nm also indicated that the truncated enzymes had very 
low expression when the Soret bands at 420nm were compared with that of the full length 
(Figure 4.3). The full length produced P450 content of 0.598 nmol/ml of total protein 
expressed. 
 
 
 
 
 
Figure 4.3: Fe
2+-
CO vs Fe 
2+
 difference spectrum of the full length 5xHis-tagged CYP6Z2 and 
the truncated isoforms, CYP6Z2(Δ3-13) & CYP6Z2(Δ3-25) showing the P450 & P420 folding 
patterns. The truncated isozymes did not fold properly. 
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4.3.3 SDS-PAGE and immunoblotting of expressed 5xHis-tagged CYP6Z2 
 
The expressed full length CYP6Z2 was loaded on two SDS-PAGE. One was stained with 
Coomasie staining solution and the other used for the immunobloting assay to confirm 
distributions and purity of the expressed protein in the various purification steps. CYP6Z2 is 
approximately 56 kDa. 
 
 
Figure 4.4: The SDS-PAGE of the expressed CYP6Z2 stained with coomassie blue dye. The 
lanes are; protein ladder (L), whole cell lysate (WC), 1
st
 washing step with 0.1% sodium 
cholate (W1), 2
nd
 washing step with 20mM imidazole (W2), 3
rd
 washing step with 40mM 
imidazole (W3), and eluted fraction with 500mM imidazole (EL)  
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Figure 4.5: SDS-PAGE stained with coomassie blue dye (A) and western blot (B) of the 
purified CYP6Z2 on affinity chromatography and further purification on SP sepharose. The 
protein ladder is in lane 1(L), Ni-NTA affinity column (Ni) and SP sepharose colmun (SP). The 
protein is seen here to be 90% pure with the ion exchange used to further purify it after affinity 
chromatography.  
 
The final purified sample yielded 1.57 mg/ml of protein, quantified with Bradford reagent 
using BSA standard curve. The P450 content of the purified full length 5xHis-tagged CYP6Z2 
is therefore 0.38 nmol P450/mg protein. 
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4.4 Discussion 
 
The relatively high hydrophobic nature of P450s, especially at the N-terminal region, was a 
great concern in designing strategies for expressing and purifying CYP6Z2 in E.coli. The N-
terminus has been shown to interact with the bacterial membrane and rendering the P450 less 
soluble in cytosolic extracts (Scott et al., 2001). Therefore various protocols for overcoming 
these problems with expression of soluble P450 were investigated.  
The level of expression was very low when, ALA, the haem precursor, was omitted and only 
iron was added to the LB. A protocol used by Modi et al. using 20mM Tris buffer, 2mM 
CHAP detergent and ALA to purify CYP2D6 (Modi et al., 1996), improved yield of the 
protein, but the expressed protein failed to  bind to a  Nickel NTA column as expected. At this 
point β-mercaptoethanol (βME) and urea were added separately to the impure fraction, prior to 
Ni-NTA affinity chromatography. Samples from the two procedures were retained on the resin 
as anticipated indicating that the C-terminus of the protein where the histidines were appended, 
may be inaccessible in their absence. βME was then used in combination with high salt 
phosphate buffer and sodium cholate during cell lysis. The affinity column was equilibrated 
with sodium cholate prior to  loading the sample and NaCl was omitted from the washing 
buffers and was added only to the elution buffer in order to improve the binding of the protein 
on the column (Scott et al., 2001).  
The presence of impurities after stringent washing during the affinity chromatography step 
indicates partial degradation (Fig. 4.4 & 4.5) of the purified protein or interaction of the protein 
with other lipoprotein from the E. coli cells which necessitated the use of the second 
purification step.  
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The isoelectric point computed using the amino acid sequence of 5xHis-tagged CYP6Z2 
specified a protein with net positive charge at pH 7.4 of the buffer. However, when the sample 
was loaded on Q-Sepharose, an ionic exchanger, the sample bound to the column indicating a 
protein with net negative charge. The sample was expected to flow through since the resin of 
Q-sepharose is positively charged and then some of the impurities that are negatively charged 
to be held on the column. The differences in the behaviour of the isoelectric point computed 
and the one observed may be due to the effect of the presence of the cofactor. The sample 
however passed through SP Sepharose without binding to the resin and protein of nearly 90% 
purity was obtained. 
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Figure 4.6: Homology model of CYP6Z2 showing the three dimensional structure of the full 
length CYP6Z2. The N-terminal hydrophobic domain truncated is the extended domain in blue.  
 
 
 
 
 
N-terminal hydrophobic domain 
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The three dimensional homology model of CYP6Z2 shown in Figure 4.6 shows the folding 
pattern and the extending N-terminal domain of the P450. In vivo, microsomal P450s are 
targeted  to the endoplasmic reticulum membrane using this hydrophobic domain  (Monier et 
al., 1988). The region also serves as anchor to the membrane and positions the catalytic domain 
to face the cytoplasmic side (Chen et al., 1997). The hydrophobic nature of this domain 
represents a major challenge for expressing and solubilising the protein in the hydrophilic 
environment of the cytosol of the E.coli. Recombinant P450s form large aggregates when 
expressed in the absence of detergent (Scott et al., 2001). Although most P450s  form smaller 
aggregates when the trans-membrane regions are deleted, but they still form oligomer when 
purified and monomer is only achieved in the presence of detergent (Scott et al., 2001).  
As important as deletion of this domain is for solubility, it also appears to be important in the 
proper folding of the P450s. Hsu et al, have suggested  that the N-Terminal of CYP2C1 may be 
contributing to the structural requirement for the proper folding and stability of the enzyme 
(Hsu et al., 1993). However, the truncation and solubilisation of CYP3A4 for crystallographic 
studies was different. The N-terminal residues 3-23 were deleted and the truncated gene was 
expressed successfully in DH5α. No other mutation or modification was made to the truncated 
CYP3A4 to produce the crystal structure (Yano et al., 2004). These structural studies revealed 
that CYP3A4  has a unique hydrophobic region the 7 “phenylalanine-cluster” (Williams et al., 
2004) and since the hydrophobic effect is one of the key determinants of protein folding 
(Southall et al., 2002), CYP3A4 may not depend on the N-terminal hydrophobic region to fold 
properly.  
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The two hydrophobic N-terminal domain truncations made in this project did not fold properly. 
This region may be interacting with the remaining part of CYP6Z2 for proper folding of the 
holoprotein (Hsu et al., 1993). 
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Chapter 5 
5 General discussion and conclusions  
5.1 The N-terminal hydrophobic region of insect P450s may be a requirement for 
structural stability and integrity  
 
The challenges encountered in producing recombinant insect P450 suitable for crystallisation 
and subsequent X-ray structural analysis may be in large part a consequence of the nature of 
the N-terminal hydrophobic sequence of these microsomal P450s. Indeed, the function of N-
terminal hydrophobic region of some P450s may not just be for  targeting the molecule for co-
translational insertion into the microsomal membranes by signal recognition particles 
(Sakaguchi et al., 1984):this region may be essential for  proper folding of the enzymes and 
deletion of part or whole of this domain may affect the enzyme’s structural stability (Hsu et al., 
1993). Introduction of  several positively charged residues after deleting the N-terminal 
hydrophobic region may increase expression and solubility as carried out in the expression of  
CYP2B1(Scott et al., 2001), but the success of this strategy in eliciting proper folding was not 
elucidated and similar modification on CYP2B6 (Gillam et al., 1994) did not improve the 
expression levels of this modified isoform over the full length in E. coli (Hanna et al., 2000). 
The addition of the positively charged amino acids after the deletion of the N-terminal in 
CYP2E1 and CYP2B4 was suggested to improve the solubility of the expressed P450s by 
altering the subcellular location of CYP2E1 and CYP2B4 to mainly cytosolic (Pernecky et al., 
1993, Scott et al., 2001).  Therefore, addition of the positively charged amino acids to the N-
terminal domain seems to further reduce the attachment of the P450 from interacting with the 
E. coli membrane after deleting the hydrophobic N-terminal domain and not for proper folding 
of the P450 being expressed. 
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Human CYP2C2 had been shown to have a spacer sequence domain between the N-terminal 
signal anchor and the catalytic domain (Chen et al., 1997). This spacer region is glycine-rich 
region between residues 22-28 and has a proline-rich region between residues 30 to 37 which 
contains the conserved PPGP sequence (Chen et al., 1997). Proline and glycine in combination, 
are α-helix breakers found in bends supporting structural folding in proteins (Engelman et al., 
1986). The PPGP is well conserved in CYP2B (Scott et al., 2001) and may be contributing to 
the proper folding of the truncated isoforms.  
Table 5.1: Comparisons of the amino acid sequences of the N-terminal hydrophobic domain of 
CYP2B sub-family with CYP6Z2 
CYP                                 Sequence P450 Yield (nmol/l) 
2B1 
2B1Δ3-20 
2B4 
2B4Δ3-20 
2B6 
2B6Δ3-20 
2B11 
2B11Δ3-20 
6Z2 
6Z2Δ3-13 
6Z2Δ3-25 
MAPSILLLLALLVGFLLLLVRGHPKSRGNFPPGP 
MA                   KKTSSKGKLPPGP 
MALLLAVLLAFLAGLLLLLFRGHPKAHGRLPPGP 
MA                   KKTSSKGKLPPGP 
MALLLAVRLALLTGLLLLLVQRHPNTHDRLPPGP 
MA                   KKTSSKGKLPPGP 
MALLLAVLLALLTGLLLLMARGHPKAYGHLPPGP 
MA                   KKTSSKGKLPPGP 
MAVYTLALVAAVIFLVLRYIYSHWERHGLPHLKP 
MA           FLVLRYIYSHWERHGLPHLKP 
MA                       RHGLPHLKP 
20 – 40 
800 – 1000 
30 - 40 
200 – 400 
<1 
50 – 100 
100 
300 – 600 
598 
0 
0 
The amino acid modifications in the isoforms are underlined. Δ represents the truncated 
isoforms and the spaces in the sequences show the amino acids deleted. The yields for CYP2B 
were from (Scott et al., 2001). The conserved PPGP in the CYP2B is absent in CYP6Z2. 
 
 
 
 
126 
 
The truncations created in CYP6Z2 in this project were without the addition of the positively 
charged amino acids (Table 5.1) just as it was created in CYP3A4. CYP3A4 formed 
holoprotein when this domain was deleted without any other modifications. The main 
challenge faced in expression of CYP3A4 was the need for detergent for solubility. The 
solubility issue was however resolved by using CHAPS to release the expressed truncated P450 
from the membrane and then substitute the detergent with CYMAL6, a mild detergent, and 
erythromycin during purification steps. CYMAL6 was eventually removed in the buffer used in 
concentrating the protein for crystallisation (Yano et al., 2004).  
Although the two truncated N-terminal CYP6Z2 created did not produce properly folded P450, 
the set aim of establishing expression and purification techniques for the full length was 
however achieved. The protocols yielded 598 nmol/l of the full length 5xHis-tagged CYP6Z2. 
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5.2 Site directed mutagenesis of amino acid residues at the active sites of CYP6Z2 and 
CYP6P3 predicted to be involved in metabolic activity, by in silico modelling. 
  
Homology modelling has some limitations as a purely  predictive method (Szklarz et al., 1995) 
but its importance in the investigation of  structure function of difficult proteins that are tough 
to crystallise cannot be over emphasised. Homology models of CYP6Z2, CP6D1 and CYP6P3, 
created using CYP3A4 as template (McLaughlin et al., 2008), made it possible for the amino 
acid residues at the active sites of the pyrethroid insecticides metabolisers to be compared with 
CYP6Z2. Deltamethrin, permethrin and cypermethin docked in the active sites of the models 
revealed the amino acid residues that may be interacting with the substrates. Most importantly, 
the orientation of the substrate and proximity to the haem iron could be evaluated. The 
composition of the amino acids at the active site of CYP6Z2 close to the substrates and the 
haem iron lack leucine and asparagines in positions 212 and 210 respectively when compared 
with the active site of CYP6D1. CYP6Z2 has phenyalanine and arginine instead. The positively 
charged amino acid replaced asparagine at position 210 in the SRS1 site and is predicted to be 
a point of protein-ligand hydrogen bond in the docking of permethrin (McLaughlin et al., 
2008). The arrangement of the amino acids in CYP6P3 compared with CYP6Z2 differs in three 
positions: tyrosine (102), phenyalanine (212) and arginine (210): these were replaced with 
phenyalanine (110), leucine (216) and asparagine (210) respectively in CYP6P3.  
The mutations at F212, Y102 and R210 revealed that these residues are involved in the 
metabolic activities of CYP6Z2. The metabolic roles of these positions were further supported 
with the swapping of the amino acids composition of CYP6Z2 in CYP6P3. The mutants 
CYP6P3 (F110Y) and CYP6P3 (L216F) acquired significantly increased metabolic activities. 
Changing the long chain hydrophobic side chain to aromatic ring in L216F caused an increase 
in the thermostability of the mutant by 10
o
C when compared with the wild type. The unique 
clustering of aromatic residues running down one side of the structure of  CYP119, a 
128 
 
thermophilic P450, was suggested to be the structural basis for its thermostability (Poulos and 
Johnson, 2005). CYP119 can withstand temperature up to 90
o
C (McLean et al., 1998) and 
mutations of one of the aromatic residues reduced this melting temperature by 10
 o
C (Park et 
al., 2002). It appears that the L216F substitution confers enhanced structural stability and it 
also (in turn) increases the rate of insecticide metabolism of this mutant.   
Identifications of these amino acid residues were made possible through homology modelling 
of the P450s examined in this thesis. Homology modelling has therefore proved to be a useful 
tool in the studies of structure-function of enzymes in the absence of crystal structures. 
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5.3 The role of cytochrome b5 in P450 metabolism depends on both the substrates and 
the P450 enzymes 
 
Cytochrome b5 plays a pleiotropic function in P450 related metabolic activities (Schenkman 
and Jansson, 1999). It has been suggested that such a  requirement for cytochrome b5 in P450 
reaction is dependent upon both the substrate being oxidised and the nature of the oxidising 
enzyme (Kuwahara and Omura, 1980). The presence of b5 did not detectably alter the activities 
of CYP6Z2 and CYP6Z3 with resorufin probes; however their activities with the DEF probe 
were increased by 3.5-fold and 1.8-fold respectively upon the addition of b5. Whereas addition 
of b5 in CYP6P3 reduced its activity with BR by 2.4-fold but increased its activity with DEF by 
7.4-fold. Therefore, b5 increased the activities of all the three enzymes with DEF, reduced the 
activities of only CYP6P3 with resorufin probes and seems to have no effect with the activities 
of both CYP6Z2 and CYP6Z3 with resorufin probes. 
The positive effect of b5 in the activities of CYP6Z2 and CYP6Z3 with the DEF probe and the 
insensitivity exhibited with resorufin probes may be due to the differences in the reaction 
mechanism required to produce the fluorescent moiety for detection in the two classes of 
probes (Figure 5.1 & 5.2). 
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Resorufin derivative probes require only one dealkylation reaction step to release the resorufin 
for detection and quantification: 
 
Figure 5.1: One step dealkylation reaction of P450 against resorufin derivative probes. 
However, fluorescein derivative probes require two dealkylation reaction steps and formation 
of an intermediate to release the fluorescein for detection and quantification. 
 
 
 
Figure 5.2: Two-step dealkylation reaction of P450 against fluorescein derivative probes 
Fluorescein 
-OH 
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Cytochrome b5 has been proposed to complex with P450 and allow two-electron transfer 
during a single interaction with reductase (Schenkman and Jansson, 2003). This would improve 
the rate of formation of compound 1 and increase reaction activities which may be required in 
substrates like DEF. The same complex may be formed with the resorufin probes but the effect 
may not be having significant impact because of the one-step reaction rate. 
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5.4 Phenylalanine residue 4.0 Å to porphyrin may be involved in stabilising coupling 
of the oxygen on the haem iron. 
 
Porphyrin plays a major role in donating an electron for oxygen bond cleavage bound to the 
haem for the activated oxygen of compound 1 to be formed (Goh and Nam, 1999, Stillman, 
2000). The proximity of phenylalanine residues close to the porphyrin of the P450s as shown in 
Table 5.2 suggests they may be engage in π-π interactions with the porphyrin ring, and 
contribute to the electrons being supplied for the formation of the activated oxygen.  
This possibility was established with the mutation of the phenylalanine to other amino acid 
residues on CYP6Z2. The mutants, F115L, F115W, F115Y and F115A, produced properly 
folded P450s but only F115A had sufficient activity to dealkylate BR.  Both F115W and 
F115Y have aromatic rings but the presence of oxygen in tyrosine and the nitrogen in the 
indole of tryptophan, also electron withdrawing groups, will affect the flow of the π electrons 
in their aromatic ring. Leucine in F115L has no π electron to contribute except for its long 
hydrophobic chain which could be involved in steric interaction with the haem. F115A has no 
π electron, no charge and no steric interaction to contribute or withdraw. This may be the 
reason why it was able to retain some level of metabolic activity but less stable P450 structure.   
Significant lost of activity observed in CYP6Z3 when it was mutated to F115A also suggested 
that mutations of any of the phenylalanine in Table 5.2 or any that is 4Å close to the porphyrin 
in P450 may be involved in the stability of the coupling of the activated oxygen to the haem. 
The mutations created to understand the role of F120 in CYP2D6 were similar to the ones 
created on CYP6Z2 in this project.  F120A, F120L, F120H and F120S were all active against 
dextromethorphan and bufuralol (Flanagan et al., 2004). However, F120 is 8.2Å (Table 5.2) 
away from the haem. Therefore, depletion of the aromatic ring did not affect the activity of the 
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enzyme. The aromatic ring close to the porphyrin that may have effect on the  π-π interactions 
is F436, which is 4.1Å away from the haem and may be the phenylalanine stabilising the 
activated oxygen in CYP2D6. The ability of F212L to retain its metabolic activity after the 
replacement of the aromatic ring as seen in chapter 2 of this thesis supports the assumption that 
only the phenylalanine close to the porphyrin may be contributing to the π-π interactions. 
Table 5.2: Predicted phenylalanine in some P450s and their closeness to the porphyrin of the 
haem.  
CYP Phe position Distance to porphyrin  
6Z1 115 4.0Å 
6Z2 115 4.1Å 
6Z3 115 4.0Å 
6P3 123 4.1Å 
6M2 124 4.3Å 
2D6 436 4.1Å 
2D6 120 8.2Å 
6Z2 212 27Å 
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Figure 5.3: Predicted phenylalanine that may be involved in π-π interactions with the porphyrin 
of the haem in CYP6Z1, CYP6Z2, CYP6Z3, CYP6P3, CYP6M2 and CYP2D6.  
 
  
 
 
 
 
 
 
  
 
CYP6Z1 CYP6Z2 
CYP6Z3 CYP6P3 
CYP6M2 CYP2D6 
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5.5 CYP6Z3 has higher metabolic activity than CYP6Z2  
Comparative kinetics reveal that CYP6Z3 exhibits greater catalytic efficiency with equivalent 
substrates compared with the isoform CYP6Z2 and may therefore represent a threat to any 
malaria control program, because its metabolic activity against pyrethroid insectides was 
higher than CYP6Z2, as confirmed in this study. This study also discovered the unique 
metabolic activity of CYP6Z3 against pyriproxyfen, a pyridine-based pesticides effective 
against various arthropoida, which prevent larvae from developing into adulthood (Ishaaya and 
Horowitz, 1995) and this could prove as a  marker in pyriproxyfen resistance vectors.  
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5.6  Conclusions 
The results in this thesis have shown that in silico studies of homology models of enzymes can 
be used to investigate structure-function especially when their three-dimensional structures 
have not been determined. 
The amino acids at the three positions examined in CYP6Z2 and CYP6P3 are important in the 
activities of the P450s. The introduction of phenylalnine increased activity and changing of 
phenylalanine, 4Å to the heam, may inactivate the activities of P450s. 
This information will be useful in quick identification of resistant mosquitoes in single 
nucleotide polymorphism (SNP) mapping carried out in the field, and in the design of new 
insecticides to eradicate malaria disease in the future.  
Increased thermostability coupled with increase in rate of reaction are important to the 
industrial applications of P450s
 
 and a single nucleotide change, as seen in this study, could 
achieve both.  
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5.7 Recommendations 
 
The current absence of a crystal structure of an insect P450 represents a major omission from 
the arsenal of knowledge required to understand and potentially manipulate insecticide 
resistance activities with respect to P450 for these disease vectors. The effort made in this 
study to produce a soluble, properly folded P450 has demonstrated that the N-terminal 
hydrophobic residues of insect P450s remain a barrier to facilitating the proper folding of 
heterologously expressed enzyme in all hosts tested, here and by others. However, since this 
study has been able to establish the expression and purification methods yielding authentically 
folded full length CYP6Z2; confirming the aggregation state of the purified protein will be of 
great value. Investigation of the purified full length enzyme with size exclusion 
chromatography will reveal the concentrations of detergent needed to have a monomer that 
could be used in high-throughput crystallization screens.  
The three amino acid residues targeted in this study, are involved in the metabolic activities of 
CYP6Z2. Two mutations, R210A and Y102F have shown a tendency to increase cellular 
metabolism in respect of deltamethrin. The substitution of phenylalanine for tyrosine in 
CYP6P3 reduced its metabolic activity, indicating the effect of the hydoxyl group at this 
position. Moreover, the absence of the positively charged arginine at the active sites of both 
CYP6P3 and CYP6D1 suggests the impact that this side chain may have in reducing the 
metabolic activity associated with CYP6Z2. It would be interesting to combine these two 
mutations (CYP6Z2 (Y102L_R210A) and verify if the metabolic activity against pyrethroid 
insecticides would improve.  
Establishing the exact point in the P450 kinetic cycle where the impact of the loss of activities 
of mutants CYP6Z2 (F115L), F115Y and F115W, is an important next objective.  The presence 
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of superoxide or hydrogen peroxide will indicate where on the catalytic steps the uncoupling of 
the oxygen is occurring.  
The importance of the aromatic ring, and its close proximity to the haem as predicted in Table 
5.2 should be investigated further. It may hold the key to turning off the activities of P450s.  
CYP6Z3 indicated its ability to metabolise pyrethroids and importantly have stronger activity 
against pyriproxyfen. These metabolic activities were established by comparing the amount of 
substrate left in the NADPH plus and NADPH minus depletion reactions. The use of HPLC 
analysis combined with Mass Spectrometry analysis would further improve the knowledge of 
the metabolic activities of these P450 enzymes especially with assays where both the substrates 
and the metabolites cannot be simultaneously detected with HPLC alone. 
CYP6Z2 and CYP6Z3 both have similar amino acids sequences at SRS 1, SRS 4 and SRS 5. 
The differences in amino acids are in SRS 2, SRS 3 and SRS 6. SRS 2 and SRS 3 are involved 
with substrates access channel while SRS 6 is involved with catalytic activity. 
SRS 2 
CYP6Z2 – N R G R N F I 
CYP6Z3 – I K S R K F M 
 
SRS 3 
 
CYP6Z2 – M T S L Q P E L 
CYP6Z3 – I T S L P P E L 
 
SRS 6 
 
CYP6Z2 – A A T V G L T 
CYP6Z3 – V A T V V V T 
 
The megaprimer mutation method could be used to create chimera of CYP6Z2 having these 
SRSs substituted for that of CYP6Z3. The chimera that gives similar activity as CYP6Z3 will 
reveal the SRS(s) responsible for the higher activities observed in CYP6Z3. 
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Chimera of CYP6Z3 on CYP6Z1 could also be created as well using the megaprimer method. 
We may be able to get CYP6Z3 to metabolise DDT since CYP6Z1 does. 
 
140 
 
References 
 
Agnandji, S. T., Lell, B., Soulanoudjingar, S. S., Fernandes, J. F., Abossolo, B. P., 
Conzelmann, C., Methogo, B., Doucka, Y., Flamen, A. & Mordmüller, B. 2011. First 
results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. The New 
England journal of medicine, 365, 1863-75. 
Agosin, M. 1985. Role of microsomal oxidations in insecticide degradation. Comprehensive 
insect physiology, biochemistry and pharmacology, 12, 647-712. 
Alexia, C.-P., Jaclyn, B., Myriam, R.-K., Jessica, R., Emilie, G.-C., Rodolphe, P., Muhammad, 
A. R., Mark, P., Chantal, D.-V. & Stephane, R. 2013. The central role of mosquito 
cytochrome P450 CYP6Zs in insecticide detoxification revealed by functional 
expression and structural modelling. Biochemical Journal, 455, 75-85. 
Anand, S. S., Bruckner, J. V., Haines, W. T., Muralidhara, S., Fisher, J. W. & Padilla, S. 2006. 
Characterization of deltamethrin metabolism by rat plasma and liver microsomes. 
Toxicology and applied pharmacology, 212, 156-166. 
Arensburger, P., Megy, K., Waterhouse, R. M., Abrudan, J., Amedeo, P., Antelo, B., 
Bartholomay, L., Bidwell, S., Caler, E. & Camara, F. 2010. Sequencing of Culex 
quinquefasciatus establishes a platform for mosquito comparative genomics. Science, 
330, 86-88. 
Atieli, F. K., Munga, S. O., Ofulla, A. V. & Vulule, J. M. 2010. The effect of repeated washing 
of long-lasting insecticide-treated nets (LLINs) on the feeding success and survival 
rates of Anopheles gambiae. Malar J, 9, 29. 
Bale, J., Van Lenteren, J. & Bigler, F. 2008. Biological control and sustainable food 
production. Philosophical Transactions of the Royal Society B: Biological Sciences, 
363, 761-776. 
141 
 
Bassat, Q., Guinovart, C., Sigaúque, B., Aide, P., Sacarlal, J., Nhampossa, T., Bardají, A., 
Nhacolo, A., Macete, E. & Mandomando, I. 2008. Malaria in rural Mozambique. Part 
II: children admitted to hospital. Malaria journal, 7, 37. 
Berka, K., Hendrychová, T., Anzenbacher, P. & Otyepka, M. 2011. Membrane position of 
ibuprofen agrees with suggested access path entrance to cytochrome P450 2C9 active 
site. The journal of physical chemistry A, 115, 11248-11255. 
Black, S. D., French, J. S., Williams, C. H. & Coon, M. J. 1979. Role of a hydrophobic 
polypeptide in the N-terminal region of NADPH-cytochrome P-450 reductase in 
complex formation with P-450LM. Biochemical and biophysical research 
communications, 91, 1528-1535. 
Bonfils, C., Balny, C. & Maurel, P. 1981. Direct evidence for electron transfer from ferrous 
cytochrome b5 to the oxyferrous intermediate of liver microsomal cytochrome P-450 
LM2. Journal of biological chemistry, 256, 9457-9465. 
Boonsuepsakul, S., Luepromchai, E. & Rongnoparut, P. 2008. Characterization of Anopheles 
minimus CYP6AA3 expressed in a recombinant baculovirus system. Archives of insect 
biochemistry and physiology, 69, 13-21. 
Bordo, D. & Argos, P. 1991. Suggestions for “safe” residue substitutions in site-directed 
mutagenesis. Journal of molecular biology, 217, 721-729. 
Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Analytical 
biochemistry, 72, 248-254. 
Brash, A. R. 2009. Mechanistic aspects of CYP74 allene oxide synthases and related 
cytochrome P450 enzymes. Phytochemistry, 70, 1522-1531. 
142 
 
Caraballo, H. & King, K. 2014. Emergency department management of mosquito-borne illness: 
malaria, dengue, and West Nile virus. Emergency medicine practice, 16, 1-23; quiz 23-
4. 
Chapman, A. D. 2009. Numbers of living species in Australia and the world. 
Chen, C.-D., Doray, B. & Kemper, B. 1997. Efficient assembly of functional cytochrome P450 
2C2 requires a spacer sequence between the N-terminal signal anchor and catalytic 
domains. Journal of Biological Chemistry, 272, 22891-22897. 
Chiu, T.-L., Wen, Z., Rupasinghe, S. G. & Schuler, M. A. 2008. Comparative molecular 
modeling of Anopheles gambiae CYP6Z1, a mosquito P450 capable of metabolizing 
DDT. Proceedings of the National Academy of Sciences, 105, 8855-8860. 
Chothia, C. & Lesk, A. M. 1986. The relation between the divergence of sequence and 
structure in proteins. The EMBO journal, 5, 823. 
Chothia, C. & Lesk, A. M. 1987. Canonical structures for the hypervariable regions of 
immunoglobulins. Journal of molecular biology, 196, 901-917. 
Coetzee, M., Horne, D., Brooke, B. & Hunt, R. 1999. DDT, dieldrin and pyrethroid insecticide 
resistance in african malaria vector mosquitoes: An historical review and implications 
for future malaria co ntrol in southern africa. South African Journal of Science, 95, 215-
218. 
Collins, W. E. 2012. Plasmodium knowlesi: A Malaria Parasite of Monkeys and Humans*. 
Annual review of entomology, 57, 107-121. 
Connell, D., Lam, P., Richardson, B. & Wu, R. Introduction to Ecotoxicology, 1999. Blackwell 
Science Ltd, Oxford. 
Correia, M. A. & Mannering, G. 1973. Reduced Diphosphopyridine Nucleotide Synergism of 
the Reduced Triphosphopyridine Nucleotide-Dependent Mixed-Function Oxidase 
143 
 
System of Hepatic Microsomes I. Effects of Activation and Inhibition of the Fatty Acyl 
Coenzyme A Desaturation System. Molecular pharmacology, 9, 455-469. 
Cosme, J. & Johnson, E. F. 2000. Engineering microsomal cytochrome P450 2C5 to be a 
soluble, monomeric enzyme mutations that alter aggregation, phospholipid dependence 
of catalysis, and membrane binding. Journal of Biological Chemistry, 275, 2545-2553. 
Daborn, P., Yen, J., Bogwitz, M., Le Goff, G., Feil, E., Jeffers, S., Tijet, N., Perry, T., Heckel, 
D. & Batterham, P. 2002. A single P450 allele associated with insecticide resistance in 
Drosophila. Science, 297, 2253-2256. 
David, J.-P., Ismail, H. M., Chandor-Proust, A. & Paine, M. J. I. 2013. Role of cytochrome 
P450s in insecticide resistance: impact on the control of mosquito-borne diseases and 
use of insecticides on Earth. Philosophical Transactions of the Royal Society B: 
Biological Sciences, 368, 20120429. 
David, J.-P., Strode, C., Vontas, J., Nikou, D., Vaughan, A., Pignatelli, P. M., Louis, C., 
Hemingway, J. & Ranson, H. 2005. The Anopheles gambiae detoxification chip: a 
highly specific microarray to study metabolic-based insecticide resistance in malaria 
vectors. Proceedings of the National Academy of Sciences of the United States of 
America, 102, 4080-4084. 
Dawson, J., Holm, R., Trudell, J., Barth, G., Linder, R., Bunnenberg, E., Djerassi, C. & Tang, 
S. 1976. Letter: Oxidized cytochrome P-450. Magnetic circular dichroism evidence for 
thiolate ligation in the substrate-bound form. Implications for the catalytic mechanism. 
Journal of the American Chemical Society, 98, 3707. 
Denisov, I. G., Makris, T. M., Sligar, S. G. & Schlichting, I. 2005. Structure and chemistry of 
cytochrome P450. Chemical reviews, 105, 2253-2278. 
144 
 
Djimdé, A., Doumbo, O. K., Cortese, J. F., Kayentao, K., Doumbo, S., Diourté, Y., Coulibaly, 
D., Dicko, A., Su, X.-Z. & Nomura, T. 2001. A molecular marker for chloroquine-
resistant falciparum malaria. New England journal of medicine, 344, 257-263. 
Djouaka, R. F., Bakare, A. A., Coulibaly, O. N., Akogbeto, M. C., Ranson, H., Hemingway, J. 
& Strode, C. 2008. Expression of the cytochrome P450s, CYP6P3 and CYP6M2 are 
significantly elevated in multiple pyrethroid resistant populations of Anopheles 
gambiae ss from Southern Benin and Nigeria. BMC genomics, 9, 538. 
Dolphin, D., Traylor, T. G. & Xie, L. Y. 1997. Polyhaloporphyrins: unusual ligands for metals 
and metal-catalyzed oxidations. Accounts of chemical research, 30, 251-259. 
Dondorp, A. M., Yeung, S., White, L., Nguon, C., Day, N. P., Socheat, D. & Von Seidlein, L. 
2010. Artemisinin resistance: current status and scenarios for containment. Nature 
Reviews Microbiology, 8, 272-280. 
Donnelly, M. J., Corbel, V., Weetman, D., Wilding, C. S., Williamson, M. S. & Black Iv, W. 
C. 2009. Does kdr genotype predict insecticide-resistance phenotype in mosquitoes? 
Trends in parasitology, 25, 213-219. 
Duangkaew, P., Pethuan, S., Kaewpa, D., Boonsuepsakul, S., Sarapusit, S. & Rongnoparut, P. 
2011. Characterization of mosquito CYP6P7 and CYP6AA3: differences in substrate 
preference and kinetic properties. Archives of insect biochemistry and physiology, 76, 
236-248. 
Dunlap, T. R. 1981. DDT: Science, Citizens, and Public Policy. Princeton: Princeton 
University Press. viii. 
Engelman, D., Steitz, T. & Goldman, A. 1986. Identifying nonpolar transbilayer helices in 
amino acid sequences of membrane proteins. Annual review of biophysics and 
biophysical chemistry, 15, 321-353. 
145 
 
Enoch, H. & Strittmatter, P. 1979. Cytochrome b5 reduction by NADPH-cytochrome P-450 
reductase. Journal of Biological Chemistry, 254, 8976-8981. 
Epstein, C. J., Goldberger, R. F. & Anfinsen, C. B. The genetic control of tertiary protein 
structure: studies with model systems.  Cold Spring Harbor symposia on quantitative 
biology, 1963. Cold Spring Harbor Laboratory Press, 439-449. 
Estabrook, R. W. 1996. I Serial Reviews I. 
Faber, K. & Johnson, C. 1996. Biotransformations in Organic Chemistry. Synthesis-Journal of 
Synthetic Organic Chemistry, 791. 
Fantuzzi, A., Fairhead, M. & Gilardi, G. 2004. Direct electrochemistry of immobilized human 
cytochrome P450 2E1. Journal of the American Chemical Society, 126, 5040-5041. 
Feyereisen, R. 1999. Insect P450 enzymes. Annual review of entomology, 44, 507-533. 
Feyereisen, R., Koener, J., Carino, F. & Daggett, A. 1990. Biochemistry and molecular biology 
of insect cytochrome P450. Molecular Insect Science. Springer. 
Feyereisen, R., Koener, J. F., Farnsworth, D. E. & Nebert, D. W. 1989. Isolation and sequence 
of cDNA encoding a cytochrome P-450 from an insecticide-resistant strain of the house 
fly, Musca domestica. Proceedings of the National Academy of Sciences, 86, 1465-
1469. 
Flanagan, J., Marechal, J., Ward, R., Kemp, C., Mclaughlin, L., Sutcliffe, M., Roberts, G., 
Paine, M. & Wolf, C. 2004. Phe120 contributes to the regiospecificity of cytochrome 
P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite. 
Biochem. J, 380, 353-360. 
Gilbert, L. I., Iatrou, K. & Gill, S. S. 2005. Comprehensive molecular insect science. 
Gillam, E. M., Guo, Z. & Guengerich, F. P. 1994. Expression of Modified Human Cytochrome 
P450 2E1 in Escherichia coli, Purification, and Spectral and Catalytic Properties. 
Archives of biochemistry and biophysics, 312, 59-66. 
146 
 
Glawischnig, E., Grün, S., Frey, M. & Gierl, A. 1999. Cytochrome P450 monooxygenases of 
DIBOA biosynthesis: specificity and conservation among grasses. Phytochemistry, 50, 
925-930. 
Goh, Y. M. & Nam, W. 1999. Significant electronic effect of porphyrin ligand on the 
reactivities of high-valent iron (IV) oxo porphyrin cation radical complexes. Inorganic 
chemistry, 38, 914-920. 
Gotoh, O. 1992. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins 
inferred from comparative analyses of amino acid and coding nucleotide sequences. 
Journal of Biological Chemistry, 267, 83-90. 
Greenwood, B. M., Bojang, K., Whitty, C. J. & Targett, G. A. 2005. Malaria. Lancet, 365, 
1487-98. 
Guengerich, F. P., Martin, M. V., Sohl, C. D. & Cheng, Q. 2009. Measurement of cytochrome 
P450 and NADPH–cytochrome P450 reductase. Nature protocols, 4, 1245-1251. 
Gullan, P. J. & Cranston, P. S. 2009. The insects: an outline of entomology, John Wiley & 
Sons. 
Haines, D. C., Tomchick, D. R., Machius, M. & Peterson, J. A. 2001. Pivotal role of water in 
the mechanism of P450BM-3. Biochemistry, 40, 13456-13465. 
Hammock, B., Kerkut, G. & Gilbert, L. 1985. Comprehensive Insect Physiology, 
Biochemistry, and Pharmacology. GA Kerkut and LI Gilbert, Pergamon Press, New 
York, 431-472. 
Hanna, I. H., Reed, J. R., Guengerich, F. P. & Hollenberg, P. F. 2000. Expression of Human 
Cytochrome P450 2B6 in Escherichia coli: Characterization of Catalytic Activity and 
Expression Levels in Human Liver. Archives of biochemistry and biophysics, 376, 206-
216. 
147 
 
Hasemann, C. A., Kurumbail, R. G., Boddupalli, S. S., Peterson, J. A. & Deisenhofer, J. 1995. 
Structure and function of cytochromes P450: a comparative analysis of three crystal 
structures. Structure, 3, 41-62. 
Hayaishi, O., Katagiri, M. & Rothberg, S. 1955. Mechanism of the pyrocatechase reaction. 
Journal of the American Chemical Society, 77, 5450-5451. 
Hayashi, N., Welschof, M., Zewe, M., Braunagel, M., Dübel, S., Breitling, F. & Little, M. 
1994. Simultaneous mutagenesis of antibody CDR regions by overlap extension and 
PCR. Biotechniques, 17, 310, 312, 314-5. 
Hemingway, J. & Ranson, H. 2000. Insecticide resistance in insect vectors of human disease. 
Annual review of entomology, 45, 371-391. 
Holt, R. A., Subramanian, G. M., Halpern, A., Sutton, G. G., Charlab, R., Nusskern, D. R., 
Wincker, P., Clark, A. G., Ribeiro, J. C. & Wides, R. 2002. The genome sequence of 
the malaria mosquito Anopheles gambiae. Science, 298, 129-149. 
Hougard, J.-M., Duchon, S., Darriet, F., Zaim, M., Rogier, C. & Guillet, P. 2003. Comparative 
performances, under laboratory conditions, of seven pyrethroid insecticides used for 
impregnation of mosquito nets. Bulletin of the World Health Organization, 81, 324-
333. 
Hsu, L., Hu, M.-C., Cheng, H.-C., Lu, J.-C. & Chung, B. 1993. The N-terminal hydrophobic 
domain of P450c21 is required for membrane insertion and enzyme stability. Journal of 
Biological Chemistry, 268, 14682-14686. 
Ishaaya, I. & Horowitz, A. R. 1995. Pyriproxyfen, a novel insect growth regulator for 
controlling whiteflies: mechanisms and resistance management. Pesticide Science, 43, 
227-232. 
Isin, E. M. & Guengerich, F. P. 2007. Complex reactions catalyzed by cytochrome P450 
enzymes. Biochimica et Biophysica Acta (BBA)-General Subjects, 1770, 314-329. 
148 
 
Johnson, M. S., Srinivasan, N., Sowdhamini, R. & Blundell, T. L. 1994. Knowledge-based 
protein modeling. Crit Rev Biochem Mol Biol, 29, 1-68. 
Jones, R. T., Bakker, S. E., Stone, D., Shuttleworth, S. N., Boundy, S., Mccart, C., Daborn, P. 
J. & Van Den Elsen, J. M. 2010. Homology modelling of Drosophila cytochrome P450 
enzymes associated with insecticide resistance. Pest management science, 66, 1106-
1115. 
Joo, H., Lin, Z. & Arnold, F. H. 1999. Laboratory evolution of peroxide-mediated cytochrome 
P450 hydroxylation. Nature, 399, 670-673. 
Karunker, I., Morou, E., Nikou, D., Nauen, R., Sertchook, R., Stevenson, B. J., Paine, M. J., 
Morin, S. & Vontas, J. 2009. Structural model and functional characterization of the  
Bemisia tabaci CYP6CM1vQ, a cytochrome P450 associated with high levels of 
imidacloprid resistance. Insect biochemistry and molecular biology, 39, 697-706. 
Kempf, A. C., Zanger, U. M. & Meyer, U. A. 1995. Truncated Human P450 2D6P: Expression 
in Escherichia coli, Ni
2+
-Chelate Affinity Purification, and Characterization of 
Solubility and Aggregation. Archives of biochemistry and biophysics, 321, 277-288. 
Klein, E. 2013. Antimalarial drug resistance: a review of the biology and strategies to delay 
emergence and spread. International journal of antimicrobial agents, 41, 311-317. 
Klingenberg, M. 1958. Pigments of rat liver microsomes. Archives of biochemistry and 
biophysics, 75, 376-386. 
Krieger, E., Darden, T., Nabuurs, S. B., Finkelstein, A. & Vriend, G. 2004. Making optimal use 
of empirical energy functions: Force‐field parameterization in crystal space. Proteins: 
Structure, Function, and Bioinformatics, 57, 678-683. 
Krieger, E., Nabuurs, S. B. & Vriend, G. 2003. Homology modeling. Methods of biochemical 
analysis, 44, 509-524. 
149 
 
Kusano, K., Waterman, M. R., Sakaguchi, M., Omura, T. & Kagawa, N. 1999. Protein 
Synthesis Inhibitors and Ethanol Selectively Enhance Heterologous Expression of 
P450s and Related Proteins in Escherichia coli. Archives of biochemistry and 
biophysics, 367, 129-136. 
Kuwahara, S.-I. & Omura, T. 1980. Different requirement for cytochrome b5 in NADPH-
supported O-deethylation of p-nitrophenetole catalyzed by two types of microsomal 
cytochrome P-450. Biochemical and biophysical research communications, 96, 1562-
1568. 
Lertkiatmongkol, P., Jenwitheesuk, E. & Rongnoparut, P. 2011. Homology modeling of 
mosquito cytochrome P450 enzymes involved in pyrethroid metabolism: insights into 
differences in substrate selectivity. BMC research notes, 4, 321. 
Li, Y. C. & Chiang, J. 1991. The expression of a catalytically active cholesterol 7 alpha-
hydroxylase cytochrome P450 in Escherichia coli. Journal of Biological Chemistry, 
266, 19186-19191. 
Ling, M. M. & Robinson, B. H. 1997. Approaches to DNA mutagenesis: an overview. 
Analytical biochemistry, 254, 157-178. 
Lipscomb, J. D., Sligar, S., Namtvedt, M. & Gunsalus, I. 1976. Autooxidation and 
hydroxylation reactions of oxygenated cytochrome P-450cam. Journal of Biological 
Chemistry, 251, 1116-1124. 
Losey, J. E. & Vaughan, M. 2006. The economic value of ecological services provided by 
insects. Bioscience, 56, 311-323. 
Lu, G., Lindqvist, Y., Schneider, G., Dwivedi, U. & Campbell, W. 1995. Structural Studies on 
Corn Nitrate Reductase: Refined Structure of the Cytochrome b5 Reductase Fragment at 
2.5 Å, its ADP Complex and an Active-site Mutant and Modeling of the Cytochrome b5 
Domain. Journal of molecular biology, 248, 931-948. 
150 
 
Martin, J. & Fay, M. 2001. Cytochrome P450 drug interactions: are they clinically relevant? 
Australian Prescriber, 24, 10-12. 
Mclaughlin, L., Niazi, U., Bibby, J., David, J. P., Vontas, J., Hemingway, J., Ranson, H., 
Sutcliffe, M. & Paine, M. 2008. Characterization of inhibitors and substrates of 
Anopheles gambiae CYP6Z2. Insect molecular biology, 17, 125-135. 
Mclean, M. A., Maves, S. A., Weiss, K. E., Krepich, S. & Sligar, S. G. 1998. Characterization 
of a Cytochrome P450 from the Acidothermophilic Archaea Sulfolobus solfataricus. 
Biochemical and biophysical research communications, 252, 166-172. 
Modi, S., Paine, M., Sutcliffe, M., Lian, L.-Y., Primrose, W., Wolf, C. & Roberts, G. 1996. A 
model for human cytochrome P450 2D6 based on homology modeling and NMR 
studies of substrate binding. Biochemistry, 35, 4540-4550. 
Momenteau, M. & Reed, C. A. 1994. Synthetic heme-dioxygen complexes. Chemical reviews, 
94, 659-698. 
Monier, S., Van Luc, P., Kreibich, G., Sabatini, D. & Adesnik, M. 1988. Signals for the 
incorporation and orientation of cytochrome P450 in the endoplasmic reticulum 
membrane. The Journal of cell biology, 107, 457-470. 
Mueller, I., Zimmerman, P. A. & Reeder, J. C. 2007. Plasmodium malariae and Plasmodium 
ovale–the ‘bashful’malaria parasites. Trends in parasitology, 23, 278-283. 
Müller, P., Donnelly, M. J. & Ranson, H. 2007. Transcription profiling of a recently colonised 
pyrethroid resistant Anopheles gambiae strain from Ghana. BMC genomics, 8, 36. 
Müller, P., Warr, E., Stevenson, B. J., Pignatelli, P. M., Morgan, J. C., Steven, A., Yawson, A. 
E., Mitchell, S. N., Ranson, H. & Hemingway, J. 2008. Field-caught permethrin-
resistant Anopheles gambiae overexpress CYP6P3, a P450 that metabolises pyrethroids. 
PLoS Genetics, 4, e1000286. 
151 
 
Munro, A. W., Leys, D. G., Mclean, K. J., Marshall, K. R., Ost, T. W., Daff, S., Miles, C. S., 
Chapman, S. K., Lysek, D. A. & Moser, C. C. 2002. P450 BM3: the very model of a 
modern flavocytochrome. Trends in biochemical sciences, 27, 250-257. 
Nebert, D. W. & Gonzalez, F. 1987. P450 genes: structure, evolution, and regulation. Annual 
review of biochemistry, 56, 945-993. 
Nelson, D. R. 2009. The cytochrome p450 homepage. Human genomics, 4, 59. 
Nene, V., Wortman, J. R., Lawson, D., Haas, B., Kodira, C., Tu, Z. J., Loftus, B., Xi, Z., Megy, 
K. & Grabherr, M. 2007. Genome sequence of Aedes aegypti, a major arbovirus vector. 
Science, 316, 1718-1723. 
Nikou, D., Ranson, H. & Hemingway, J. 2003. An adult-specific CYP6 P450 gene is 
overexpressed in a pyrethroid-resistant strain of the malaria vector, Anopheles gambiae. 
Gene, 318, 91-102. 
Nisimoto, Y. & Lambeth, J. D. 1985. NADPH-cytochromeP450 reductase-cytochrome b5 
interactions: Crosslinking of the phospholipid vesicle-associated proteins by a water-
soluble carbodiimide. Archives of biochemistry and biophysics, 241, 386-396. 
Noshiro, M., Harada, N. & Omura, T. 1980. Immunochemical study on the route of electron 
transfer from NADH and NADPH to cytochrome P-450 of liver microsomes. Journal of 
biochemistry, 88, 1521-1535. 
Omura, T. & Sato, R. 1962. A new cytochrome in liver microsomes. Journal of Biological 
Chemistry, 237, PC1375-PC1376. 
Omura, T. & Sato, R. 1964. The carbon monoxide-binding pigment of liver microsomes. I. 
Evidence for its hemoprotein nature. J. biol. Chem, 239, 2370-2378. 
Paine, M. J., Scrutton, N. S., Munro, A. W., Gutierrez, A., Roberts, G. C. & Wolf, C. R. 2005. 
Electron transfer partners of cytochrome P450. Cytochrome P450. Springer. 
152 
 
Park, S.-Y., Yamane, K., Adachi, S.-I., Shiro, Y., Weiss, K. E., Maves, S. A. & Sligar, S. G. 
2002. Thermophilic cytochrome P450 (CYP119) from Sulfolobus solfataricus: high 
resolution structure and functional properties. Journal of inorganic biochemistry, 91, 
491-501. 
Pears, F. & Cranshaw, W. 2010. Mosquito Management (Supplement to Fact Sheet 5.526). 
Pernecky, S. J., Larson, J. R., Philpot, R. M. & Coon, M. J. 1993. Expression of truncated 
forms of liver microsomal P450 cytochromes 2B4 and 2E1 in Escherichia coli: 
influence of NH2-terminal region on localization in cytosol and membranes. Proc Natl 
Acad Sci U S A, 90, 2651-5. 
Phyo, A. P., Nkhoma, S., Stepniewska, K., Ashley, E. A., Nair, S., Mcgready, R., Ler Moo, C., 
Al-Saai, S., Dondorp, A. M. & Lwin, K. M. 2012. Emergence of artemisinin-resistant 
malaria on the western border of Thailand: a longitudinal study. The Lancet, 379, 1960-
1966. 
Podust, L. M., Poulos, T. L. & Waterman, M. R. 2001. Crystal structure of cytochrome P450 
14α-sterol demethylase (CYP51) from Mycobacterium tuberculosis in complex with 
azole inhibitors. Proceedings of the National Academy of Sciences, 98, 3068-3073. 
Poulos, T. L., Finzel, B. C. & Howard, A. J. 1987. High-resolution crystal structure of 
cytochrome P450cam. Journal of molecular biology, 195, 687-700. 
Poulos, T. L. & Johnson, E. F. 2005. Structures of cytochrome P450 enzymes. Cytochrome 
P450. Springer. 
Presnell, S. R. & Cohen, F. E. 1989. Topological distribution of four-alpha-helix bundles. 
Proceedings of the National Academy of Sciences, 86, 6592-6596. 
Price, R. & Nosten, F. 2001. Drug resistant falciparum malaria: clinical consequences and 
strategies for prevention. Drug resistance updates, 4, 187-196. 
153 
 
Pritchard, M. P., Ossetian, R., Li, D. N., Henderson, C. J., Burchell, B., Wolf, C. R. & 
Friedberg, T. 1997. A General Strategy for the Expression of Recombinant Human 
Cytochrome P450s in< i> Escherichia coli</i> Using Bacterial Signal Peptides: 
Expression of CYP3A4, CYP2A6, and CYP2E1. Archives of biochemistry and 
biophysics, 345, 342-354. 
Pyke, F. M., Bogwitz, M. R., Perry, T., Monk, A., Batterham, P. & Mckenzie, J. A. 2004. The 
genetic basis of resistance to diazinon in natural populations of Drosophila 
melanogaster. Genetica, 121, 13-24. 
Pylypenko, O. & Schlichting, I. 2004. Structural aspects of ligand binding to and electron 
transfer in bacterial and fungal P450s. Annual review of biochemistry, 73, 991-1018. 
Qian, W., Sun, Y.-L., Wang, Y.-H., Zhuang, J.-H., Xie, Y. & Huang, Z.-X. 1998. The 
influence of mutation at Glu44 and Glu56 of cytochrome b 5 on the protein's 
stabilization and interaction between cytochrome c and cytochrome b 5. Biochemistry, 
37, 14137-14150. 
Raag, R. & Poulos, T. L. 1989. The structural basis for substrate-induced changes in redox 
potential and spin equilibrium in cytochrome P-450CAM. Biochemistry, 28, 917-922. 
Rabhi, I., Guedel, N., Chouk, I., Zerria, K., Barbouche, M. R., Dellagi, K. & Fathallah, D. M. 
2004. A novel simple and rapid PCR-based site-directed mutagenesis method. 
Molecular biotechnology, 26, 27-34. 
Ranson, H., Claudianos, C., Ortelli, F., Abgrall, C., Hemingway, J., Sharakhova, M. V., Unger, 
M. F., Collins, F. H. & Feyereisen, R. 2002. Evolution of supergene families associated 
with insecticide resistance. Science, 298, 179-181. 
Ravichandran, K. G., Boddupalli, S. S., Hasermann, C., Peterson, J. A. & Deisenhofer, J. 1993. 
Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal 
P450's. Science, 261, 731-736. 
154 
 
Rendic, S. & Carlo, F. J. D. 1997. Human cytochrome P450 enzymes: a status report 
summarizing their reactions, substrates, inducers, and inhibitors. Drug metabolism 
reviews, 29, 413-580. 
Ricoux, R., Raffy, Q. & Mahy, J.-P. 2007. New biocatalysts mimicking oxidative 
hemoproteins: Hemoabzymes. Comptes Rendus Chimie, 10, 684-702. 
Riveron, J. M., Irving, H., Ndula, M., Barnes, K. G., Ibrahim, S. S., Paine, M. J. & Wondji, C. 
S. 2013. Directionally selected cytochrome P450 alleles are driving the spread of 
pyrethroid resistance in the major malaria vector Anopheles funestus. Proceedings of 
the National Academy of Sciences, 110, 252-257. 
Robert, L. 2002. Metcalf Insect Control in Ullmann’s Encyclopedia of Industrial Chemistry” 
Wiley-VCH. Wienheim. 
Roberts, L. S. & Janovy, J. 2005. Gerald D. Schmidt & Larry S. Roberts' Foundations of 
Parasitology, McGraw-Hill Higher Education Boston. 
Robins, K. T., Osorio-Lozada, A., Avi, M. & Meyer, H.-P. 2009. Lonza: biotechnology–a key 
ingredient for success in the future. CHIMIA International Journal for Chemistry, 63, 
327-330. 
Roper, C., Pearce, R., Bredenkamp, B., Gumede, J., Drakeley, C., Mosha, F., Chandramohan, 
D. & Sharp, B. 2003. Antifolate antimalarial resistance in southeast Africa: a 
population-based analysis. The Lancet, 361, 1174-1181. 
Rupasinghe, S. G., Wen, Z., Chiu, T.-L. & Schuler, M. A. 2007. Helicoverpa zea CYP6B8 and 
CYP321A1: different molecular solutions to the problem of metabolizing plant toxins 
and insecticides. Protein Engineering Design and Selection, 20, 615-624. 
Sagara, Y., Barnes, H. & Waterman, M. 1993. Expression in Escherichia coli of Functional 
Cytochrome P450 Lacking Its Hydrophobic Amino-Terminal Signal Anchor. Archives 
of biochemistry and biophysics, 304, 272-278. 
155 
 
Sakaguchi, M., Mihara, K. & Sato, R. 1984. Signal recognition particle is required for co-
translational insertion of cytochrome P-450 into microsomal membranes. Proceedings 
of the National Academy of Sciences, 81, 3361-3364. 
Schenkman, J. B. & Jansson, I. 1999. Interactions between cytochrome P450 and cytochrome 
b5. Drug metabolism reviews, 31, 351-364. 
Schenkman, J. B. & Jansson, I. 2003. The many roles of cytochrome b5 Pharmacology & 
therapeutics, 97, 139-152. 
Schenkman, J. B. & Jansson, I. 2006. Spectral analyses of cytochromes P450. Cytochrome 
P450 Protocols. Springer. 
Schmid, F. X. 2001. Biological Macromolecules: UV‐visible Spectrophotometry. eLS. 
Schoch, G. A., Yano, J. K., Wester, M. R., Griffin, K. J., Stout, C. D. & Johnson, E. F. 2004. 
Structure of human microsomal cytochrome P450 2C8 Evidence for a peripheral fatty 
acid binding site. Journal of Biological Chemistry, 279, 9497-9503. 
Schuler, M. A. & Berenbaum, M. R. 2013. Structure and function of cytochrome P450S in 
insect adaptation to natural and synthetic toxins: insights gained from molecular 
modeling. J Chem Ecol, 39, 1232-45. 
Scott, E. E., He, Y. A., Wester, M. R., White, M. A., Chin, C. C., Halpert, J. R., Johnson, E. F. 
& Stout, C. D. 2003. An open conformation of mammalian cytochrome P450 2B4 at 
1.6-Å resolution. Proceedings of the National Academy of Sciences, 100, 13196-13201. 
Scott, E. E., Spatzenegger, M. & Halpert, J. R. 2001. A truncation of 2B subfamily 
cytochromes P450 yields increased expression levels, increased solubility, and 
decreased aggregation while retaining function. Archives of biochemistry and 
biophysics, 395, 57-68. 
Scott Mathews, F. 1985. The structure, function and evolution of cytochromes. Progress in 
biophysics and molecular biology, 45, 1-56. 
156 
 
Shaik, S., Kumar, D., De Visser, S. P., Altun, A. & Thiel, W. 2005. Theoretical perspective on 
the structure and mechanism of cytochrome P450 enzymes. Chemical reviews, 105, 
2279-2328. 
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y. & Guengerich, F. P. 1994. Inter individual 
variations in human liver cytochrome P-450 enzymes involved in the oxidation of 
drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese 
and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 
414-423. 
Sligar, S. G. 1976. Coupling of spin, substrate, and redox equilibriums in cytochrome P450. 
Biochemistry, 15, 5399-5406. 
Sono, M., Roach, M. P., Coulter, E. D. & Dawson, J. H. 1996. Heme-containing oxygenases. 
Chemical Reviews, 96, 2841-2888. 
Southall, N. T., Dill, K. A. & Haymet, A. 2002. A view of the hydrophobic effect. The Journal 
of Physical Chemistry B, 106, 521-533. 
Stephenson, G. R., Ferris, I. G., Holland, P. T. & Nordberg, M. 2006. Glossary of terms 
relating to pesticides (IUPAC Recommendations 2006). Pure and Applied Chemistry, 
78, 2075-2154. 
Stevenson, B. J., Bibby, J., Pignatelli, P., Muangnoicharoen, S., O’neill, P. M., Lian, L.-Y., 
Müller, P., Nikou, D., Steven, A. & Hemingway, J. 2011. Cytochrome P450 6M2 from 
the malaria vector Anopheles gambiae metabolizes pyrethroids: Sequential metabolism 
of deltamethrin revealed. Insect biochemistry and molecular biology, 41, 492-502. 
Stillman, M. 2000. Formation and electronic properties of ring-oxidized and ring-reduced 
radical species of the phthalocyanines and porphyrins. Journal of Porphyrins and 
Phthalocyanines, 4, 374-376. 
157 
 
Szklarz, G. D., He, Y. A. & Halpert, J. R. 1995. Site-directed mutagenesis as a tool for 
molecular modeling of cytochrome P450 2B1. Biochemistry, 34, 14312-14322. 
Tamburini, P. P., Jansson, I., Favreau, L. V., Backes, W. L. & Schenkman, J. B. 1986. 
Differences in the spectral interactions between NADPH-cytochrome P-450 reductase 
and a series of cytochrome P-450 enzymes. Biochemical and biophysical research 
communications, 137, 437-442. 
Tamburini, P. P. & Schenkman, J. B. 1986. Mechanism of interaction between cytochromes 
P450 RLM5 and b5: Evidence for an electrostatic mechanism involving cytochrome b5 
heme propionate groups. Archives of biochemistry and biophysics, 245, 512-522. 
Tanaka, E. 1998. Clinically important pharmacokinetic drug–drug interactions: role of 
cytochrome P450 enzymes. Journal of clinical pharmacy and therapeutics, 23, 403-
416. 
Vallette, F., Mege, E., Reiss, A. & Adesnik, M. 1989. Construction of mutant and chimeric 
genes using the polymerase chain reaction. Nucleic acids research, 17, 723-733. 
Van Den Berg, H. 2009. Global status of DDT and its alternatives for use in vector control to 
prevent disease. Environmental Health Perspectives, 117, 1656-1663. 
Von Wachenfeldt, C., Richardson, T. H., Cosme, J. & Johnson, E. F. 1997. Microsomal P450 
2C3 Is Expressed as a Soluble Dimer in Escherichia coli  Following Modifications of 
Its N-terminus. Archives of biochemistry and biophysics, 339, 107-114. 
Wellems, T. E. & Plowe, C. V. 2001. Chloroquine-resistant malaria. Journal of Infectious 
Diseases, 184, 770-776. 
Wester, M. R., Johnson, E. F., Marques-Soares, C., Dansette, P. M., Mansuy, D. & Stout, C. D. 
2003. Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 Å 
resolution: evidence for multiple substrate binding modes. Biochemistry, 42, 6370-
6379. 
158 
 
Whitaker, I. S., Twine, C., Whitaker, M. J., Welck, M., Brown, C. S. & Shandall, A. 2007. 
Larval therapy from antiquity to the present day: mechanisms of action, clinical 
applications and future potential. Postgraduate medical journal, 83, 409-413. 
Williams, P. A., Cosme, J., Vinković, D. M., Ward, A., Angove, H. C., Day, P. J., Vonrhein, 
C., Tickle, I. J. & Jhoti, H. 2004. Crystal structures of human cytochrome P450 3A4 
bound to metyrapone and progesterone. Science, 305, 683-686. 
Williams, P. A., Cosme, J., Ward, A., Angove, H. C., Vinković, D. M. & Jhoti, H. 2003. 
Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature, 424, 
464-468. 
Wondji, C. S., Irving, H., Morgan, J., Lobo, N. F., Collins, F. H., Hunt, R. H., Coetzee, M., 
Hemingway, J. & Ranson, H. 2009. Two duplicated P450 genes are associated with 
pyrethroid resistance in Anopheles funestus, a major malaria vector. Genome research, 
19, 452-459. 
World Health Organization 1982. Manual on environmental management for mosquito control, 
with special emphasis on malaria vectors. 
World Health Organization 2010. First WHO report on neglected tropical diseases: working to 
overcome the global impact of neglected tropical diseases. First WHO report on 
neglected tropical diseases: Working to overcome the global impact of neglected 
tropical diseases. WHO. 
World Health Organization 2013. Malaria entomology and vector control, World Health 
Organization. 
Yadouleton, A. W., Padonou, G., Asidi, A., Moiroux, N., Bio-Banganna, S., Corbel, V., 
N'guessan, R., Gbenou, D., Yacoubou, I. & Gazard, K. 2010. Insecticide resistance 
status in Anopheles gambiae in southern Benin. Malar J, 9, 10.1186. 
159 
 
Yano, J. K., Wester, M. R., Schoch, G. A., Griffin, K. J., Stout, C. D. & Johnson, E. F. 2004. 
The structure of human microsomal cytochrome P450 3A4 determined by X-ray 
crystallography to 2.05-Å resolution. Journal of Biological Chemistry, 279, 38091-
38094. 
Yoshio, I. 1981. The roles of cytochrome b5 in reconstituted monooxygenase systems 
containing various forms of hepatic microsomal cytochrome P-450. Journal of 
biochemistry, 89, 351-362. 
Zhang, M. & Scott, J. G. 1996. Cytochrome b5 Is Essential for Cytochrome P450 6D1-
Mediated Cypermethrin Resistance in LPR House Flies. Pesticide biochemistry and 
physiology, 55, 150-156. 
Zhu, F., Parthasarathy, R., Bai, H., Woithe, K., Kaussmann, M., Nauen, R., Harrison, D. A. & 
Palli, S. R. 2010. A brain-specific cytochrome P450 responsible for the majority of 
deltamethrin resistance in the QTC279 strain of Tribolium castaneum. Proceedings of 
the National Academy of Sciences, 107, 8557-8562. 
Zoller, M. J. 1991. New molecular biology methods for protein engineering. Current Opinion 
in Structural Biology, 1, 605-610. 
Zoller, M. J. 1992. New recombinant DNA methodology for protein engineering. Current 
opinion in biotechnology, 3, 348-354. 
 
  
160 
 
Appendix 1: Plasmid pB13  
 
All plasmids used in this project were provided by Dr. Mark Paine of Liverpool School of 
Tropical medicine, LSTM.  
 
pB13 is a modified vector of pCW ori. The Chemotaxis gene(500bp) on pCW was cut out 
using Nde I and Xba I and was replaced with a pair of linker oligos (LINK48 and LINK49 ) to 
create additional restriction sites on the new vector. This vector is also known as 
pCWmod1(10) or pCWmod1 (Barnes et al; 1991). 
 
 Fig. A2.1 Plasmid map of pCW ori 
 
 
Sequence of MCS: 
               ___________     ________ 
CAT ATG GAA GTG AAT TCC CGG GTA CCG AGG CTC TAG AGT CGA 
     Nde I                   Eco RI           Kpn I                        Xba  I   Acc I, Sal I 
    Xma I, Sma I 
__        _________ 
CCT GCA GCC CAA GCT TAT CGA TGA TAA G 
        Pst I                 Hind III     Cla I 
 
 
 
Properties:- 
Ptac Ptac (Tac promoter):- Hybrid of trp and lac 
promoters 
M13:- Bacteriophage origin of replication 
Lac Z:- β-galactosidase gene  
Lac IQ:- Mutation in the promoter of the lacI gene of 
E. coli for increased transcription and higher levels of 
lac repressor within cells 
Ori :- Origin of replication, uses host’s replicating 
protein for replication 
Amp r:- Ampicillin resistant gene, selectable marker 
MCS:- Multiple cloning site 
Transcript. Term-Transcription Terminator 
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Appendix 2:  DNA Sequence confirmation of SDM of CYP6Z2(R210A)  
 
SDM             CATATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGTAGCG 60 
Primer          ------------------------------------------------------------ 
CYP             CATATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGTAGCG 60 
                                                                             
 
SDM             CAGGCCGCTCCGATGGCTGTTTATACTCTTGCTCTTGTTGCGGCCGTGATCTTTCTCGTG 120 
Primer          ------------------------------------------------------------ 
CYP             CAGGCCGCTCCGATGGCTGTTTATACTCTTGCTCTTGTTGCGGCCGTGATCTTTCTCGTG 120 
                                                                             
 
SDM             CTCCGCTACATCTACTCTCACTGGGAGAGGCATGGACTTCCGCATCTAAAGCCAGAGATT 180 
Primer          ------------------------------------------------------------ 
CYP             CTCCGCTACATCTACTCTCACTGGGAGAGGCATGGACTTCCGCATCTAAAGCCAGAGATT 180 
                                                                             
 
SDM             CCGTACGGCAACATACGCACCGTTGCCGAGAAGAAAGAATCATTCGGCACTGCCATCAAC 240 
Primer          ------------------------------------------------------------ 
CYP             CCGTACGGCAACATACGCACCGTTGCCGAGAAGAAAGAATCATTCGGCACTGCCATCAAC 240 
                                                                             
 
SDM             AACCTGTACCACAAGTCGTCCGACCGTCTGCTGGGAATCTACCTGTTCTTCCGCCCTGCT 300 
Primer          ------------------------------------------------------------ 
CYP             AACCTGTACCACAAGTCGTCCGACCGTCTGCTGGGAATCTACCTGTTCTTCCGCCCTGCT 300 
                                                                             
 
SDM             ATCTTGATTCGCGATCCTCATCTCGCGAAGCGTATTATGGTAAACGACTTCCAGAACTTT 360 
Primer          ------------------------------------------------------------ 
CYP             ATCTTGATTCGCGATCCTCATCTCGCGAAGCGTATTATGGTAAACGACTTCCAGAACTTT 360 
                                                                             
 
SDM             CACGATCGCGGTGTCGCCTGCAATGAAGAGCACGATCCCTTCTCGGCCAATCTGTTCGCT 420 
Primer          ---GATCGCGGTGTCGCCTGCAATGAAGAGCACG-------------------------- 31 
CYP             CACGATCGCGGTGTCTACTGCAATGAAGAGCACGATCCCTTCTCGGCCAATCTGTTCGCT 420 
                   ************  *****************                           
 
SDM             CTGCCCGGTCAGCGGTGGAAGAACTTGCGTGCGAAGCTCACGCCGACCTTCACGTCCGGA 480 
Primer          ------------------------------------------------------------ 
CYP             CTGCCCGGTCAGCGGTGGAAGAACTTGCGTGCGAAGCTCACGCCGACCTTCACGTCCGGA 480 
                                                                             
 
SDM             CAACTGCGTAACATGCTCCCCACCCTGCTGGACGTCGGAAACAAGTTGATCGATCGTATG 540 
Primer          ------------------------------------------------------------ 
CYP             CAACTGCGTAACATGCTCCCCACCCTGCTGGACGTCGGAAACAAGTTGATCGATCGTATG 540 
                                                                             
 
SDM             AACAAGGTGGCCGACGAGAAGGCGATCGTCGATATGCGTGATATTGCGTCACGGTTTGTG 600 
Primer          ------------------------------------------------------------ 
CYP             AACAAGGTGGCCGACGAGAAGGCGATCGTCGATATGCGTGATATTGCGTCACGGTTTGTG 600 
                                                                             
 
SDM             CTCGACACGATCGCTTCGGTGTTCTTCGGCTTTGAGGCAAACTGTATTCACAACTCGGAA 660 
Primer          ------------------------------------------------------------ 
CYP             CTCGACACGATCGCTTCGGTGTTCTTCGGCTTTGAGGCAAACTGTATTCACAACTCGGAA 660 
                                                                             
 
SDM             GATCCCTTCCTATCGACACTGCGCCGTGCTAATCGGGGACGCAACTTTATCGATAACTTC 720 
Primer          ------------------------------------------------------------ 
CYP             GATCCCTTCCTATCGACACTGCGCCGTGCTAATCGGGGACGCAACTTTATCGATAACTTC 720 
                                                                             
 
SDM             CGTTCGTCTGGTGTATTTATTTGTCCCGGGCTGTTGAAGCTTACCCGCATGACATCTCTC 780 
Primer          ------------------------------------------------------------ 
CYP             CGTTCGTCTGGTGTATTTATTTGTCCCGGGCTGTTGAAGCTTACCCGCATGACATCTCTC 780 
                                                                             
 
SDM             CAGCCTGAATTGATTAAGTTTGTGATGGAGATCATCACCCATCAGATTGATCATCGCGAG 840 
Primer          ------------------------------------------------------------ 
CYP             CAGCCTGAATTGATTAAGTTTGTGATGGAGATCATCACCCATCAGATTGATCATCGCGAG 840 
                                                                             
 
SDM             AAGAACCAGATCACTCGCAAAGACTTTGTTCAGCTACTGATTGATCTGCGTCGTGAAGCT 900 
Primer          ------------------------------------------------------------ 
CYP             AAGAACCAGATCACTCGCAAAGACTTTGTTCAGCTACTGATTGATCTGCGTCGTGAAGCT 900 
162 
 
                                                                             
 
SDM             GATAAAGGTTCGGAAGAAGCACTTACAATCGAACAGTGTGCAGCCAATGTGTTCCTGTTT 960 
Primer          ------------------------------------------------------------ 
CYP             GATAAAGGTTCGGAAGAAGCACTTACAATCGAACAGTGTGCGGCCAATGTGTTCCTGTTT 960 
                                                                             
 
SDM             TACATTGNCCGNNGCGGAAACGTCAACAGCAACGATCTCGTTCACGCTCCACGAGCTTTC 1020 
Primer          ------------------------------------------------------------ 
CYP             TACATTGCCGGTGCGGAAACGTCAACAGCAACGATCTCGTTCACGCTCCACGAGCTTTCG 1020 
                                                                             
 
SDM             GCACAATCCAGAAGCGATGGCAAACTGCAGCAAGAAATTGACGA---------------- 1064 
Primer          ------------------------------------------------------------ 
CYP             CACAATCCAGAAGCGATGGCAAAACTGCAGCAAGAAATTGACGAGATGATGGAGCGATAT 1080 
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Appendix 3: PCR reactions 
 
Phusion Polymerase was used to create the two truncations in a thermal Cycle of 35 as follows: 
Reaction Mixture Volume 
10 x buffer 2.5ul 
Forward Primer 1ul 
Reverse Primer 1ul 
Template 1ul 
DNTPs 0.5ul 
Phusion Polymerase 0.5ul 
Water 18.5ul 
Total Volume 25ul 
 
Phusion high fidelity polymerase thermal Cycle 
 Temperature Time Cycle 
Initial Denaturation 90
o
C 30s 1 
Denaturation 90
o
C 10s  
35 Annealing 65
o
C 5s 
Extention 72
o
C  
Final Extention 72
o
C 10min 1 
Hold 4
o
C  1 
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Appendix 4: CPR quantification graphs and total protein evaluations 
 
NADPH – Cytochrome C Reduction Assay Co-expressed with CYP6Z2(Wild Type) 
 
NADPH – Cytochrome C Reduction Assay Co-expressed with CYP6Z2(F115A) 
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CYP6Z2 TYPE TOTAL 
PROTEIN
(mg/ml) 
P450 
CONTENT 
(µM) 
P450 
CONTENT 
(nmol/mg 
protein) 
P450 
REDUCTASE 
ACTIVITY(n
mol/min/mg 
CYP6Z2(wild) 49.37 8.43 0.171 25.14 
CYP6Z2(F115A) 36.36 1.889 0.052 29.47 
CYP6Z2(F115L) 32.66 2.633 0.082 18.51 
CYP6Z2(F115Y) 35.62 4.089 0.115 20.05 
CYP6Z2(Y102A) 38.61 0.712 0.018 18.50 
CYP6Z2(Y102F) 49.92 1.91 0.038 28.62 
CYP6Z2(F212L) 46.70 2.486 0.053 18.04 
 
 
CYP6P3 TOTAL 
PROTEIN 
(mg/ml) 
P450 
CONTE
NT (uM) 
P450 
CONTENT 
(nmol/mg 
protein) 
P450 
REDUCTAS
E 
ACTIVITY(n
mol/min/mg 
protein 
Wild –CYP6P3 15.80 1.364 0.0863 721.04 
 Mutant CYP6P3 
(F110Y) 
16.33 0.6478 0.039 772.31 
Mutant CYP6P3 
(L216F) 
18.27 2.188 0.119 401.62 
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Appendix 5: Amino Acid sequence confirmation of double mutant CYP6Z2 
(F212L,Y102F)  
Amino Acid Alignment ompACYP6Z2 
 
CYP6Z2          MKKTAIAIAVALAGFATVAQAAPMAVYTLALVAAVIFLVLRYIYSHWERHGLPHLKPEIP 60 
SDM             MKKTAIAIAVALAGFATVAQAAPMAVYTLALVAAVIFLVLRYIYSHWERHGLPHLKPEIP 60 
                ************************************************************ 
 
CYP6Z2          YGNIRTVAEKKESFGTAINNLYHKSSDRLLGIYLFFRPAILIRDPHLAKRIMVNDFQNFH 120 
SDM             YGNIRTVAEKKESFGTAINNLYHKSSDRLLGIYLFFRPAILIRDPHLAKRIMVNDFQNFH 120 
                ************************************************************ 
 
CYP6Z2          DRGVFCNEEHDPFSANLFALPGQRWKNLRAKLTPTFTSGQLRNMLPTLLDVGNKLIDRMN 180 
SDM             DRGVYCNEEHDPFSANLFALPGQRWKNLRAKLTPTFTSGQLRNMLPTLLDVGNKLIDRMN 180 
                ****:******************************************************* 
 
CYP6Z2          KVADEKAIVDMRDIASRFVLDTIASVFFGFEANCIHNSEDPFLSTLRRANRGRNLIDNFR 240 
SDM             KVADEKAIVDMRDIASRFVLDTIASVFFGFEANCIHNSEDPFLSTLRRANRGRNFIDNFR 240 
                ******************************************************:***** 
 
CYP6Z2          SSGVFICPGLLKLTRMTSLQPELIKFVMEIITHQIDHREKNQITRKDFVQLLIDLRREAD 300 
SDM             SSGVFICPGLLKLTRMTSLQPELIKFVMEIITHQIDHREKNQITRKDFVQLLIDLRREAD 300 
                ************************************************************ 
 
CYP6Z2          KGSEEALTIEQCAANVFLFYIAGAETSTATISFTLHELSHNPEAMAKLQQEIDEMMERYN 360 
SDM             KGSEEALTIEQCAANVFLFYIAGAETSTATISFTLHELSHNPEAMAKLQQEIDEMMERYN 360 
                ************************************************************ 
 
CYP6Z2          GEITYENIKEMKYLDLCVKETLRKYPGLPILNRECTIDYKVPDSDVVIRKGTQVIIPLLS 420 
SDM             GEITYENIKEMKYLDLCVKETLRKYPGLPILNRECTIDYKVPDSDVVIRKGTQVIIPLLS 420 
                ************************************************************ 
 
CYP6Z2          ISMNEKYFPDPELYSPERFDEATKNYDADAYYPFGAGPRNCIGLRQGVLVSKIGLVFLLS 480 
SDM             ISMNEKYFPDPELYSPERFDEATKNYDADAYYPFGAGPRNCIGLRQGVLVSKIGLVFLLS 480 
                ************************************************************ 
 
CYP6Z2          KFNFQATTPAKVKFAAATVGLTPDAGFPMRIDHRK 515 
SDM             KFNFQATTPAKVKFAAATVGLTPDAGFPMRIDHRK 515 
                *********************************** 
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Appendix 6: Amino acid sequence confirmation of double mutant 
CYP6Z2(F212L,Y102A)  
 
CYP6Z2_Wild_Type_        MKKTAIAIAVALAGFATVAQAAPMAVYTLALVAAVIFLVLRYIYSHWERHGLPHLKPEIP 60 
CYP6Z2_Y102A_F212L_      MKKTAIAIAVALAGFATVAQAAPMAVYTLALVAAVIFLVLRYIYSHWERHGLPHLKPEIP 60 
                         ************************************************************ 
 
CYP6Z2_Wild_Type_        YGNIRTVAEKKESFGTAINNLYHKSSDRLLGIYLFFRPAILIRDPHLAKRIMVNDFQNFH 120 
CYP6Z2_Y102A_F212L_      YGNIRTVAEKKESFGTAINNLYHKSSDRLLGIYLFFRPAILIRDPHLAKRIMVNDFQNFH 120 
                         ************************************************************ 
 
CYP6Z2_Wild_Type_        DRGVYCNEEHDPFSANLFALPGQRWKNLRAKLTPTFTSGQLRNMLPTLLDVGNKLIDRMN 180 
CYP6Z2_Y102A_F212L_      DRGVACNEEHDPFSANLFALPGQRWKNLRAKLTPTFTSGQLRNMLPTLLDVGNKLIDRMN 180 
                         **** ******************************************************* 
 
CYP6Z2_Wild_Type_        KVADEKAIVDMRDIASRFVLDTIASVFFGFEANCIHNSEDPFLSTLRRANRGRNFIDNFR 240 
CYP6Z2_Y102A_F212L_      KVADEKAIVDMRDIASRFVLDTIASVFFGFEANCIHNSEDPFLSTLRRANRGRNLIDNFR 240 
                         ******************************************************:***** 
 
CYP6Z2_Wild_Type_        SSGVFICPGLLKLTRMTSLQPELIKFVMEIITHQIDHREKNQITRKDFVQLLIDLRREAD 300 
CYP6Z2_Y102A_F212L_      SSGVFICPGLLKLTRMTSLQPELIKFVMEIITHQIDHREKNQITRKDFVQLLIDLRREAD 300 
                         ************************************************************ 
 
CYP6Z2_Wild_Type_        KGSEEALTIEQCAANVFLFYIAGAETSTATISFTLHELSHNPEAMAKLQQEIDEMMERYN 360 
CYP6Z2_Y102A_F212L_      KGSEEALTIEQCAANVFLFYIAGAETSTATISFTLHELSHNPEAMAKLQQEIDEMMERYN 360 
                         ************************************************************ 
 
CYP6Z2_Wild_Type_        GEITYENIKEMKYLDLCVKETLRKYPGLPILNRECTIDYKVPDSDVVIRKGTQVIIPLLS 420 
CYP6Z2_Y102A_F212L_      GEITYENIKEMKYLDLCVKETLRKYPGLPILNRECTIDYKVPDSDVVIRKGTQVIIPLLS 420 
                         ************************************************************ 
 
CYP6Z2_Wild_Type_        ISMNEKYFPDPELYSPERFDEATKNYDADAYYPFGAGPRNCIGLRQGVLVSKIGLVFLLS 480 
CYP6Z2_Y102A_F212L_      ISMNEKYFPDPELYSPERFDEATKNYDADAYYPFGAGPRNCIGLRQGVLVSKIGLVFLLS 480 
                         ************************************************************ 
 
CYP6Z2_Wild_Type_        KFNFQATTPAKVKFAAATVGLTPDAGFPMRIDHRK 515 
CYP6Z2_Y102A_F212L_      KFNFQATTPAKVKFAAATVGLTPDAGFPMRIDHRK 515 
                         *********************************** 
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Appendix 7: Resorufin standard curve 
 
 
 
 
1 unit of activity = ΔFLU/min x dilution factor of sample 
(pmole/ml/min)       (FLU/pmole)  
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Appendix 8:  DNA sequence alignments of documented alleles of CYP6Z2 amino acid with 
the gene used in this project. 
 
CYP6Z2_Q7PNB5_      -----------------------MFVYTLALVAAVIFLVLRYIYSHWERHGLPHLKPEIP 37 
CYP6Z2_A8I285_      -----------------------MFVYTLALVAAVIFLVLRYIYSHWERHGLPHLKPEIP 37 
CYP6Z2_Q8T625_      -----------------------MFVYTLALVAAVIFLVLRYIYSHWERHGLPHLKPEIP 37 
SDM                 MKKTAIAIAVALAGFATVAQAAPMAVYTLALVAAVIFLVLRYIYSHWERHGLPHLKPEIP 60 
                                           * *********************************** 
 
CYP6Z2_Q7PNB5_      YGNIRTVAEKKESFGTAINNLYHKSSDRLLGIYLFFRPAILIRDPHLAKRIMVNDFQNFH 97 
CYP6Z2_A8I285_      YGNIRTVAEKKESFGTAINNLYHKSSDRLLGIYLFFRPAILIRDPHLAKRIMVNDFQNFH 97 
CYP6Z2_Q8T625_      YGNIRTVAEKKESFGTAINNLYHKSSDRLLGIYLFFRPAILIRDPHLAKRIMVNDFQNFH 97 
SDM                 YGNIRTVAEKKESFGTAINNLYHKSSDRLLGIYLFFRPAILIRDPHLAKRIMVNDFQNFH 120 
                    ************************************************************ 
 
CYP6Z2_Q7PNB5_      DRGVYCNEEHDPFSANLFALPGQRWKNLRAKLTPTFTSGQLRNMLPTLLDVGNKLIDRMN 157 
CYP6Z2_A8I285_      DRGVYCNEEHDPFSANLFALPGQRWKNLRAKLTPTFTSGQLRNMLPTLLDVGNKLIDRMN 157 
CYP6Z2_Q8T625_      DRGVYCNEEHDPFSANLFALPGQRWKNLRAKLTPTFTSGQLRNMLPTLLDVGNKLIDRMN 157 
SDM                 DRGVYCNEEHDPFSANLLALPGQRWKNLRAKLTPTFTSGQLRNMLPTLLDVGNKLIDRMN 180 
                    *****************:****************************************** 
 
CYP6Z2_Q7PNB5_      KVADEKAIVDMRDIASRFVLDTIASVFFGFEANCIHNSEDPFLSTLRRANRGRNFIDNFR 217 
CYP6Z2_A8I285_      KVADEKAIVDMRDIASRFVLDTIASVFFGFEANCIHNSEDPFLTTLRRANRGRNFIDNFR 217 
CYP6Z2_Q8T625_      KVADEKAIVDMRDIASRFVLDTIASVFFGFEANCIHNSEDPFLSTLRRANRGRNFIDNFR 217 
SDM                 KVADEKAIVDMRDIASRFVLDTIASVFFGFEANCIHNSEDPFLSTLRRANRGRNFIDNFR 240 
                    *******************************************:**************** 
 
CYP6Z2_Q7PNB5_      SSGVFICPGLLKLTRMTSLQPELIKFVMEIITHQIDHREKNQITRKDFVQLLIDLRREAD 277 
CYP6Z2_A8I285_      SSGVFICPGLLKLTRMTSLQPELIKFVMEIITHQIDHREKNQITRKDFVQLLIDLRREAD 277 
CYP6Z2_Q8T625_      SSGVFICPGLLKLTRMTSLQPELIKFVMEIITHQIDHREKNQITRKDFVQLLIDLRREAD 277 
SDM                 SSGVFICPGLLKLTRMTSLQPELIKFVMEIITHQIDHREKNQITRKDFVQLLIDLRREAD 300 
                    ************************************************************ 
 
CYP6Z2_Q7PNB5_      KGSEEALTIEQCAANVFLFYIAGAETSTATISFTLHELSHNPEAMAKLQQEIDEMMERYN 337 
CYP6Z2_A8I285_      KGSEEALTIEQCAANVFLFYIAGAETSTATISFTLHELSHNPEAMAKLQQEIDEMMERYN 337 
CYP6Z2_Q8T625_      KGSEEALTIEQCAANVFLFYIAGAETSTATISFTLHELSHNPEAMAKLQQEIDEMMERYN 337 
SDM                 KGSEEALTIEQCAANVFLFYIAGAETSTATISFTLHELSHNPEAMAKLQQEIDEMMERYN 360 
                    ************************************************************ 
 
CYP6Z2_Q7PNB5_      GEITYENIKEMKYLDLCVKETLRKYPGLPILNRECTIDYKVPDSDVVIRKGTQVIIPLLS 397 
CYP6Z2_A8I285_      GEITYENIKEMKYLDLCVKETLRKYPGLPILNRECTIDYKVPDSDVVIRKGTQVIIPLLS 397 
CYP6Z2_Q8T625_      GEITYENIKEMKYLDLCVKETLRKYPGLPILNRECTIDYKVPDSDVVIRKGTQVIIPLLS 397 
SDM                 GEITYENIKEMKYLDLCVKETLRKYPGLPILNRECTIDYKVPDSDVVIRKGTQVIIPLLS 420 
                    ************************************************************ 
 
CYP6Z2_Q7PNB5_      ISMNEKYFPDPELYSPERFDEATKNYDADAYYPFGAGPRNCIGLRQGVLVSKIGLVFLLS 457 
CYP6Z2_A8I285_      ISMNEKYFPDPELYSPERFDEATKNYDADAYYPFGAGPRNCIGLRQGVLVSKIGLVFLLS 457 
CYP6Z2_Q8T625_      ISMNEKYFPDPELYSPERFDEATKNYDADAYYPFGAGPRNCIG--QGVLVSKIGLVFLLS 455 
SDM                 ISMNEKYFPDPELYSPERFDEATKNYDADAYYPFGAGPRNCIGLRQGVLVSKIGLVFLLS 480 
                    *******************************************  *************** 
 
CYP6Z2_Q7PNB5_      KFKFQATTPAKVKFAAATVGLTPDAGFPMRIDHRK 492 
CYP6Z2_A8I285_      KFKFQATTPAKVKFAAATVGLTPDAGFPMRIDHRK 492 
CYP6Z2_Q8T625_      KFNFQATTPAKVKFAAATVGLTPDAGFPMRIDHRK 490 
SDM                 KFNFQATTPAKVKFAAATVGLTPDAGFPMRIDHRK 515 
                    **:******************************** 
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Appendix 9: Analysis of mutations observed in the polymorphism of CYP6Z2 
 
Swissprot 
accession code 
Amino 
Acid 
Position 1 Position 2 Position 3 Position 4 No of 
mutations- 
To working 
gene 
CYP6Z2_Q7PNB5 492 S201 L441 R442 K460 1 
CYP6Z2_A8I285 492 T201 L441 R442 K460 2 
CYP6Z2_Q8T625 490 S201 NA NA N458 2 
Working Gene 492 S201 L441 R442 N460  
 
The closest to the working gene is CYP6Z2_Q7PNB5 with 1 mutation at K60N. 
 
Nucleotide Alignment with CYP6Z2_Q7PNB5  
 
CYP6Z2_Q7PNB5      ATGTTTGTTTACACTCTCGCGCTCGTGGCGGCCGTGATCTTTCTCGTGCTCCGCTACATC 60 
Working            ATGGCTGTTTATACTCTTGCTCTTGTTGCGGCCGTGATCTTTCTCGTGCTCCGCTACATC 60 
                   ***  ****** ***** ** ** ** ********************************* 
 
CYP6Z2_Q7PNB5      TACTCTCACTGGGAGAGGCATGGACTTCCTCATCTAAAGCCAGAGATTCCGTACGGCAAC 120 
Working            TACTCTCACTGGGAGAGGCATGGACTTCCGCATCTAAAGCCAGAGATTCCGTACGGCAAC 120 
                   ***************************** ****************************** 
 
CYP6Z2_Q7PNB5      ATACGCACCGTTGCCGAGAAGAAAGAATCATTCGGCACTGCCATCAACAACCTGTACCAC 180 
Working            ATACGCACCGTTGCCGAGAAGAAAGAATCATTCGGCACTGCCATCAACAACCTGTACCAC 180 
                   ************************************************************ 
 
CYP6Z2_Q7PNB5      AAGTCGTCCGACCGTCTGCTGGGAATCTATCTGTTCTTCCGCCCTGCTATCTTGATTCGC 240 
Working            AAGTCGTCCGACCGTCTGCTGGGAATCTACCTGTTCTTCCGCCCTGCTATCTTGATTCGC 240 
                   ***************************** ****************************** 
 
CYP6Z2_Q7PNB5      GATCCTCATCTCGCGAAGCGTATCATGGTAAACGACTTCCAGAACTTTCACGATCGCGGT 300 
Working            GATCCTCATCTCGCGAAGCGTATTATGGTAAACGACTTCCAGAACTTTCACGATCGCGGT 300 
                   *********************** ************************************ 
 
CYP6Z2_Q7PNB5      GTCTACTGCAATGAAGAGCACGATCCCTTCTCGGCCAATCTGTTCGCTCTGCCCGGTCAG 360 
Working            GTCTACTGCAATGAAGAGCACGATCCCTTCTCGGCCAATCTGTTCGCTCTGCCCGGTCAG 360 
                   ************************************************************ 
 
CYP6Z2_Q7PNB5      CGGTGGAAGAACTTACGTGCGAAGCTCACGCCGACCTTCACGTCCGGACAACTACGTAAC 420 
Working            CGGTGGAAGAACTTGCGTGCGAAGCTCACGCCGACCTTCACGTCCGGACAACTGCGTAAC 420 
                   ************** ************************************** ****** 
 
CYP6Z2_Q7PNB5      ATGCTCCCCACTCTCCTGGACGTCGGCAACAAGCTGATCGATCGTATGAACAAGGTGGCG 480 
Working            ATGCTCCCCACCCTGCTGGACGTCGGAAACAAGTTGATCGATCGTATGAACAAGGTGGCC 480 
                   *********** ** *********** ****** *************************  
 
CYP6Z2_Q7PNB5      GACGAGAAGGCGATCGTTGATATGCGTGATATTGCGTCACGGTTTGTGCTCGACACGATC 540 
Working            GACGAGAAGGCGATCGTCGATATGCGTGATATTGCGTCACGGTTTGTGCTCGACACGATC 540 
                   ***************** ****************************************** 
 
CYP6Z2_Q7PNB5      GCTTCGGTGTTCTTCGGCTTCGAGGCAAACTGTATTCACAACTCGGAAGATCCCTTCCTA 600 
Working            GCTTCGGTGTTCTTCGGCTTTGAGGCAAACTGTATTCACAACTCGGAAGATCCCTTCCTA 600 
                   ******************** *************************************** 
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CYP6Z2_Q7PNB5      TCGACACTGCGCCGTGCTAATCGGGGACGCAACTTTATCGATAACTTCCGTTCGTCTGGT 660 
Working            TCGACACTGCGCCGTGCTAATCGGGGACGCAACTTTATCGATAACTTCCGTTCGTCTGGT 660 
                   ************************************************************ 
 
CYP6Z2_Q7PNB5      GTATTTATTTGTCCTGGGTTGTTGAAGCTTACCCGCATGACATCTCTCCAGCCTGAATTG 720 
Working            GTATTTATTTGTCCCGGGCTGTTGAAGCTTACCCGCATGACATCTCTCCAGCCTGAATTG 720 
                   ************** *** ***************************************** 
 
CYP6Z2_Q7PNB5      ATTAAGTTTGTGATGGAGATCATCACCCATCAGATTGATCATCGCGAGAAGAATCAAATC 780 
Working            ATTAAGTTTGTGATGGAGATCATCACCCATCAGATTGATCATCGCGAGAAGAACCAGATC 780 
                   ***************************************************** ** *** 
 
CYP6Z2_Q7PNB5      ACTCGCAAAGACTTTGTGCAGCTACTGATTGATCTGCGTCGTGAAGCTGATAAAGGTTCG 840 
Working            ACTCGCAAAGACTTTGTTCAGCTACTGATTGATCTGCGTCGTGAAGCTGATAAAGGTTCG 840 
                   ***************** ****************************************** 
 
CYP6Z2_Q7PNB5      GAAGAAGCACTTACAATCGAACAGTGTGCGGCCAATGTGTTCCTGTTCTACATTGCCGGT 900 
Working            GAAGAAGCACTTACAATCGAACAGTGTGCAGCCAATGTGTTCCTGTTTTACATTGCCGGT 900 
                   ***************************** ***************** ************ 
 
CYP6Z2_Q7PNB5      GCAGAAACATCAACGGCAACGATCTCGTTCACACTCCATGAACTTTCGCACAATCCAGAA 960 
Working            GCGGAAACGTCAACAGCAACGATCTCGTTCACGCTCCACGAGCTTTCGCACAATCCAGAA 960 
                   ** ***** ***** ***************** ***** ** ****************** 
 
CYP6Z2_Q7PNB5      GCGATGGCAAAGCTGCAGCAAGAAATTGACGAGATGATGGAGCGATATAACGGCGAAATC 1020 
Working            GCGATGGCAAAGCTGCAGCAAGAAATTGACGAGATGATGGAGCGATATAACGGCGAAATC 1020 
                   ************************************************************ 
 
CYP6Z2_Q7PNB5      ACGTATGAGAACATAAAAGAGATGAAGTACTTGGATTTGTGCGTGAAAGAAACGCTTCGA 1080 
Working            ACGTATGAGAACATAAAAGAGATGAAGTACTTGGATTTGTGCGTGAAGGAAACGCTTCGA 1080 
                   *********************************************** ************ 
 
CYP6Z2_Q7PNB5      AAGTATCCGGGCTTGCCGATTCTGAACCGAGAGTGCACGATCGACTACAAAGTGCCGGAC 1140 
Working            AAGTATCCTGGCTTGCCGATTCTGAACCGAGAGTGCACGATCGACTACAAAGTGCCGGAC 1140 
                   ******** *************************************************** 
 
CYP6Z2_Q7PNB5      AGTGATGTTGTGATACGCAAGGGAACTCAGGTGATCATACCGTTGTTGAGTATCAGTATG 1200 
Working            AGTGATGTTGTGATACGCAAGGGAACTCAGGTGATCATACCGTTGTTGAGTATCAGTATG 1200 
                   ************************************************************ 
 
CYP6Z2_Q7PNB5      AACGAGAAGTACTTCCCCGATCCAGAGCTCTATTCTCCAGAGCGGTTTGACGAGGCCACG 1260 
Working            AACGAGAAGTACTTCCCCGATCCAGAGCTCTATTCTCCAGAGCGGTTTGACGAGGCCACA 1260 
                   ***********************************************************  
 
CYP6Z2_Q7PNB5      AAGAACTACGATGCAGATGCGTACTATCCGTTCGGAGCTGGTCCTCGCAATTGCATCGGC 1320 
Working            AAGAACTACGATGCAGATGCGTACTATCCGTTCGGAGCTGGTCCTCGCAATTGCATCGGC 1320 
                   ************************************************************ 
 
CYP6Z2_Q7PNB5      CTTCGACAAGGTGTATTGGTGTCCAAAATAGGGCTTGTTTTCTTGCTGTCAAAGTTCAAG 1380 
Working            CTTCGACAAGGTGTATTGGTGTCCAAAATAGGACTTGTTTTCTTGCTGTCAAAGTTCAAC 1380 
                   ******************************** **************************  
 
CYP6Z2_Q7PNB5      TTCCAGGCCACAACTCCTGCAAAAGTAAAGTTTGCAGCCGCTACTGTAGGTCTCACTCCA 1440 
Working            TTCCAAGCCACAACTCCGGCAAAGGTAAAGTTTGCCGCCGCTACTGTAGGTCTCACTCCA 1440 
                   ***** *********** ***** *********** ************************ 
 
CYP6Z2_Q7PNB5      GACGCTGGATTCCCAATGAGGATAGACCATAGAAAGTGA 1479 
Working            GACGCTGGATTCCCAATGAGGATAGACCATAGAAAGTGA 1479 
                   ***************************************       
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The alignment above shows 33mutations. 32 of the mutations are silent, thus are synonymous 
SNPs. However, the mutation at position 1380, from G to C caused a non-synonymous SNP by 
changing the amino acid from Lysine to Asparagine. 
Conclusion 
My working gene is a closer allele of CYP6Z2_Q7PNB5. 
 
NB: 
Please note that the mutations observed at the beginning of the gene were deliberately done to 
improve the expression of the working gene. 
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Appendix 10: Amino acid sequence confirmation of CYP6P3  
 
Primers         MKKTAIAIAVALAGFATVAQAGMELINAVLAAFIFAVSIVYLFIRNKHNYWKDNGFPYAP 60 
CYP6P3          ----------------------MELINAVLAAFIFAVSIVYLFIRNKHNYWKDNGFPYAP 38 
                                      ************************************** 
 
Primers         NPHFLFGHAKGQAQTRHGADIHQELYRYFKQRGERYGGISQFIVPSVLVIDPELAKTILV 120 
CYP6P3          NPHFLFGHAKGQAQTRHGADIHQELYRYFKQRGERYGGISQFIVPSVLVIDPELAKTILV 98 
                ************************************************************ 
 
Primers         KDFNVFHDHGVFTNAKDDPLTGHLFALEGQPWRLMRQKLTPTFTSGRMKQMFGTIWDVGL 180 
CYP6P3          KDFNVFHDHGVFTNAKDDPLTGHLFALEGQPWRLMRQKLTPTFTSGRMKQMFGTIRDVGL 158 
                ******************************************************* **** 
 
Primers         ELEKCMEQSYNQPEVEMKDILGRFTTDVIGTCAFGIECNTLKTTDSEFRKYGNKAFELNT 240 
CYP6P3          ELEKCMEQSYNQPEVEMKDILGRFTTDVIGTCAFGIECNTLKTTDSEFRKYGNKAFELNT 218 
                ************************************************************ 
 
Primers         MIMMKTFLASSYPTLVRNLHMKITYNDVERFFLDIVKETVDYREANNVKRNDFMNLMLQI 300 
CYP6P3          MIMMKTFLASSYPTLVRNLHMKITYNDVERFFLDIVKETVDYREANNVKRNDFMNLMLQI 278 
                ************************************************************ 
 
Primers         KNKGKLDDSDDGSVGKGEVGMTQNELAAQAFVFFLAGFETSSTTQSFCLYELAKNPDIQE 360 
CYP6P3          KNKGKLDDSDDGSLGKGEVGMTQNELAAQAFVFFLAGFETSSTTQSFCLYELAKNPDIQE 338 
                *************:********************************************** 
 
Primers         RLREEINRAIAENGGEVTYDVVMNIKYLDNVIDETLRKYPPVESLTRVPSVDYLIPGTKH 420 
CYP6P3          RLREEINRAIAENGGEVTYDVVMNIKYLDNVIDETLRKYPPVESLTRVPSVDYLIPGTKH 398 
                ************************************************************ 
 
Primers         VIPKRTLVQIPAYAIQRDPDHYPDPERFNPDRFLPEEVKKRHPFTFIPFGEGPRICIGLR 480 
CYP6P3          VIPKRTLVQIPAYAIQRDPDHYPDPERFNPDRFLPEEVKKRHPFTFIPFGEGPRICIGLR 458 
                ************************************************************ 
 
Primers         FGLMQTKVGLITLLRKFRFSPSARTPERVEYDPKMITIAPKAGNYLKVEKLHHHHHH 537 
CYP6P3          FGLMQTKVGLITLLRKFRFSPSARTPERVEYDPKMITIAPKAGNYLKVEKL------ 509 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
174 
 
 
Appendix 11: HPLC Chromatograms 
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Appendix 12: No of nucleotide change and the effects on enzyme activities. 
 
Sequence Alignment of wild type and 
mutants 
No of 
base 
mutated 
Fold increase 
AAGGCGTTCGAGTTGAATACGATGATCATGATGAAGA –CYP6P3(wild) 
CAAGGCGTTCGAGTTCAATACGATGATCATGATGAAG – CYP6P3(L216F) 
*************** *********************  
1     
 15- Fold (DEF) 
GATCACGGCGTGTTTACCAATGCAAAGGACGACC –CYP6P3(wild) 
GATCACGGCGTGTATACCAATGCAAAGGACGACC –CYP6P3(F110Y) 
  ************* ******************** 
1      
  4-Fold (DEF) 
GATCGCGGTGTCTACTGCAATGAAGAGCACG - CYP6Z2 (wild) 
GATCGCGGTGTCTTCTGCAATGAAGAGCACG - CYP6Z2 (Y102) 
************* *****************     
1     
  2-Fold(MR) 
AATCGGGGACGCAACTTTATCGATAACTTCCG CYP6Z2 (wild) 
AATCGGGGACGCAACTTGATCGATAACTTCCG CYP6Z2 (f212l) 
***************** ************** 
1     
  4-Fold (MR) 
GTGCTAATCGGGGACGCAACTTTATCGATAAC – CYP6Z2 (wild) 
GTGCTAATCGGGGAGCCAACTTTATCGATAAC - CYP6Z2 (R210A)                               
**************  **************** 
2    
  2-Fold (BR) 
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Appendix 13:  Amino acids sequence alignment of CYP6Z1, CYP6Z2 & CYP6Z3 
 
 
 
Amino Acids sequence alignment of CYP6Z1, CYP6Z2 and CYP6Z3. Asterisks represent 
identical residues, colons represent conserved residues, and dots represent semi conserved 
residues in the three sequences. The alignment indicates 332 identical positions and 116 similar 
positions. The amino acid identity of the three proteins is 67.206%. (Swissprot accession codes 
are Q8T631, Q8T625 and Q86LT6 respectively) -  UniProtKB/Swiss-Prot. www.uniprot.org 
 
 
 
 
181 
 
Appendix 14:  Amino acids sequence alignment of CYP6Z1, CYP6Z2 & CYP3A4 
 
Amino Acids sequence alignment of CYP6Z1, CYP6Z2, and CYP3A4. An. Gambiae CYP6Z1 
from the RSP-ST strain (GenBank accession no. AF487535), An. Gambiae CYP6Z2 from the 
PEST strain (GenBank accession no. XP_317252), and human CYP3A4 (Protein Data Bank ID 
code 1TQN) are shown with underlines representing α-helices and gray blocks representing 
SRS regions. Asterisks represent identical residues, colons represent conserved residues, and 
dots represent semi conserved residues in the three sequences. Residues in the 
CYP6Z1 sequence predicted to exist within 4.5 Å of DDT are boxed (Chiu et al. 2008). 
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Appendix 15: % amino acids identities between CYP6Z1, CYP6Z2, CYP6Z3 and 
CYP3A4 
Swissprot 
Accession 
Code  
Enzyme  Amino 
Acids 
Length  
Amino 
Acids % 
Identity  to 
CYP6Z1  
Amino Acids % 
Identity to 
CYP6Z2  
Amino 
Acids % 
Identity to 
CYP6Z3  
Amino 
Acids % 
Identity to 
CYP3A4  
Q8T631  CYP6Z1  494  -  69.433  68.623  27.132  
Q8T625  CYP6Z2  490  69.433  -  93.699  28.185  
Q86LT6  CYP6Z3  492  68.623  93.699  -  29.207  
P08684  CYP3A4  503  27.132  28.185  29.207  -  
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Appendix 16: DNA Sequence confirmation of ompACYP6Z1 
 
6z1template      ------------------------------------------------------------ 
forward          CATATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGTAGCG 60 
6z1template      ------------ATGATCCTTTACACGATCGGACTGATCGTGGCGTTTGTTTTCCTCGCC 48 
forward          CAGGCCGCTCCGATGATCCTTTACACGATCGGACTGATCGTGGCGTTTGTTTTCCTCGCC 120 
                             ************************************************ 
6z1template      CTCAAGTACGTCTACTCGTACTGGGATCGACAGGGGCTGCCGAATTTGAGGCCCGAAATT 108 
forward          CTCAAGTACGTCTACTCGTACTGGGATCGACAGGGGCTGCCGAATTTGAGGCCCGAAATT 180 
                 ************************************************************ 
6z1template      CCCTACGGCAATCTACGCATTCTAGCCCAAAAGAAAGAATCCTTCAATGTGGCTATTAAC 168 
forward          CCCTACGGCAATCTACGCATTCTAGCCCAAAAGAAAGAATCCTTCAATGTGGCTATTAAC 240 
                 ************************************************************ 
6z1template      GATCTGTACGACCGTTCCAGTGAACGGTTGGTTGGAGTTTATCTGTTCTTCCGCCCAGCG 228 
forward          GATCTGTACGACCGTTCCAGTGAACGGTTGGTTGGAGTTTATCTGTTCTTCCGCCCAGCG 300 
                 ************************************************************ 
6z1template      ATCCTGGTCCGGGATGCGCATCTCGCCAAGCGGATAATGATGAACGATTTCCAGCACTTT 288 
forward          ATCCTGGTCCGGGATGCGCATCTCGCCAAGCGGATAATGATGAACGATTTCCAGCACTTT 360 
                 ************************************************************ 
6z1template      CACGACCGTGGCGTCTACTGCAACGAGCACAGTGATCCGATGTCGGCCAACCTGTTCGCC 348 
forward          CACGACCGTGGCGTCTACTGCAACGAGCACAGTGATCCGATGTCGGCCAACCTGTTCGCC 420 
                 ************************************************************ 
6z1template      CTGCCCGGCCAGCGGTGGAAAAATCTGCGTGCGAAGCTTACACCAACCTTCACCTCCGGC 408 
forward          CTGCCCGGCCAGCGGTGGAAAAATCTGCGTGCGAAGCTTACACCAACCTTCACCTCCGGC 480 
                 ************************************************************ 
6z1template      CAGCTACGGCACATGCTGCCAACGTTTCTGGCAGTGGGCAGCAAGCTCGAGCAGTATCTC 468 
forward          CAGCTACGGCACATGCTGCCAACGTTTCTGGCAGTGGGCAGCAAGCTCGAGCAGTATCTC 540 
                 ************************************************************ 
6z1template      GAACGCTTGGCAAACGAAAAACAGTCCG---ACATGCGTGACATCGTTTCGCGCTACGTG 525 
forward          GAACGCTTGGCAAACGAAAAACAGTCCG---ACATGCGTGACATCGTTTCGCGCTACGTG 597 
                 ****************************   ***************************** 
 
6z1template      CTCGATGTGGTGGCTTCAGTGTTTTTCGGCTTCGAAGCCAACTGTCTGCACGATCCCGAC 585 
forward          CTCGATGTGGTGGCTTCAGTGTTTTTCGGCTTCGAAGCCAACTGTCTGCACGATCCCGAC 657 
184 
 
                 ************************************************************ 
6z1template      GATGCGTTCCGTGTGGCGTTGCGTGATCTTAACAATCCGGACAGCTTCATGAACAACATC 645 
forward          GATGCGTTCCGTGTGGCGTTGCGTGATCTTAACAATCCGGACAGCTTCATGAACAACATC 717 
                 ************************************************************ 
6z1template      CGAACAGCCGGCGTTTTTCTGTGTCCCGGGCTGCTAAAGTTTACCGGCATCAAATCGCTA 705 
forward          CGAACAGCCGGCGTTTTTCTGTGTCCCGGGCTGCTAAAGTTTACCGGCATCAAATCGCTA 777 
                 ************************************************************ 
6z1template      TCGCCTCCGATGAAAAAGTTTACCACAGAAGTGATCAGTTCCCATCTGCACCAGCGTGAG 765 
forward          TCGCCTCCGATGAAAAAGTTTACCACAGAAGTGATCAGTTCCCATCTGCACCAGCGTGAG 837 
                 ************************************************************ 
6z1template      ACGGGCCAGGTGATGCGCAAGGACTTTATCCAGATGCTAACGGATCTGCGCCGCAAGGCT 825 
forward          ACGGGCCAGGTGATGCGCAAGGACTTTATCCAGATGCTAACGGATCTGCGCCGCAAGGCT 897 
                 ************************************************************ 
6z1template      GGTAGCAGTGGGGAAGAAACGCTCACCGATGCACAGTGTGCGGCCAATGTGTTTCTGTTT 885 
forward          GGTAGCAGTGGGGAAGAAACGCTCACCGATGCACAGTGTGCGGCCAATGTGTTTCTG--- 954 
                 *********************************************************    
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Appendix 17: DNA Sequence confirmation of SDM of CYP6Z3 (F115A)  
 
FW Primer 1 
primer          CATATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTTCGCTACCGTAGCG 60 
Template        ------------------------------------------------------------ 
                                                                             
 
primer          CAGGCCGCTCCGATGGCTGTTTACACTCTCGCGCTCGTGGCGGCCGTGATCTTTCTCGTG 120 
Template        ------------ATGTTTGTTTACACTCTCGCGCTCGTGGCGGCCGTGATCTTTCTCGTG 48 
                            ***  ******************************************* 
 
primer          CTCCGCTACATCTACTCTCACTGGGAGAGGCATGGACTTCCGCATCTAAAGCCAGAGATT 180 
Template        CTCCGCTACATCTACTCTCACTGGGAGAGGCATGGACTTCCGCATCTAAAGCCAGAGATT 108 
                ************************************************************ 
 
primer          CCGTACGGCAACATACGCACCGTTGCCGAGAAGAAAGAATCATTCGGAATTGCCATCAAC 240 
Template        CCGTATGGCAACATACGCACCGTTGCCGAGAAGAAAGAATCATTCGGAATTGCCATCAAC 168 
                ***** ****************************************************** 
 
primer          AACCTGTACCACAAGTCGTCCGACCGTCTGCTGGGAATCTACCTGTTCTTCCGCCCTGCT 300 
Template        AACCTGTACCACAAGTCGTCCGACCGTCTGCTGGGAATCTATCTGTTCTTCCGCCCTGCT 228 
                ***************************************** ****************** 
 
primer          ATCTTGATTCGCGATCCTCATCTCGCGAAGCGTATTATGGTAAACGACTTCCAGAACTTT 360 
Template        ATCTTGATTCGCGATCCTCATCTCGCGAAGCGTATTATGGTAAACGACTTCCAGAACTTT 288 
                ************************************************************ 
 
primer          CACGATCGCGGTGTCTACTGCAACGAAGAGCACGATCCCTTCTCGGCCAATCTGGCCGCT 420 
Template        CACGATCGCGGTGTCTACTGCAATGAAGAGCACGATCCCTTCTCGGCCAATCTGTTCGCT 348 
                *********************** ******************************  **** 
 
primer          CTGCCCGGTCAGCGGTGGAAGAACTTGCGTGCGAAGCTCACGCCGACCTTCACGTCCGGA 480 
Template        CTGCCCGGTCAGCGGTGGAAGAACTTGCGTGCGAAGCTCACGCCGACCTTCACGTCCGGA 408 
                ************************************************************ 
 
primer          CAACTGCGTAACATGCTCCCCNCCCTGCTGGACGTCGGCAACAAGCTGATCGATCGTATG 540 
Template        CAACTGCGTAACATGCTCCCCACCCTGCTGGACGTCGGCAACAAGCTGATCGATCGTATG 468 
                ********************* ************************************** 
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Appendix 18: Protein standard curve 
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R² = 0.9426 
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